Human anti-il-32 antibodies

ABSTRACT

Provided are novel IL-32 binding molecules of human origin, particularly human anti-IL-32 antibodies as well as IL-32 binding fragments, derivatives and variants thereof. In addition, pharmaceutical compositions, kits and methods for use in diagnosis and therapy are described.

FIELD OF THE INVENTION

The present invention generally relates to novel molecules bindingInterleukin-32 (IL-32) of mammal, preferably human origin, particularlyhuman monoclonal antibodies as well as fragments, derivatives andvariants thereof. In particular, the present invention relates torecombinant human patient-derived anti-IL-32 antibodies and IL-32binding fragments thereof. In addition, compositions comprising suchbinding molecules, antibodies and mimics thereof useful in the treatmentand diagnosis of disorders are described. Furthermore, the presentinvention relates to the anti-IL-32 antibodies and mentioned equivalentsthereof for use in immunotherapy as well as targets in the therapeuticintervention of autoimmune and autoinflammatory disorders as well asmalignancies, such as various forms of arthritis, inflammatory boweldisease (IBD), myasthenia gravis (MG), chronic obstructive pulmonarydisease (COPD), asthma, vascular inflammation & atherosclerosis, atopicdermatitis and cancer.

BACKGROUND OF THE INVENTION

Inappropriate responses of the immune system may cause stressfulsymptoms to the involved organism. Exaggerated immune answers to foreignsubstances or physical states which usually do not have a significanteffect on the health of an animal or human may lead to allergies withsymptoms ranging from mild reactions, such as skin irritations tolife-threatening situations such as an anaphylactic shock or varioustypes of vasculitis. Immune answers to endogenous antigens may causeautoimmune disorders such as systemic lupus erythematosus, idiopathicautoimmune hemolytic anemia, pernicious anemia, type 1 diabetesmellitus, blistering skin diseases and different kinds of arthritis.

Immune responses occur in a coordinated manner, involving several celltypes and requiring communication by signaling molecules such ascytokines between the cell types involved. This communication may beinfluenced or inhibited by, e.g., interception of the signals or blockof the respective receptors.

Cytokines are secreted soluble proteins, peptides and glycoproteinsacting as humoral regulators at nano- to picomolar concentrationsbehaving like classical hormones in that they act at a systemic leveland which, either under normal or pathological conditions, modulate thefunctional activities of individual cells and tissues. Cytokines differfrom hormones in that they are not produced by specialized cellsorganized in specialized glands, i.e. there is not a single organ orcellular source for these mediators as they are expressed by virtuallyall cells involved in innate and adaptive immunity such as epithelialcells, macrophages, dendritic cells (DC), natural killer (NK) cells andespecially by T cells, prominent among which are T helper (Th)lymphocytes.

Depending on their respective functions, cytokines may be classifiedinto three functional categories: regulating innate immune responses,regulating adaptive immune responses and stimulating hematopoiesis. Dueto their pleiotropic activities within said three categories, e.g.,concerning cell activation, proliferation, differentiation, recruitment,or other physiological responses, e.g., secretion of proteinscharacteristic for inflammation by target cells, disturbances of thecell signaling mediated by aberrantly regulated cytokine production havebeen found as a cause of many disorders associated with defective immuneresponse, for example, inflammation and cancer.

Interleukin-32 (IL-32, also known as Natural killer cells protein 4) isa recently discovered cytokine with important functions in host defenseand innate immunity. The human IL-32 gene is located on chromosome16p13.3. Besides human and simian, so far bovine, swine and equinehomologues have been found, however no mouse homologues are known sofar. Six IL-32 isoforms are known, produced by alternative splicing(Chen et al., Vitam Horm 74 (2006), 207-228). The longest isoform,IL-32gamma (IL-32γ or IL-32g), comprises 234aa (UniProtKB/Swiss-Protidentifier: P24001-1). The second isoform, also known as IL-32beta(IL-32β or IL-32b; UniProtKB/Swiss-Prot identifier: P24001-2) has 188aa.The third isoform of 178aa is also known as IL-32delta (IL-32δ orIL-32d; UniProtKB/Swiss-Prot identifier: P24001-3). IL-32alpha (IL-32αor IL-32a) of 131aa is the fourth isoform (UniProtKB/Swiss-Protidentifier: P24001-4). Isoform 5 (UniProtKB/Swiss-Prot identifier:P24001-5) and isoform 6 UniProtKB/Swiss-Prot identifier: P24001-6) have168aa respective 179aa. However, also further isotypes may exist, e.g.,a 112 aa potential new isotype has been reported by Imaeda et al., (MolMed Rep. 4 (2011), 483-487).

The receptor for IL-32 is unknown so far. However, some data existindicating that IL-32 may be bound and cleaved at the cell membrane byproteinase 3 implicating this molecule as a possible receptor, whereinthe produced fragments may have biological activity and activatemacrophage inflammatory protein-2 and IL-8 (Dinarello and Kim, Ann RheumDis. 65 Suppl. 3 (2006); iii 61-64). IL-32 is implicated as a majorcontroller of inflammatory pathways with a pronounced synergy with TNFαin form of a self-perpetuating loop where IL-32 promotes TNFα expressionand vice versa resulting in the amplification of proinflammatorymediators. It has been reported to induce various cytokines such asTNFA/TNF-alpha, IL-1β, IL-6, IL-8, and macrophage inflammatory protein-2(MIP-2), to activate typical cytokine signaling pathways of NF-kappa-Band p38 MAPK and it is an IL-18 inducible gene (Kim et al., Immunity 22(2005), 131-142; Netea et al., Proc Natl Acad Sci USA. 105 (2008),3515-3520; Netea et al., Proc Natl Acad Sci USA. 102 (2005),16309-16314; Joosten et al., Proc. Natl. Acad. Sci. USA 103 (2006),3298-3303). Recently, it was also shown that IL-32 increases IFN-γproduction by Peripheral Blood Mononuclear Cells (PBMCs; Nold et al., JImmunol. 181 (2008), 557-565; Netea et al., PLoS Med. 3 (2006), e277).

IL-32 has been reported as being produced mainly by NK cells, Tlymphocytes, epithelial cells, and blood monocytes stimulated by IL-2 orIFN-γ (Dahl et al., J Immunol. 148 (1992), 597-603; Kim et al., (2005)).Furthermore, IL-32 has been observed to be overexpressed in rheumatoidarthritis (RA) synovial tissue biopsies, wherein the level of IL-32expression correlated positively with the severity of inflammation(Alsaleh et al., Arthritis Res Ther. 12 (2010), R135; Cagnard et al.,Eur Cytokine Netw. 16 (2005), 289-292.). Besides various forms ofarthritis, such as rheumatoid arthritis (RA) or ankylosing spondylitis(Ciccia et al., Rheumatology 51 (2012), 1966-1972), which belongs to thefamily of spondyloarthropathies, IL-32 was found functionally associatedwith several other inflammatory bowel disease (IBD), myasthenia gravis(MG), chronic obstructive pulmonary disease (COPD), asthma, Crohn'sdisease, psoriasis, atopic dermatitis and cancer (Alsaleh et al.,(2010); Breenan and Beech, Curr. Opin. Rheumatol., 19 (2007), 296-301;Asquith and McInnes, Curr. Opin. Rheumatol., 19 (2007), 246-251;Dinarello and Kim, Ann Rheum Dis. 65 Suppl 3 (2006); iii 61-64; Fantiniet al., Inflamm Bowel Dis. 13 (2007), 1419-1423; Lee et al., OncologyLetters 3 (2012), 490-496). The high rate of atherosclerosis in RAsuggested also a possible role of IL-32 in the inflammatory pathways ofvascular inflammation and atherosclerosis, which implications have beenalso verified, e.g., by detection of IL-32 expression, with theexpression of IL-32β and IL-32γ mRNA significantly enhanced in humanatherosclerotic arterial vessel wall (Kobayashi et al., PLoS One. 5(2010); e9458; Heinhuis et al., Cytokine. (2013), S1043-4666). IL-32 mayalso play a role in immune responses to tuberculosis (Kundu and Basu,PLoS Med., 3 (2006), e274; Netea et al., 2006). Also, increasedtranscription of IL-32 has been observed after infection by bacteria andviruses, such as Mycobacterium tuberculosis (Netea et al., 2006) orInfluenza A (Li at al., PLoS One. 3 (2008), e1985) indicating itspossible role in host defense.

Accordingly, IL-32 represents a not yet fully understood, however,important new therapeutic target and there is requirement for IL-32specific binding molecules, which neutralize the function of all IL-32isotypes, selected sub-ranges thereof or singular IL-32 isotypes, e.g.,IL-32γ.

First attempts to provide such molecules have been already met. Forexample, U.S. Pat. No. 7,641,904 B2 by Kim et al. provides murine IL-32monoclonal antibodies, wherein one of the antibodies selectivelyrecognizes IL-32α, wherein another antibody binds IL-32α, IL-32β, andIL-32γ. International application WO 2005/047478 describes thegeneration of murine antibody fragments specific for IL-32α and IL-32β.However, apparently no antibodies specific for IL-32γ have been providedyet.

Furthermore, due to immunological responses to foreign antibodies, asmouse antibodies in humans (HAMA-response; Schroff et al., Cancer Res.45 (1985), 879-885; Shawler et al., J. Immunol. 135 (1985), 1530-1535),mostly humanized versions of antibodies are used in present therapeuticapproaches (Chan et Carter, Nature Reviews Immunology 10 (2010),301-316; Nelson et al., Nature Reviews Drug Discovery 9 (2010),767-774). One approach to gain such antibodies was to transplant thecomplementarity determining regions (CDR) into a completely humanframework, a process known as antibody humanization (Jones et al.,Nature 321 (1986), 522-525). This approach is often complicated by thefact that mouse CDR do not easily transfer to a human variable domainframework, resulting in lower affinity of the humanized antibody overtheir parental murine antibody. Therefore, additional and elaboratemutagenesis experiments are often required, to increase the affinity ofthe so engineered antibodies. Another approach for achieving humanizedantibodies is to immunize mice which have had their innate antibodygenes replaced with human antibody genes and to isolate the antibodiesproduced by these animals. However, this method still requiresimmunization with an antigen, which is not possible with all antigensbecause of the toxicity of some of them. Furthermore, this method islimited to the production of transgenic mice of a specific strain.

Another method to generate antibodies is to use libraries of humanantibodies, such as phage display, as described, for example, for thegeneration of IL-13 specific antibodies in international application WO2005/007699. Here, bacteriophages are engineered to display humanscFv/Fab fragments on their surface by inserting a human antibody geneinto the phage population. Unfortunately, there is a number ofdisadvantages of this method as well, including size limitation of theprotein sequence for polyvalent display, the requirement of secretion ofthe proteins, i.e. antibody scFv/Fab fragments, from bacteria, the sizelimits of the library, limited number of possible antibodies producedand tested, a reduced proportion of antibodies with somatichypermutations produced by natural immunization and that allphage-encoded proteins are fusion proteins, which may limit the activityor accessibility for the binding of some proteins. A further severedrawback of this technique is that the antibodies so produced bear therisk of undesired cross-reactivity against self-antigens and lack thecharacteristics of evolutionary optimized natural human antibodiesproduced by the human immune system. Furthermore, such antibodies maynot be specific enough because of cross-reactivity with other proteinsand/or with the target protein in context with normal physiologicalenvironment and function. Similarly, European patent application EP 0616 640 A1 describes the production of auto-antibodies from antibodysegment repertoires displayed on phage. Phage libraries are generatedfrom unimmunized humans in this respect (see, e.g., Example 1; page 16,lines 43-51; Example 2, at page 17, paragraph [0158], lines 57-58).However, also the methods described in this patent application sufferfrom above mentioned general disadvantages of antibodies generated fromphage libraries, in comparison to antibodies produced and matured in amammalian, i.e. human body.

In view of the above, there is still a need for additional and newcompounds for treatment and diagnosis of disorders or conditionsassociated with detrimental IL-32 activity, like binding molecules ofhigh specificity for IL-32 or specific for a selected range of or asingle IL-32 isotype, in particular of antibodies specific for IL-32γ,which are tolerable in humans either for monotherapy or combinatorialapproaches.

The solution to this problem is provided by the embodiments of thepresent invention as characterized in the claims and disclosed in thedescription and illustrated in the Examples and Figures further below.

SUMMARY OF THE INVENTION

The present invention relates to IL-32 specific human monoclonalantibodies and IL-32 binding fragments and derivatives thereof. Inparticular, human monoclonal anti-IL-32 antibodies are provided with aselective binding profile towards IL-32 isotypes and displaying bindingand neutralizing activity in vitro and in vivo as shown in the appendedExamples and the Figures. Due to their neutralization properties, theantibodies of the present invention have therapeutic, prognostic anddiagnostic utility, which make them in particular valuable forapplications in relationship with diverse autoimmune and inflammatorydisorders and conditions associated with/involving IL-32 activity ininitiation and/or maintenance of undesired immune responses, such asvarious forms of arthritis (e.g., rheumatoid arthritis (RA) orspondyloarthritis), myasthenia gravis (MG), inflammatory bowel disease(IBD), pulmonary diseases such as chronic obstructive pulmonary disease(COPD) and asthma, Crohn's disease, psoriasis, vascular inflammation &atherosclerosis, atopic dermatitis and cancer; see also the Backgroundof the invention section above for these and further possible anti-IL-32therapeutic and diagnostic indications.

The antibodies of the present invention have been isolated from mammals,in particular humans, which are affected with an impaired central and/orperipheral tolerance or loss of self-tolerance which may be due to orassociated with a disrupted or deregulated genesis of self-tolerance,preferably caused by a monogenic autoimmune disorder. Examples ofmammals which provide a particularly suitable source for autoantibodiesin accordance with the present invention are mammals, e.g., humanshaving a disorder associated with a mutation in the AIRE (AutoimmuneRegulator) gene such as Autoimmune polyendocrinopathy syndrome type 1(APS1) (Peterson et al., Nat. Rev. Immunol. 8 (2008), 948-957),Autoimmune polyendocrinopathy syndrome type 2 (APS2) (Baker et al., J.Clin. Endocrinol. Metab. 95 (2010), E263-E270) and immunodysregulationpolyendocrinopathy enteropathy X-linked syndrome (IPEX) (Powell et al.,J. Pediatr. 100 (1982), 731-737; Ochs et al., Immunol. Rev. 203 (2005),156-164). Preferably, the patients from whom the antibodies wereisolated were displaying seroreactivity against at least one of thehuman IL-32 isotypes, most preferably towards IL-32γ.

In particular, experiments performed in accordance with the presentinvention were successful in the isolation of IL-32, in particular ofIL-32γ-specific antibodies from APS1 patients. Therefore, the presentinvention generally relates to high affinity IL-32 neutralizingmonoclonal antibodies. Accordingly, monoclonal human antibodies (mAbs,or MABs) against several or singular IL-32 isotypes, which will bedescribed in detail below are provided by the present invention, whichare considered to be safe and effective therapeutics for disorders inwhich those cytokines are involved.

Naturally, the present invention extends to nucleic acids, in particularcDNA encoding at least one variable, constant and/or complementaritydetermining region of the antibodies of the present invention, vectorscomprising such nucleic acids, antibody producing cell lines andrecombinant cells. The present invention further relates topharmaceutical compositions, diagnostic assays and kits that comprisethe binding molecules or peptides recognized by the antibodies isolatedin accordance with the present invention and to therapeutic methodsbased thereon.

Further embodiments of the present invention will be apparent from thedescription and Examples that follow. When doing so, and if notindicated otherwise the terms “monoclonal antibody”, “mAb”, “MAB” and“MAb” are used interchangeably herein.

Furthermore, while the invention is illustrated and described by way ofreference to the human-derived antibody originally obtained in theexperiments performed in accordance with the present invention anddescribed in the Examples it is to be understood that the antibody orantibody fragment of the present invention include synthetic andbiotechnological derivatives of an antibody which means any engineeredantibody or antibody-like IL-32-binding molecule, synthesized bychemical or recombinant techniques, which retains one or more of thefunctional properties of the subject antibody, in particular itsneutralizing activity towards IL-32. Thus, while the present inventionmay be described for the sake of conciseness by way of reference to anantibody, unless stated otherwise synthetic and biotechnologicalderivatives thereof as well as equivalent IL-32 binding molecules aremeant as well and included with the meaning of the term antibody.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1: Amino acid sequences of the variable region, i.e. heavy chainand kappa/lambda light chain (VH, VL) of IL-32 specific human antibodiesof the present invention. A: antibody 2C2 (IgG3, lambda); B: antibody14B3 (IgG1, lambda); C: antibody 19A1 (IgG1, lambda); D: antibody 26A6(IgG1, lambda). Framework (FR) and complementarity determining regions(CDRs) are indicated with the CDRs being underlined.

FIG. 2: Comparison of IL-32α (filled diamonds) and IL-32γ (filledsquares) ELISA seroreactivities in sera isolated from APS1 patients. Theindividual patient is indicated on the X-axis and the OD450 measurementsof MABs binding on the Y-axis.

FIG. 3: EC50 ELISA determination of binding of exemplary anti-IL32 2C2,14B3, 19A1 and 26A6 antibodies to A: IL-32γ (R&D) or B: IL-32α(ImmunoTools). All antibodies tested bind with high affinity IL-32γ.Antibody 2C2 binds with a low affinity IL-32α as well. Remainingantibodies 14B3, 19A1 and 26A6 do not show any substantial binding ofIL-32α.

FIG. 4: Binding and neutralization characteristics of exemplaryantibodies of the invention. A: EC50 ELISA determination of binding ofexemplary anti-IL32 2C2 antibody to IL-32γ (R&D) and IL-32α(ImmunoTools), BSA used as control for non-specific binding. Exemplaryantibody 2C2 binds with high affinity IL-32γ and with a much loweraffinity IL-32α. B: Neutralization capacity of exemplary anti-IL32antibodies 2C2 and 19A1 of IL-32γ activity.

FIG. 5: CytoEar ear thickness measurements calculated as fold changerelative to day 0 measurements, then normalized to relevant PBScontrols, for each cohort. Mean+/−SEM, N stated on figure. P valuesobtained by 2-way ANOVA testing, ns (not significant)=P>0.05; *=P≦0.05;**=P≦0.01; ***=P≦0.001, ****=p<0.0001. IP=intraperitoneal antibodyinjection, ID=intradermal ear injection.

FIG. 6: CytoEar ear thickness measurements shown as absolute values (mm)for each cohort. Mean+/−SEM, N stated on figure. P values obtained byANOVA testing. IP=intraperitoneal antibody injection, ID=intradermal earinjection. P value indications as in FIG. 5.

FIG. 7: CytoEar assay—weight monitoring. No significant weight changeswere observed in either of the animals tested in the experiment.

FIG. 8: Detailed analysis of the sensograms concerning the binding ofIL-32 to the anti-IL-32 2C2 antibody of the present invention. Non 1:1behavior was observed, which allows best fit to a heterogeneous ligand.(A) Overlayed graphs for the Langmuir fit and experimental data of thebinding reaction indicate a good fit to 1.1 Langmuir model. IL-32 wasinjected in concentrations of A1: 100 nM, A2: 33.33 nM, A3: 11.11 nM A4:3.70 nM A5: 1.23 nM. Residuals plot (B) shows a random scatter with themagnitude of the noise level indicating a good residual fit. (C) Tablebelow the figures shows the kinetic parameters derived from the fittedcurves for the association (ka), dissociation (kd), Rmax and thecalculated dissociations constant KD. KD of the exemplary anti-IL-32 2C2antibody of the present invention appears to be in nM range.

FIG. 9: Effect of 19A1 blocking antibody following hIL-32γ inducedinflammation in comparison to 2C2 in CytoEar assay. To induceinflammation hIL-32γ was injected at a concentration of 6.25 μg/ml, 125ng/ear. A: Exemplary 10-day experimental timeline. B: Overview of theexperimental treatment of the experimental animal groups A to F. C-F:Mice cohorts (C57/BL6, 8 weeks) were IP injected with stated amounts of2C2 or 19A1 antibodies (or IgG control) at experiment initial day, while125 ng hrIL-32γ cytokine in 20 ul of PBS (or PBS control) wasintradermally injected into mice ears every 48-72 hours. Ear thicknessmeasurements were taken with a Mitutoyo digital micrometer. CytoEar earthickness measurements calculated as fold change relative to initial daymeasurements, then normalised to relevant PBS controls, for each cohort.Mean+/−SEM, N stated on figure. P values obtained by ANOVA testing.IP=intraperitoneal antibody injection, ID=intradermal ear injection,NT=non-treated control.

FIG. 10: Effect of different doses of 19A1 antibody following hIL-32γinduced inflammation in CytoEar assay. To induce inflammation hIL-32γwas injected at a concentration of 6.25 μg/ml, 125 ng/ear. A: Exemplary10-day experimental timeline. B: Overview of the experimental treatmentof the experimental animal groups A to K. C-F: Mice cohorts (C57/BL6, 8weeks) were IP injected with stated amounts of 2C2 or 19A1 antibodies(or IgG control) at experiment initial day, while 125 ng hrIL-32γcytokine in 20 ul of PBS (or PBS control) was intradermally injectedinto mice ears every 48-72 hours. Ear thickness measurements were takenwith a Mitutoyo digital micrometer. CytoEar ear thickness measurementscalculated as fold change relative to initial day measurements, thennormalised to relevant PBS controls, for each cohort. Mean+/−SEM, Nstated on figure. P values obtained by ANOVA testing. IP=intraperitonealantibody injection, ID=intradermal ear injection, NT=non-treatedcontrol.

FIG. 11: Dose dependency of IL-32 in inducing inflammation in CytoAnkleassay. To induce inflammation mice obtained intraarticular ankleinjections of 10 μl hIL-32γ in the right ankle, whereas the left anklewas injected with PBS. A: Exemplary 13-day experimental timeline. B:Overview of the experimental treatment of the experimental animal cagesA1 to D2. C-D: Mice cohort (C57/BL6, 8 weeks) were IA injected withstated amounts of hrIL-32γ cytokine in 10 ul of PBS (or PBS control)into mice ankles every 48-72 hours. Axial ankle thickness measurementswere taken with a Mitutoyo digital micrometer. CytoAnkle thicknessmeasurements calculated as fold change relative to initial daymeasurements, then normalised to relevant PBS controls, for each cohort.Mean+/−SEM, N stated on figure. P values obtained by ANOVA testing.IA=intraarticular ankle injection.

FIG. 12: Effect of 2C2 antibody following hIL-32γ induced inflammationin CytoAnkle assay. CytoAnkle test: +/−IL-32γ+/−2C2. A: Exemplary 10-dayexperimental timeline. B: Overview of the experimental treatment of theexperimental animal cages A1 to D2. C-D: Mice cohort (C57/BL6, 8 weeks)were IP injected with 200 μg of 2C2 antibodies (or IgG control) atexperiment initial day, while 500 ng of hrIL-32γ cytokine in 10 μl ofPBS (or PBS control) was IA injected into mice ankles every 48-72 hours.Axial ankle thickness measurements were taken with a Mitutoyo digitalmicrometer. CytoAnkle thickness measurements calculated as fold changerelative to initial day measurements, then normalised to relevant PBScontrols, for each cohort. Mean+/−SEM, N stated on figure. P valuesobtained by ANOVA testing. IP=intraperitoneal antibody injection,IA=intraarticular ankle injection.

DETAILED DESCRIPTION OF THE INVENTION

The present invention generally relates to novel molecules binding IL-32of mammal, preferably human origin, particularly human monoclonalantibodies as well as fragments, derivatives and variants thereof thatrecognize different isotypes of IL-32.

There have been already efforts to provide IL-32 specific antibodies, asdescribed in the background section, however, the antibodies providedand used at present are, as indicated above, not of human origin, whichgreatly impairs their therapeutic use in humans due to theirimmunogenicity. Furthermore, while murine antibodies against IL-32α orof a broader specificity against several IL-32 isotypes are available,they may have an undesirable side effect profile due to their broadbinding specificity and potentially lead therefore to adverse effectsand diseases. In addition, apparently no human IL-32γ specificantibodies are available yet.

As described in the examples, the subject antibodies of the presentinvention were isolated by a method disclosed in applicant's co-pendinginternational application WO 2013/098419 A1, based on screening the seraof patients with an impaired central and/or peripheral tolerance or lossof self-tolerance, such as APECED/APS1 patients for autoantibodiesagainst IL-32 proteins. Within these screens, the surprising observationwas made that autoantibodies recognizing specific IL-32 isotypes werepresent in these sera. This cytokine has only recently been identifiedas a proinflammatory cytokine, and there is still relatively littleknown about its role in disease (at least compared with many otherpro-inflammatory cytokines). In this connection, the presence of IL-32autoantibodies in APS1 patients, which do not develop many of the commonautoimmune and inflammatory conditions and diseases, such as RA, lendsfurther support to an important role of this cytokine in the etiology ofthese diseases and validates the approach of the present invention, ofits targeted antibody-based inhibition for therapeutic intervention, andits use in diagnostic applications.

In view of the above, experiments performed in accordance with thepresent invention were directed towards the provision of IL-32 bindingmolecules, in particular antibodies showing a binding specificitytowards all IL-32 isotypes, or only a sub-range of IL-32 isotypes, oreven only against a singular isotype, preferably specifically bindingIL-32γ which immunoreactivity has been shown in APECED/APS1 patients tobe protective against the onset of, e.g., RA and/or IBD. Preferably, theIL-32 binding molecules are capable of neutralizing a biologicalactivity of IL-32. As illustrated by way of the exemplary anti-IL-32 2C2antibody of the present invention in the appended Examples and Figures,in particular FIG. 3 and FIG. 4A showing the binding affinities, FIG. 4Band FIGS. 5, 6 and 9 to 12 showing the neutralizing activity andtherapeutic utility of the subject antibody in an animal model, theproblem underlying the present invention has been solved.

Accordingly, in its broadest aspect the present invention relates torecombinant human monoclonal anti-interleukin-32 (IL-32) antibodies andIL-32 binding fragments thereof as well as biotechnological derivativesthereof which bind one or more of the IL-32 isotypes; see also thebackground section supra for description of the IL-32 isotypes,including, e.g., IL-32γ, IL-32α, IL-32β and IL-32δ. In one embodiment,the human monoclonal anti-IL-32 antibody or IL-32 binding fragmentthereof is capable of neutralizing a biological activity of IL-32γand/or IL-32α. Concerning the binding and neutralization properties ofthe antibodies of the present invention they may be substantially equaltowards the different IL-32 isotypes or may have a preferential bindingand/or neutralizing activity towards the respective IL-32 isotypes.

In a preferred embodiment of the present invention, the human monoclonalanti-IL-32 antibody or IL-32 binding fragment thereof

-   (i) is capable of binding recombinant human IL-32gamma (IL-32γ);-   (ii) is binding preferentially to human IL-32γ over IL32 alpha    (IL-32α) and/or does not substantially bind IL-32α; and/or-   (iii) is capable of neutralizing a biological activity of IL-32γ    Preferably, the antibody or IL-32 binding fragment thereof or an    equivalent binding molecule of the present invention comprises in    its variable region:-   (a) at least one complementarity determining region (CDR) of the    V_(H) and/or V_(L) variable region amino acid sequences depicted in    -   (i) FIG. 1 (V_(H)) (SEQ ID NOs: 2, 10, 18 and 26); and    -   (ii) FIG. 1 (V_(L)) (SEQ ID NOs: 4, 12, 20 and 28);-   (b) an amino acid sequence of the V_(H) and/or V_(L) region as    depicted in FIG. 1;-   (c) at least one CDR consisting of an amino acid sequence resulted    from a partial alteration of any one of the amino acid sequences of    (a); and/or-   (d) a heavy chain and/or light variable region comprising an amino    acid sequence resulted from a partial alteration of the amino acid    sequence of (b).

As described herein below in more detail, the antibody orantigen-binding fragment thereof of the present invention can be of orderived from any type, class or subclass of an immunoglobulin molecule.However, in a preferred embodiment, the antibody of the presentinvention is provided, which is of the IgG isotype, most preferably ofthe IgG1 or IgG3 subclass.

In order to provide such humanized, chimeric and in particular fullyhuman antibodies and native Fab fragments thereof, in one embodiment theantibody or IL-32 binding fragment of the present invention furthercomprises a C_(H) and/or C_(L) constant region comprising an amino acidsequence selected from the C_(H) and C_(L) amino acid sequences setforth in Table 1 (SEQ ID NOs.: 6, 8, 14, 16, 22, 24 and 30) or an aminoacid sequence with at least 60% identity, preferably 70% identity, morepreferably 80% identity, still more preferably 90% identity, andparticularly preferred at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%or 99%, identity to the mentioned reference sequences.

As described above, it has been found that IL-32 proinflammatoryactivity induces various cytokines such as TNFA/TNF-alpha, IL-1β, IL-6,IL-8, MIP-2 (see Kim et al., (2005); Netea et (2005); Netea et al.,(2008); Joosten et al., (2006), supra). This activation mechanism hasbeen used within the present invention for designing in vitro and invivo assays for determining IL-32-activity, such as monitoring of theIL-6 expression by IL-32 stimulated RAW 264.7 macrophages and the earinflammation assay as described in Example 3 and in FIGS. 4B, 5 and 6 tomonitor the neutralizing properties of the antibodies of the presentinvention. As described in detail therein, the antibodies of the presentinvention have been found to have a potent neutralizing activity towardsIL-32γ, wherein one antibody also shows residual binding activitytowards IL-32α as specified in detail further below. Accordingly, in oneembodiment the antibody or IL-32 binding fragment thereof of the presentinvention is capable of reducing the biological activity of human IL-32,preferably of IL-32γ. In a preferred embodiment the biological activityis human IL-32γ induced inflammation. Furthermore, in one embodiment ofthe present invention, the biological activity is determined in an IL-6induction assay and/or ear inflammation assay.

Furthermore, the binding affinities of the antibodies of the presentinvention have been tested by ELISA as described herein, e.g., inExample 2 and shown in FIGS. 3 and 4A. In accordance with the results ofthese experiments, the present invention provides several exemplaryanti-IL-32 antibodies and IL-32 binding fragments thereof showing adifferential binding affinity towards distinct IL-32 isotypes, whichexemplify the binding and neutralization characteristics of the IL-32binding molecules provided herein.

Since the exemplary anti-IL-32 antibodies described in the Examples havebeen derived from a human patient, the present invention advantageouslyprovides fully human antibodies particularly useful in therapeuticapplications, which are substantially devoid of immunological responsesotherwise typically observed for foreign antibodies, such as formouse-derived antibodies in humans (HAMA-response) or humanized andhuman-like antibodies.

In this context, contrary to humanized antibodies and otherwisehuman-like antibodies, see also the discussion infra, the human-derivedantibodies of the present invention are characterized by comprising CDRswhich have been seen by human body and therefore are substantiallydevoid of the risk of being immunogenic. Therefore, the antibody of thepresent invention may still be denoted human-derived if at least one,preferably two and most preferably all three CDRs of one or both thevariable light and heavy chain of the antibody are derived from thehuman antibodies illustrated herein.

The human-derived antibodies may also be called “human auto-antibodies”in order to emphasize that those antibodies were indeed expressedinitially by the subjects and are not in vitro selected constructsgenerated, for example, by means of human immunoglobulin expressingphage libraries or xenogeneic antibodies generated in a transgenicanimal expressing part of the human immunoglobulin repertoire, whichhitherto represented the most common method for trying to providehuman-like antibodies. On the other hand, the human-derived antibody ofthe present invention may be denoted synthetic, recombinant, and/orbiotechnological in order to distinguish it from human serum antibodiesper se, which may be purified via protein A or affinity column.

However, the present invention uses and envisages further studies of theantibodies of the present invention in animal models, e.g., intransgenic mice expressing human IL-32. To avoid immunogenic effects inthe experimental animals analogous to the HAMA-response in humans, inone aspect, the antibody or binding fragment of the present invention isprovided, which is a chimeric antibody, preferably a chimericrodent-human or a rodentized antibody, mostly preferred a chimericmurine-human or a murinized antibody.

As mentioned above, the antibodies of the present invention have beenisolated from APECED/APS1 patients. In this context, experimentsdisclosed in applicant's co-pending international application WO2013/098419 A1 surprisingly revealed that APECED/APS1 patients displayan auto-immunosome, i.e. an autoantibody profile comprising as well abroad spectrum of binding molecules specific for different IL-32isotypes. APS1 is a rare autoimmune disease caused by mutations in theAutoimmune Regulator (AIRE) gene. The AIRE protein governs theexpression in medullary thymic epithelium of many peripheralself-antigens (e.g., insulin) that are presented by MHC to toleratedeveloping thymocytes. In APS1, AIRE mutations cause aberrant negativeselection, which enables autoreactive T cells to escape to theperiphery. Accordingly, the patients show an extremely variable spectrumof clinical features in APS1, but usually with several autoimmunedisorders of endocrine tissues. The defining APS1 triad compriseschronic mucocutaneous candidiasis, hypoparathyroidism and adrenalfailure (Perheentupa, Endocrinol. Metab. Clin. North Am. 31 (2002),295-320). Other clinical conditions seen in APECED patients includethyroid autoimmune diseases, diabetes mellitus, gonadal failure,vitiligo, alopecia, chronic hepatitis, chronic gastritis and perniciousanemia and different forms other gastrointestinal symptoms. For furtherdetails concerning APECED/APS1 patients and the screening of theirauto-immunosome see the description of international application WO2013/098419 A1 and the Examples described therein, in particular theMaterial and Methods section on pages 112-117; Example 1 on pages117-118 and Example 7 on page 128 and the following Tables 1 to 14; andExample 17 on pages 168-171, the disclosure content of which isincorporated herein by reference.

As described in above, in one preferred embodiment, the antibody of thepresent invention is obtained or obtainable from a sample of a humansubject affected with autoimmunepolyendocrinopathy-candidiasis-ectodermal dystrophy (APECED/APS1) orfrom a patient affected with a similar autoimmune disease as describedin international application WO 2013/098419 A1 and the Examples therein,in particular the Materials and Methods section on pages 112-117;Example 1 on pages 117-118; in Example 10 on pages 156-161, specificallyin section “Patients and controls” on page 156 therein; and Example 17on pages 168-171, the disclosure content of which is incorporated hereinby reference. Furthermore, in a preferred embodiment the APS1 subject ischaracterized by displaying seroreactivity against human IL-32,preferably against IL-32γ and/or IL-32α.

In this context it is noted that the subject anti-IL-32 antibodies ofthe present invention have been cloned by a novel and proprietary methodof isolating human antibodies, which is disclosed in applicant'sco-pending international application WO 2013/098420 A1, the disclosurecontent of which is incorporated herein by reference.

Briefly, the sample for isolating the antibody of interest comprises orconsists of peripheral blood mononuclear cells (PBMC) and serum for thedetection of possible antibody reactivities. The sample derived from thesubject may either be directly used for, e.g., testing seroreactivityagainst one or more of the desired antigen(s) or may be furtherprocessed, for example enriched for B lymphocytes. In particular, it ispreferred that the sample comprises or is derived from B cells thatproduce the antibody of interest, most preferably memory B-cells. Thememory B cells are cultured under conditions allowing only a definitelife span of the B cells, typically no more than 1 to 2 weeks untilsingling out the cells from B cell cultures which are reactive againstthe desired antigen subsequently followed by RT-PCR of single sortedcells for obtaining the immunoglobulin gene repertoire; see for detaileddescription Examples 1 and 2 on pages 118 to 120 of WO 2013/098419 A1and in particular Examples 1 to 4 on pages 27 to 31 of WO 2013/0984220A1, the disclosure content of which is incorporated herein by reference.Naturally, the present invention extends to the human B memorylymphocyte and B cell, respectively, that produces the antibody havingthe distinct and unique characteristics as defined herein above andbelow.

Thus, besides using a selected patient pool, preferably an APS1 subjectcharacterized by displaying seroreactivity against at least one of thehuman IL-32 isotypes neutralized by an exemplary antibody of the presentinvention, the anti-IL-32 antibodies have been provided by employing aparticular method specifically developed and adapted for isolating humanmonoclonal antibodies from B cells of patients with an autoimmunedisease such as APECED/APS1 patients.

In one embodiment, the antibody or IL-32 binding molecule of the presentinvention comprises an amino acid sequence of the V_(H) and/or V_(L)region as depicted in FIG. 1 or as encoded by the corresponding nucleicacids as indicated in Table 1. In addition, in another embodiment thepresent invention relates to an anti-IL-32 antibody or IL-32 bindingmolecule, which competes with an antibody of the present invention asdefined hereinabove for specific binding to human IL-32, preferably toIL-32γ. In particular, anti-IL-32 antibodies are provided whichdemonstrate the immunological binding characteristics and/or biologicalproperties as outlined for the antibodies illustrated in the Examplesand in the Figures. Where present, the term “immunological bindingcharacteristics,” or other binding characteristics of an antibody withan antigen, in all of its grammatical forms, refers to the specificity,affinity, cross-reactivity, and other binding characteristics of anantibody.

In one embodiment, the antibody of the present invention is an antibodyfragment. For example, the antibody or antibody fragment of the presentinvention may be s elected from the group consisting of a single chainFv fragment (scFv), an F(ab′) fragment, an F(ab) fragment, an F(ab′)2fragment and a single domain antibody fragment (sdAB).

A further advantage of the antibodies of the present invention is thatdue to the fact that the humoral immune response has been elicitedagainst the native antigen in its physiologic and cellular environment,typically autoantibodies are produced and can be isolated whichrecognize a conformational epitope of the antigen due to itspresentation in context for example with other cellular components,presentation on a cell surface membrane and/or binding to a receptor. Incontrast, conventional methods of generating monoclonal antibodies suchas mouse monoclonals, humanized versions thereof or antibodies obtainedfrom phage display typically employ an antigenic fragment of the targetprotein for immunizing an non-human mammal and detection, respectively,upon which usually antibodies are obtained which recognize linearepitopes or conformational epitopes limited to a two-dimensionalstructure of the immunogen rather than the presence of the nativeprotein in its physiological and cellular context. Accordingly, it isprudent to expect that the autoantibodies of the present invention areunique in terms of their epitope specificity. Therefore, the presentinvention also relates to antibodies and like-binding molecules whichdisplay substantially the same binding specificity as the autoantibodiesisolated in accordance with the method of the present invention. Suchantibodies can be easily tested by for example competitive ELISA or moreappropriately in a cell based neutralization assay using an autoantibodyand a monoclonal derivative, respectively, thereof of the presentinvention as a reference antibody and the immunological tests describedin the Examples or otherwise known to the person skilled in the art.

The present invention exemplifies IL-32 binding molecules, i.e.antibodies and binding fragments thereof which may be generallycharacterized by comprising in their variable region, i.e. bindingdomain at least one complementarity determining region (CDR) of theV_(H) and/or V_(L) of the variable region comprising the amino acidsequence depicted in FIG. 1 of (V_(H)) (SEQ ID NOs: 2, 10, 18 and 26)and (V_(L)) (SEQ ID NOs: 4, 12, 20 and 28)—see the exemplary CDRsequences underlined in FIG. 1 and identified in Table 1. However, asdiscussed in the following the person skilled in the art is well awareof the fact that in addition or alternatively CDRs may be used, whichdiffer in their amino acid sequence from those indicated in FIG. 1 byone, two, three or even more amino acids, in particular in case of CDR2and CDR3.

As has been further demonstrated for the antibodies of the presentinvention, they are capable of neutralizing the biological activity oftheir target protein; see, e.g., the results of the IL-6 neutralizationassay described in Example 3, FIG. 4B and IL-32 ear inflammation assay

(CytoEar assay) and ankle inflammation assay (CytoAnkle assay) describedin Example 4, FIGS. 5 and 6 as well as FIGS. 9 to 12. In this context,the term “neutralizing” means that the anti-IL-32 antibody or IL-32binding fragment thereof of the present invention is capable ofintervening with the biological activity of its target protein in abiochemical, cell-based or in vivo assay as can be evaluated byperforming the respective assay in the presence of the subject antibodyof the present invention, wherein the biological activity of the targetprotein is reduced concomitantly with increasing level of the antibodyof the present invention subjected to the assay compared to thebiological activity of the protein without the presence of the antibodyof the present invention and in the presence of a compound for example acontrol antibody which is known to leave the biological activity of thetarget protein unaffected in kind Such biochemical, in vitro and in vivobased assay can also be performed using a reference antibody known to becapable of neutralizing the biological activity of the target proteinsuch as has been shown for the anti-IL-32 antibodies of the presentinvention and subjecting the candidate antibody to the test sample,wherein either an additive neutralizing effect may be observed resultingfrom the combined activity of the reference and candidate antibody or acompetition of the candidate antibody and reference antibody is observedwhich may be determined by labelling either antibody. Thus, in apreferred embodiment of the present invention, the antibody obtained bythe method of the present invention is capable of neutralizing thebiological activity of its antigen, e.g., at least one human IL-32isotype, preferably of IL-32γ. The neutralizing effect may be assessed,e.g, in the terms of the amount by which the IL-32 activity is reducedor by the time, at which such a reduction can be observed afterintroduction of the IL-32 binding molecules of the present invention,or, of course, in the combined terms of both.

The antibodies or antigen-binding fragments, e.g., peptides,polypeptides or fusion proteins of the present invention may beprovided, as indicated in detail below, by expression in a host cell orin an in vitro cell-free translation system, for example. To express thepeptide, polypeptide or fusion protein in a host cell, the nucleic acidmolecule encoding said peptide, polypeptide or fusion protein may beinserted into appropriate expression vector, i.e. a vector whichcontains the necessary elements for the transcription and translation ofthe inserted coding sequence. Methods which are well known to thoseskilled in the art may be used to construct expression vectorscontaining sequences encoding a polypeptide of interest and appropriatetranscriptional and translational control elements. These methodsinclude in vitro recombinant DNA techniques, synthetic techniques, andin vivo genetic recombination. Such techniques are described in Sambrooket al., Molecular Cloning, A Laboratory Manual (1989), and Ausubel etal., Current Protocols in Molecular Biology (1989); see also thesections “Polynucleotides” and “Expressions” further below andliterature cited in the Examples section for further details in thisrespect.

A suitable host cell for expression of the product may be anyprokaryotic or eukaryotic cell; e.g., bacterial cells such as E. coli orB. subtilis, insect cells (baculovirus), yeast cells, plant cell or ananimal cell. For efficient processing, however, mammalian cells arepreferred. Typical mammalian cell lines useful for this purpose includeCHO cells, HEK 293 cells, COS cells and NSO cells.

The isolated antibodies of the present invention may of course not beapplied as such to a patient, but usually have to be pharmaceuticallyformulated to ensure, e.g., their stability, acceptability andbioavailability in the patient. Therefore, in one embodiment, the methodof the present invention is provided, further comprising the step ofadmixing the isolated monoclonal antibody or a fragment thereof with apharmaceutically acceptable carrier. Pharmaceutically acceptablecarriers will be described in detail further below.

As a measure to obtain a stable and permanent source of bindingmolecules of the present invention, heterologous genes encoding thesebinding molecules may be isolated by direct cloning, PCR amplification,or artificial synthesis and introduced and expressed in suitable hostcells or organisms. Therefore, it is also an object of the presentinvention to provide a method for preparing a recombinant cell usefulfor the production of a recombinant human anti-IL-32 antibody or IL-32binding fragment thereof, comprising the steps of:

-   (a) preparing a B-cell by a method as described above;-   (b) sequencing a nucleic acid and/or obtaining from the B-cell a    nucleic acid that encodes;    -   (i) at least one of the C_(H) and C_(L) amino acid sequences set        forth in Table 1 (SEQ ID NOs.: 6, 8, 14, 16, 22, 24 and 30) or        an amino acid sequence with at least 60% identity;    -   (ii) at least one complementarity determining region (CDR) of        the V_(H) and/or V_(L) variable region amino acid sequences        depicted in        -   FIG. 1 (V_(H)) (SEQ ID NOs: 2, 10, 18 and 26); and        -   FIG. 1 (V_(L)) (SEQ ID NOs: 4, 12, 20 and 28);    -   (iii) an amino acid sequence of the V_(H) and/or V_(L) region as        depicted in FIG. 1;    -   (iv) at least one CDR consisting of an amino acid sequence        resulted from a partial alteration of any one of the amino acid        sequences of (a);    -   (v) a heavy chain and/or light variable region comprising an        amino acid sequence resulted from a partial alteration of the        amino acid sequence of (ii); and/or-   (c) inserting the nucleic acid into an expression host in order to    permit expression of the antibody of interest in that host.

Host cells as described herein may be used as well in the precedingmethod and as described in detail in the “Host” section of thisspecification. In this respect, in one embodiment the above method isprovided, where the expression host is a yeast cell, a plant cell or ananimal cell.

In respect of the above described methods for production of therespective antibody of interest, in one embodiment the present inventionprovides a method, wherein the nucleic acid is manipulated between abovesteps (b) and (c) to introduce restriction sites, to change codon usage,and/or to add or optimize transcription and/or translation regulatorysequences.

As demonstrated in appended Examples 2 and 3 and summarized in Table 3,binding molecules, i.e. antibodies have been identified and cloned,which display a particularly high apparent binding affinity (EC50/ED50)for human IL-32. In this respect, in one embodiment of the presentinvention the antibody or binding fragment thereof is as definedhereinabove is provided with a high affinity for its respective targetmolecule, e.g., human IL-32 isotypes as defined hereinabove, preferablyfor IL-32γ, showing an EC50 at concentrations below 2000 ng/ml or 1500ng/ml, preferably below 1000, 900, 800, 700, 600, 500, 400, 300, 200 or100 ng/ml and more preferably below 50, 20 or 10 ng/ml. Alternatively orin addition, in one embodiment the antibody or antigen binding fragmentthereof as defined hereinabove is provided with high neutralizingability for a human IL-32 isotype, preferably for IL-32γ, showing IC50at concentrations below 500 or 400 ng/ml, preferably below 300, 200 or100 ng/ml, more preferably below 50, 20 or 10 ng/ml. For more details inrespect of the binding affinity of the antibodies of the presentinvention see, e.g., section “Binding characteristics” further below. Inone embodiment the antibody or IL-32 binding fragment of the presentinvention specifically binds more than one IL-32 isotype, preferablywherein IL-32γ is one of the isotypes recognized. In one embodiment, thesecond isotype is IL-32α. In a preferred embodiment, the anti-IL-32antibody or IL-32 binding fragment thereof preferably binds IL-32γ overthe second recognized isotype. Furthermore, in one embodiment, theanti-IL-32 antibody or IL-32 binding fragment thereof of the presentinvention binds one IL-32 isotype and does not or does not substantiallybind any other IL-32 isotype.

The present invention also relates to polynucleotides encoding at leasta variable region of an immunoglobulin chain of the antibody orantigen-binding fragment of the invention. Preferably, said variableregion comprises at least one complementarity determining region (CDR)of the V_(H) and/or V_(L) of the variable region as set forth in FIG. 1.

In case of a derived sequence, said sequence shows at least 60%identity, more preferably (in the following order) at least 70%, atleast 75%, at least 80%, at least 85%, at least 90%, and most preferably95%, at least 96-99%, or even 100% identity to a sequence of the groupconsisting of those sequences referred to above and identified in theSequence Listing. The percent identity between two sequences is afunction of the number of identical positions shared by the sequences,taking into account the number of gaps, and the length of each gap,which need to be introduced for optimal alignment of the two sequences.The comparison of sequences and determination of percent identitybetween two sequences can be accomplished using a mathematicalalgorithm, which is well known to those skilled in the art. Theidentities referred to herein are to be determined by using the BLASTprograms as further referred to herein infra.

As mentioned above, in a preferred embodiment the present inventionrelates to substantially fully human antibodies, preferably IgGincluding at least the constant heavy chain I (C_(H)1) and thecorresponding light chain of the constant region, i.e. γ-1, γ-2, γ-3 orγ-4 in combination with lambda or kappa. In a particularly preferredembodiment, the nucleotide and amino acid sequences of those constantregions isolated for the subject antibodies illustrated in the Examplesare used as depicted in Table 1 below and in SEQ ID NOs: 5, 7, 13, 15,21, 23 and 29 in respect of the nucleotide sequences and/or SEQ ID NOs:6, 8, 14, 16, 22, 24 and 30 in respect of the amino acid sequences oramino acid sequences with at least 60% identity to these referencedbefore.

In accordance with the above, in one embodiment the present inventionalso provides a polynucleotide encoding at least the variable region ofone immunoglobulin chain of the antibody or antigen-binding fragment ofthe present invention. Typically, said variable region encoded by thepolynucleotide comprises at least one complementarity determining region(CDR) of the V_(H) and/or V_(L) of the variable region of the saidantibody. Variable and constant regions of antibodies are described inmore detail in the section “IgG structure” below. In a preferredembodiment of the present invention, the polynucleotide comprises,consists essentially of, or consists of a nucleic acid having apolynucleotide sequence encoding the V_(H) or V_(L) region of anantibody of the present invention as depicted in Table 1 below. In thisrespect, the person skilled in the art will readily appreciate that thepolynucleotides encoding at least the variable domain of the lightand/or heavy chain may encode the variable domain of eitherimmunoglobulin chains or only one of them. In a preferred embodiment,the polynucleotide encodes the anti-IL-32 antibody or IL-32 bindingfragment thereof as defined hereinabove.

TABLE 1Nucleotide sequences of the variable and constant regions (V_(H), V_(L),C_(H), C_(L)) regions of IgG3, lambda, IL-32 specific 2C2 antibody andof IgG1, lambda, IL-32 specific 14B3, 19A1 and 26A6 antibodies ofthe present invention. Underlined, bold nucleotides or amino acidsindicate the CDR coding regions in the variable chain sequence.Underlined, italic nucleotides or amino acids indicate sequenceswhich have not been sequenced but obtained from database. In theconstant chains, such regions are aligned with and tuned inaccordance with the pertinent human germ line variable regionsequences in the database; see, e.g., Vbase (http://vbase.mrc-cpe.cam.ac.uk) hosted by the MRC Centre for Protein Engineering(Cambridge, UK). Nucleotide and amino acid sequences of variable heavy(VH) and variable light (VL), constant heavy (CH) and Antibodyconstant light (CL) chains. 2C2-V_(H) cagctgcgggtgcaggagtcgggcccaggactgttgaagcctgcggagacgctgtccctcacctgcagtgtctctagtggctccgtcagc aatagtcgttattactgggcc tggatccgccagtccccagggaagggactggagtggattggg agtatgtattatcgtgggaggtcctactacaacccgtccctcaagagt cgcctcaccatttcgattgacacgtccaagaatcagttctccctgaaactgacctctctgaccgccgcagacacggccgtctattattgtgccgca gcagtttatcacgaccttgacta c tggggccagggaaccctggtcaccgtctcctca SEQ ID NO: 1 2C2-V_(H) QLRVQESGPGLLKPAETLSLTCSVSSGSVSNSRYYWA WIRQSPGKGLEWIG SMYYR GRSYYNPSLKSRLTISIDTSKNQFSLKLTSLTAADTAVYYCAA AVYHDLDY WGQGT LVTVSS SEQ ID NO: 22C2-V_(L) cagtctgtgttgacgcagccgccctcagtgtctgcggccccaggacagaaggtcaclambda-type catctcctgc tctggaagcggctccagcattgggaacaattatgtctcc tggtaccagcaactcccaggagcagcccccaaactcctcatttat gacaatactaagcgaccc tcagggattcctgaccgattctctggctccaagtctggcacgtcagccaccctggccatcaccggactccaacctggggacgcggccgattattactgc ggaacatgggatagtagtttcagtgttttttgggta ttcggcggagggaccaagctgaccgtccta SEQ ID NO: 32C2-V_(L) QSVLTQPPSVSAAPGQKVTISC SGSGSSIGNNYVS WYQQLPGAAPKLLIY DNTKRPlambda-type S GIPDRFSGSKSGTSATLAITGLQPGDAADYYC GTWDSSFSVFWV FGGGTKLTVLSEQ ID NO: 4 2C2-C_(H)gcttccaccaagggcccatcggtcttccccctggcgccctgctccaggagcacctctgggggcacagcggccctgggctgcctggtcaaggactacttccccgaaccggtgacggtgtcgtggaactcaggcgccctgaccagcggcgtgcacaccttcccggctgtcctacagtcctcaggactctactccctcagcagcgtggtgaccgtgccctccagcagcttgggcacccagacctacacctgcaacgtgaatcacaagcccagcaacaccaaggtggacaagagagttgagctcaaaaccccacttggtgacacaactcacacatgcccacggtgcccagagcccaaatcttgtgacacacctcccccgtgcccacggtgcccagagcccaaatcttgtgacacacctcccccatgcccacggtgcccagagcccaaatcttgtgacacacctcccccgtgcccaaggtgcccagcacctgaactcctgggaggaccgtcagtcttcctcttccccccaaaacccaaggatacccttatgatttcccggacccctgaggtcacgtgcgtggtggtggacgtgagccacgaagaccccgaggtccagttcaagtggtacgtggacggcgtggaggtgcataatgccaagacaaagctgcgggaggagcagtacaacagcacgttccgtgtggtcagcgtcctcaccgtcctgcaccaggactggctgaacggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaaccatctccaaaaccaaaggacagccccgagaaccacaggtgtacaccctgcccccatcccgggaggagatgaccaagaaccaggtcagcctgacctgcctggtcaaaggcttctaccccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaacaccacgcctcccatgctggactccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacatcttctcatgctccgtgatgcatgaggctctgcacaaccgctacacgcagaagagcctctccctgtctccgggtaaatga SEQ ID NO: 5 2C2-C_(H)ASTKGPSVFPLAPCSRSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYTCNVNHKPSNTKVDKRVELKTPLGDTTHTCPRCPEPKSCDTPPPCPRCPEPKSCDTPPPCPRCPEPKSCDTPPPCPRCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFKWYVDGVEVHNAKTKLREEQYNSTFRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYNTTPPMLDSDGSFFLYSKLTVDKSRWQQGNIFSCSVMHEALHNRYTQKSLSLSPGK SEQ ID NO: 6 2C2-C_(L)agtcagcccaaggctgccccctcggtcactctgttcccgccctcctctgaggagct lambda-typetcaagccaacaaggccacactggtgtgtctcataagtgacttctacccgggagccgtgacagtggcctggaaggcagatagcagccccgtcaaggcgggagtggagaccaccacaccctccaaacaaagcaacaacaagtacgcggccagcagctacctgagcctgacgcctgagcagtggaagtcccacaaaagctacagctgccaggtcaca catgaagggagcaccgtggagaagacagtggcccctacagaatgttcatag  SEQ ID NO: 7 2C2-C_(L)SQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETT lambda-typeTPSKQSNNKYAASSYLSLTPEQWKSHKSYSCQVT HEGSTVEKTVAPTECS SEQ ID NO: 814B3-V_(H) caggtgcagctggtggagtctgggggaggcgtggtccagcctgggaggtccctgagactctcctgtgtagcgtctggactcactttcagg acctatggcatgcac tgggtccgccaggctccaggcaacgggctggagtgggtggca atcatatggcatgatggtaataaaaaatactatgcagactccgtaaagggc cgattcaccatctccagggacaattccaagaacagtctatatctccaaatgaacagcctgagagtcgaggacacggctgtgt attactgtgcgagagaaatgaatggcatcgacgtc tggggccaagggaccacggtc accgtctcctca SEQ ID NO: 914B3-V_(H) QVQLVESGGGVVQPGRSLRLSCVASGLTFR TYGMH WVRQAPGNGLEWVA IIWHDGNKKYYADSVKG RFTISRDNSKNSLYLQMNSLRVEDTAVYYCAR EMNGIDV WGQGTTVTVSS SEQ ID NO: 10 14B3-V_(L)tcctatgagctgacccagccaccctcggtgtcagtgtccccaggacaaacggccag lambda-typegatcacctgc tctggagatgcgttgccagaaacatatgtttat tggtaccagcagaagtcaggccaggcccctgtgaagctcatctat gaggacagcgaacgaccctcc gggatccctgagagattctctggctccagctcagggacattggccaccttgactatcagtggggcccatgtggaggatgaagctgactactactgt tactcaacagacagtagtg gtatcggggtgttcggaggagggaccaagctgaccgtccta SEQ ID NO: 11 14B3-V_(L)SYELTQPPSVSVSPGQTARITC SGDALPETYVY WYQQKSGQAPVKLIY EDSERPS G lambda-typeIPERFSGSSSGTLATLTISGAHVEDEADYYC YSTDSSGIGV FGGGTKLTVL SEQ ID NO: 1214B3-C_(H) gcctccaccaagggcccatcggtcttccccctggcaccctcctccaagagcacctctgggggcacagcggccctgggctgcctggtcaaggactacttccccgaaccggtgacggtgtcgtggaactcaggcgccctgaccagcggcgtgcacaccttcccggctgtcctacagtcctcaggactctactccctcagcagcgtggtgaccgtgccctccagcagcttgggcacccagacctacatctgcaacgtgaatcacaagcccagcaacaccaaggtggacaagagagttgagcccaaatcttgtgacaaaactcacacatgcccaccgtgcccagcacctgaactcctggggggaccgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaaccatctccaaagccaaagggcagccccgagaaccacaggtgtacaccctgcccccatcccgggaggagatgaccaagaaccaggtcagcctgacctgcctggtcaaaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgctggactccgacggctccttcttcctctatagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtccccgggtaaatga SEQ ID NO: 13 14B3-C_(H)ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK SEQ ID NO: 1414B3-C_(L) agtcagcccaaggctgccccctcggtcactctgttcccgccctcctctgaggagctlambda-type tcaagccaacaaggccacactggtgtgtctcataagtgacttctacccgggagccgtgacagtggcctggaaggcagatagcagccccgtcaaggcgggagtggagaccaccacaccctccaaacaaagcaacaacaagtacgcggccagcagctacctgagcctgacgcctgagcagtggaagtcccacaaaagctacagctgccaggtcaca catgaagggagcaccgtggagaagacagtggcccctacagaatgttcatag  SEQ ID NO: 15 14B3-C_(L)SQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETT lambda-typeTPSKQSNNKYAASSYLSLTPEQWKSHKSYSCQVT HEGSTVEKTVAPTECS SEQ ID NO: 1619A1-V_(H) caggtgcacctggtggagtctgggggaggcgtggtccagcctgggaggtccctgagactctcctgtgtcgcgtctggactcactttcagg acctatggcatgcac tgggtccgccaggctccaggcaacgggctggagtgggtggca attatatggcatgatggtaataaaaaatactatgcagactccgtaaagggc cgattcaccatctccagggacaattccaagaacagtctatatctccaaatgaacagcctgagagtcgaggacacggctgtgt attactgtgcgagagaaatgaatggcatcgacgtc tggggccaagggaccacggtc accgtctcctca SEQ ID NO: 1719A1-V_(H) QVHLVESGGGVVQPGRSLRLSCVASGLTFR TYGMH WVRQAPGNGLEWVA IIWHDGNKKYYADSVKG RFTISRDNSKNSLYLQMNSLRVEDTAVYYCAR EMNGIDV WGQGTTVTVSS SEQ ID NO: 18 19A1-V_(L)tcctatgagctgacccagccaccctcggtgtcagtgtccccaggacaaacggccag lambda-typegatcacctgc tctggagatgcgttgccagaaacatatgtttat tggtaccagcagaagtcaggccaggcccctgtgaagctcatctat gaggacagcgaacgaccctcc gggatccctgagagattctctggctccagctcagggacattggccaccttgactatcagtggggcccatgtggaggatgaagctgactactactgt tactcaacagacagtagtg gtatcggggtgttcggaggagggaccaagctgaccgtccta SEQ ID NO: 19 19A1-VLSYELTQPPSVSVSPGQTARITC SGDALPETYVY WYQQKSGQAPVKLIY EDSERPS G lambda-typeIPERFSGSSSGTLATLTISGAHVEDEADYYC YSTDSSGIGV FGGGTKLTVL SEQ ID NO: 2019A1-C_(H) gcctccaccaagggcccatcggtcttccccctggcaccctcctccaagagcacctctgggggcacagcggccctgggctgcctggtcaaggactacttccccgaaccggtgacggtgtcgtggaactcaggcgccctgaccagcggcgtgcacaccttcccggctgtcctacagtcctcaggactctactccctcagcagcgtggtgaccgtgccctccagcagcttgggcacccagacctacatctgcaacgtgaatcacaagcccagcaacaccaaggtggacaagagagttgagcccaaatcttgtgacaaaactcacacatgcccaccgtgcccagcacctgaactcctggggggaccgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaaccatctccaaagccaaagggcagccccgagaaccacaggtgtacaccctgcccccatcccgggaggagatgaccaagaaccaggtcagcctgacctgcctggtcaaaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgctggactccgacggctccttcttcctctatagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtccccgggtaaatga SEQ ID NO: 21 19A1-C_(H)ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK SEQ ID NO: 2219A1-C_(L) agtcagcccaaggctgccccctcggtcactctgttcccgccctcctctgaggagctlambda-type tcaagccaacaaggccacactggtgtgtctcataagtgacttctacccgggagccgtgacagtggcctggaaggcagatagcagccccgtcaaggcgggagtggagaccaccacaccctccaaacaaagcaacaacaagtacgcggccagcagctacctgagcctgacgcctgagcagtggaagtcccacaaaagctacagctgccaggtcaca catgaagggagcaccgtggagaagacagtggcccctacagaatgttcatag  SEQ ID NO: 23 19A1-C_(L)SQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETT lambda-typeTPSKQSNNKYAASSYLSLTPEQWKSHKSYSCQVT HEGSTVEKTVAPTECS SEQ ID NO: 2426A6-V_(H) caggtgcagctggtggagtctgggggaggcgtggtccagcctgggaggtccctgagactctcctgtgtagcgtctggactcactttcagg acctatggcatgcac tgggtccgccaggctccaggcaacgggctggagtgggtggca atcatatggcatgatggtaataaaaaatactttgctgactccgtaaagggc cgattcaccatctccagggacaattccaagaacagtctatatctccaaatgaacagcctgagagtcgaggacacggctgttt attactgtgcgagagaaatgaatggcatcgacgtc tggggccaagggaccacggtc accgtctcctca SEQ ID NO: 2526A6-V_(H) QVQLVESGGGVVQPGRSLRLSCVASGLTFR TYGMH WVRQAPGNGLEWVA IIWHDGNKKYFADSVKG RFTISRDNSKNSLYLQMNSLRVEDTAVYYCAR EMNGIDV WGQGTTVTVSS SEQ ID NO: 26 26A6-V_(L)tcctatgagctgacccagccaccctcggtgtcagtgtccccaggacaaacggccag lambda-typegatcacctgc tctggagatgcgttgccagaaacatatgtttat tggtaccagcagaagtcaggccaggcccctgtgaagctcatctat gaggacagcgaacgaccctcc gggatccctgagagattctctggctccagctcagggacattggccaccttgactatcagtggggcccatgtggaggatgaagctgactactactgt tactcaacagacagtagtg gtatcggggtgttcggaggagggaccaaggtgaccgtccta SEQ ID NO: 27 26A6-V_(L)SYELTQPPSVSVSPGQTARITC SGDALPETYVY WYQQKSGQAPVKLIY EDSERPS G lambda-typeIPERFSGSSSGTLATLTISGAHVEDEADYYC YSTDSSGIGV FGGGTKVTVL SEQ ID NO: 2826A6-C_(L) agtcagcccaaggctgccccctcggtcactctgttcccgccctcctctgaggagctlambda-type tcaagccaacaaggccacactggtgtgtctcataagtgacttctacccgggagccgtgacagtggcctggaaggcagatagcagccccgtcaaggcgggagtggagaccaccacaccctccaaacaaagcaacaacaagtacgcggccagcagctacctgagcctgacgcctgagcagtggaagtcccacaaaagctacagctgccaggtcaca catgaagggagcaccgtggagaagacagtggcccctacagaatgttcatag  SEQ ID NO: 29 26A6-C_(L)SQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETT lambda-typeTPSKQSNNKYAASSYLSLTPEQWKSHKSYSCQVT HEGSTVEKTVAPTECS SEQ ID NO: 30

The person skilled in the art will readily appreciate that the variabledomain of the antibody having the above-described variable domain can beused for the construction of other polypeptides or antibodies of desiredspecificity and biological function. Thus, the present invention alsoencompasses polypeptides and antibodies comprising at least one CDR ofthe above-described variable domain and which advantageously havesubstantially the same or similar binding properties as the antibodydescribed in the appended examples. The person skilled in the art willreadily appreciate that using the variable domains or CDRs describedherein antibodies can be constructed according to methods known in theart, e.g., as described in European patent applications EP 0 451 216 A1and EP 0 549 581 A1. Furthermore, the person skilled in the art knowsthat binding affinity may be enhanced by making amino acid substitutionswithin the CDRs or within the hypervariable loops (Chothia and Lesk, J.Mol. Biol. 196 (1987), 901-917) which partially overlap with the CDRs asdefined by Kabat. Thus, the present invention also relates to antibodieswherein one or more of the mentioned CDRs comprise one or more,preferably not more than two amino acid substitutions. Preferably, theantibody of the invention comprises in one or both of its immunoglobulinchains two or all three CDRs of the variable regions as set forth forV_(H) regions in SEQ ID NOs: 2, 10, 18 and 26, and for V_(L) regions inSEQ ID NOs: 4, 12, 20 and 28 or as indicated in FIG. 1.

The polynucleotide of the invention encoding the above describedantibody may be, e.g., DNA, cDNA, RNA or synthetically produced DNA orRNA or a recombinantly produced chimeric nucleic acid moleculecomprising any of those polynucleotides either alone or in combination.In one embodiment, the polynucleotide is a cDNA encoding the variableregion and at least part of the constant domain. In a preferredembodiment a vector comprising the above polynucleotide is provided,optionally in combination with said polynucleotide which encodes thevariable region of the other immunoglobulin chain of said antibody. Suchvectors may comprise further genes such as marker genes which allow forthe selection of said vector in a suitable host cell and under suitableconditions.

Preferably, the polynucleotide of the invention is operatively linked toexpression control sequences allowing expression in prokaryotic oreukaryotic cells. Expression of said polynucleotide comprisestranscription of the polynucleotide into a translatable mRNA. Regulatoryelements ensuring expression in eukaryotic cells, preferably mammaliancells, are well known to those skilled in the art. They usually compriseregulatory sequences ensuring initiation of transcription and optionallypoly-A signals ensuring termination of transcription and stabilizationof the transcript. Additional regulatory elements may includetranscriptional as well as translational enhancers, and/or naturallyassociated or heterologous promoter regions.

In this respect, the person skilled in the art will readily appreciatethat the polynucleotides encoding at least the variable domain of thelight and/or heavy chain may encode the variable domains of bothimmunoglobulin chains or one chain only.

Likewise, said polynucleotides may be under the control of the samepromoter or may be separately controlled for expression. Possibleregulatory elements permitting expression in prokaryotic host cellscomprise, e.g., the P_(L), lac, trp or tac promoter in E. coli, andexamples for regulatory elements permitting expression in eukaryotichost cells are the AOX1 or GAL1 promoter in yeast or the CMV-, SV40-,RSV-promoter, CMV-enhancer, SV40-enhancer or a globin intron inmammalian and other animal cells.

Beside elements which are responsible for the initiation oftranscription such regulatory elements may also comprise transcriptiontermination signals, such as the SV40-poly-A site or the tk-poly-A site,downstream of the polynucleotide. Furthermore, depending on theexpression system used leader sequences capable of directing thepolypeptide to a cellular compartment or secreting it into the mediummay be added to the coding sequence of the polynucleotide of theinvention and are well known in the art. The leader sequence(s) is (are)assembled in appropriate phase with translation, initiation andtermination sequences, and preferably, a leader sequence capable ofdirecting secretion of translated protein, or a portion thereof, intothe periplasmic space or extracellular medium. Optionally, theheterologous sequence can encode a fusion protein including a C- orN-terminal identification peptide imparting desired characteristics,e.g., stabilization or simplified purification of expressed recombinantproduct. In this context, suitable expression vectors are known in theart such as Okayama-Berg cDNA expression vector pcDV1 (Pharmacia),pCDM8, pRc/CMV, pcDNA1, pcDNA3 (Invitrogen), or pSPORT1 (GIBCO BRL).

Preferably, the expression control sequences will be eukaryotic promotersystems in vectors capable of transforming or transfecting eukaryotichost cells, but control sequences for prokaryotic hosts may also beused. Once the vector has been incorporated into the appropriate host,the host is maintained under conditions suitable for high levelexpression of the nucleotide sequences, and, as desired, the collectionand purification of the immunoglobulin light chains, heavy chains,light/heavy chain dimers or intact antibodies, binding fragments orother immunoglobulin forms may follow; see, Beychok, Cells ofImmunoglobulin Synthesis, Academic Press, N.Y., (1979).

Furthermore, the present invention relates to vectors, particularlyplasmids, cosmids, viruses and bacteriophages used conventionally ingenetic engineering that comprise a polynucleotide encoding the antigenor preferably a variable domain of an immunoglobulin chain of anantibody of the invention; optionally in combination with apolynucleotide of the invention that encodes the variable domain of theother immunoglobulin chain of the antibody of the invention. Preferably,said vector is an expression vector and/or a gene transfer or targetingvector.

Expression vectors derived from viruses such as retroviruses, vacciniavirus, adeno-associated virus, herpes viruses, or bovine papillomavirus, may be used for delivery of the polynucleotides or vector of theinvention into targeted cell population. Methods which are well known tothose skilled in the art can be used to construct recombinant viralvectors; see, for example, the techniques described in Sambrook,Molecular Cloning A Laboratory Manual, Cold Spring Harbor Laboratory(1989) N.Y. and Ausubel, Current Protocols in Molecular Biology, GreenPublishing Associates and Wiley Interscience, N.Y. (1994).Alternatively, the polynucleotides and vectors of the invention can bereconstituted into liposomes for delivery to target cells. The vectorscontaining the polynucleotides of the invention (e.g., the heavy and/orlight variable domain(s) of the immunoglobulin chains encoding sequencesand expression control sequences) can be transferred into the host cellby well-known methods, which vary depending on the type of cellularhost. For example, calcium chloride transfection is commonly utilizedfor prokaryotic cells, whereas calcium phosphate treatment orelectroporation may be used for the transformation of other cellularhosts; see Sambrook, supra.

In respect to the above, the present invention furthermore relates to ahost cell comprising said polynucleotide or vector. Said host cell maybe a prokaryotic or eukaryotic cell. The polynucleotide or vector of theinvention which is present in the host cell may either be integratedinto the genome of the host cell or it may be maintainedextrachromosomally. The host cell can be any prokaryotic or eukaryoticcell, such as a bacterial, insect, fungal, plant, animal or human cell;suitable host cells and methods for production of the antibodies of thepresent invention are described in more detail in the section “Hostcells” below.

Using the above-mentioned host cells it is possible to produce andprepare an antibody of the present invention for, e.g., a pharmaceuticaluse or as a target for therapeutic intervention. Therefore, in oneembodiment, it is also an object of the present invention to provide amethod for preparing an anti-IL-32 antibody or IL-32 binding fragmentthereof, said method comprising

-   (a) culturing the cell as defined hereinabove; and-   (b) isolating said antibody or IL-32 binding fragment thereof from    the culture.

Accordingly, the present invention relates to a recombinant, preferablyhuman anti-IL-32 antibody and IL-32 binding fragment thereof,immunoglobulin chain(s) thereof encoded by the polynucleotide of thepresent invention or obtainable by the above-mentioned method forpreparing an anti-IL-32 antibody or immunoglobulin chain(s) thereof.Means and methods for the recombinant production of antibodies andmimics thereof as well as methods of screening for competing bindingmolecules, which may or may not be antibodies, are known in the art.However, as described herein, in particular with respect to therapeuticapplications in human the antibody of the present invention is a humanantibody in the sense that application of said antibody is substantiallyfree of an immune response directed against such antibody otherwiseobserved for chimeric and even humanized antibodies.

The binding molecules, antibodies or fragments thereof may be directlyused as a therapeutic agent. However, in one embodiment the antibody orantigen-binding fragment which is provided by the present invention, isdetectably labeled or attached to a drug, preferably wherein thedetectable label is selected from the group consisting of an enzyme, aradioisotope, a fluorophore, a peptide and a heavy metal. Labeledantibodies or antigen-binding fragments of the present invention may beused to detect specific targets in vivo or in vitro including“immunochemistry/immunolabelling” like assays in vitro. In vivo they maybe used in a manner similar to nuclear medicine imaging techniques todetect tissues, cells, or other material expressing the antigen ofinterest. Labels, their use in diagnostics and their coupling to thebinding molecules of the present invention are described in more detailin section “labels and diagnostics” further below.

The antibodies of the present invention are isolated from animals orhumans affected by an autoimmune disorder. On the other hand, IL-32specific antibodies identified in the present invention may be involvedin severely impairing the immune system of the affected individual,which is associated with, e.g., symptoms observed in APECED patients.

Therefore, it is a further aspect of the present invention, toextinguish or at least relieve the pathological reactions of subjectssuffering from autoimmune disorders by providing means and measures tominimize the number of auto-antibodies and/or their effects in adiseased human patient or animal. Thus, in one embodiment the presentinvention also relates to a peptide or peptide-based compound comprisingan epitope specifically recognized by an autoantibody of the presentinvention. A similar effect as by application of competitive antigens,sequestering and preventing thereby the binding of the autoantibodies totheir respective targets may be obtained by anti-idiotypic antibodies,as described in detail further below. Therefore, in one embodiment thepresent invention also provides an anti-idiotypic antibody of anautoantibody of the present invention.

As already indicated above, the present invention also relates to theanti-idiotypic antibody or the peptide or peptide-based compound of thepresent invention for use in the treatment of a disorder as definedabove, i.e. a disorder associated with a disrupted or deregulatedgenesis of self-tolerance. These isolated antibodies or fragmentsthereof of the present invention can be used as immunogenes to generatea panel of monoclonal anti-idiotypes. For suitable methods for thegeneration of anti-idiotypic antibodies see Raychadhuri et al., J.Immunol. 137 (1986), 1743 and for T-cells see Ertl et al., J. Exp. Med.159 (1985), 1776. The anti-idiotypic antibodies will be characterizedwith respect to the expression of internal image and non-internal imageidiotypes using standard assays routinely practiced in the art asdescribed in detail by Raychaudhuri et al., J. Immunol. 137 (1986),1743. If an anti-idiotypic antibody structurally mimics the antigen ofthe antibody it is binding to or bound by, it is called the “internalimage” of the antigen.

Methods of providing molecules which mimic an idiotype of an autoimmunedisease-associated auto-antibody (autoantibodies) are described in theart; see, e.g., international application WO03/099868, the disclosurecontent of which incorporated herein by reference. For example, suchmethod may comprise the following steps: (a) providing autoantibodies inaccordance with the method of the present invention; (b) binding theautoantibodies to a solid phase to form an affinity matrix; (c)contacting pooled plasma or B cells comprising immunoglobulins with theaffinity matrix followed by removal of unbound plasma components; (d)eluting bound immunoglobulins, being anti-Idiotypic antibodies (anti-Id)to autoantibodies, from the matrix; (e) providing a molecular librarycomprising a plurality of molecule members; and (e) contacting theanti-Id with the molecular library and isolating those bound moleculeswhich are bound by the anti-Id, the bound molecules being moleculeswhich mimic an idiotype of autoantibodies. A method of isolatingidiotypic autoantibodies in disclosed in international applicationWO2010/136196, the disclosure content of which incorporated herein byreference, which describes immunoglobulin preparations containingnatural polyclonal IgG-reactive antibodies (Abs) isolated from normalhuman serum (NHS), for the treatment of autoimmune diseases and immunesystem disorders. The IgG-reactive Abs potently neutralizedisease-associated or pathogenic autoantibodies present in sera ofpatients suffering from autoimmune diseases, by binding to theirantigenic determinants located either within or near (e.g. overlappingwith) the antigen combining sites.

The present invention also relates to compositions comprising any one ofthe aforementioned anti-IL32 antibodies or IL-32 binding fragmentsthereof, the polynucleotide, the vector, the cell, the peptide orpeptide-based compound of the present invention and/or a cocktail ofanti-IL32 antibodies or IL-32 binding fragments thereof which incombination display the features of anti-IL32 an antibody or IL-32binding fragment thereof of the present invention. In addition oralternatively in one embodiment the composition or the kit of thepresent invention comprises the anti-idiotypic antibody of the presentinvention. In one embodiment the composition is a pharmaceuticalcomposition and further comprises a pharmaceutically acceptable carrier.Pharmaceutically acceptable carriers, administration routes and dosageregimen can be taken from corresponding literature known to the personskilled in the art and are described as well in more detail in sections“Pharmaceutical carriers” and “Dosage regimen” further below.

In addition, the present invention relates to a process for themanufacture of a composition comprising the anti-IL-32 monoclonalantibody or a IL-32 binding fragment or biotechnological derivativethereof, which manufacture comprises the step of preparation of theantibody, IL-32 binding fragment or biotechnological derivative thereofby expression in a recombinant host organism of transforming DNAencoding the antibody, a IL-32 binding fragment or biotechnologicalderivative thereof. In one embodiment, the composition is apharmaceutical composition, wherein the step of preparation of theantibody, IL-32 binding fragment or biotechnological derivative thereofis followed, optionally after one or more steps in between by admixingthe antibody, IL-32 binding fragment or biotechnological derivativethereof with a pharmaceutically acceptable carrier in the manufacture ofa pharmaceutical composition. For example, before formulating in thepharmaceutical composition, the antibody or IL-32 binding fragmentthereof may be purified from the cell culture to pharmaceutical gradeand/or derivatized, for example pegylated or conjugated to a diagnosticlabel or drug so as obtain the pharmaceutical composition.

Besides biochemical and cell based in vitro assays therapeutic utilityof the antibodies of the present invention can be validated inappropriate animal models as described in detail in the Examples sectionfurther below.

In one embodiment the pharmaceutical composition further comprises anadditional agent useful for treating an inflammation or an autoimmunedisorder, preferably wherein said agent is selected from the groupconsisting of Non-Steroidal Antiinflammatory Drugs (NSAIDs),Corticosteroids, Anti-Histamines and combinations thereof. In additionor alternatively, in a further embodiment the pharmaceutical compositionfurther comprises an additional agent useful for treating aninflammation related disease, selected from the group consisting ofimmunosuppressive and anti-inflammatory or “anti-rheumatic” drugs.

In another embodiment, the composition is a diagnostic composition orkit and further comprises reagents conventionally used in immuno- ornucleic acid based diagnostic methods.

Furthermore, the present invention provides the aforementionedanti-IL-32 antibody or IL-32 binding fragment thereof, or thecomposition as defined hereinabove for use in a method of:

-   (a) treating or preventing the progression of an immune mediated or    autoimmune disease or condition;-   (b) amelioration of symptoms associated with an immune mediated or    autoimmune disease or condition; and/or-   (c) diagnosing or screening a subject for the presence or for    determining a subject's risk for developing an immune mediated or    autoimmune disease or condition;    wherein the disorder is associated with the expression of IL-32,    elevated and/or detrimental IL-32 activity in a patient.

In this respect, several application routes may be used. In oneembodiment of the present invention the aforementioned antibody orantigen-binding fragment, the anti-idiotypic antibody or peptide orpeptide-based compound and/or a cocktail of antibodies which incombination display the features of an antibody of the present inventionis provided, which is designed to be administered intravenously,intramuscularly, subcutaneously, intraperitoneally, intranasally,parenterally or as an aerosol.

As indicated above, due to their binding specificity, the molecules ofthe present invention such as antibodies and fragments thereof maypreferably be used in the above defined method of treatment,amelioration, diagnosing and/or screening of an immune mediated orautoimmune disorder or condition associated with and/or caused byexpression of IL-32, elevated and/or detrimental activity of IL-32. Forexample, expression, elevated and/or detrimental IL-32 activity has beenobserved in rheumatoid arthritis (RA) synovial tissue biopsies, whereinthe level of IL-32 expression correlated positively with the severity ofinflammation (Alsaleh et al., (2010), supra; Cagnard et al., (2005),supra). Besides rheumatoid arthritis (RA), IL-32 was found functionallyassociated with several other disorders, e.g., ankylosing spondylitis(Ciccia et al., (2012), supra), inflammatory bowel disease (IBD),Myasthenia gravis (MG), chronic obstructive pulmonary disease (COPD),Asthma, Crohn's disease, psoriasis, Vascular inflammation &atherosclerosis (Kobayashi et al., (2010)), atopic dermatitis and cancer(Alsaleh et al., (2010); Breenan and Beech, (2007); Asquith and McInnes(2007); Dinarello and Kim, (2006); Fantini et al., (2007; all supra).IL-32 may also play a role in immune responses to tuberculosis (Kunduand Basu, (2006); Netea et al., (2006); supra). Also, increasedtranscription of IL-32 has been observed after infection by bacteria andviruses, such as Mycobacterium tuberculosis (Netea et al., (2006),supra) or Influenza A (Li at al., (2008), supra) indicating its possiblerole in host defense.

Therefore, in one embodiment the anti-IL-32 antibody or IL-32 bindingfragment thereof or the composition as defined hereinabove for use inthe above-mentioned method is provided, wherein said disease is anautoimmune disease, preferably selected from the group consisting ofrheumatoid arthritis (RA), ankylosing spondylitis and other forms ofspondyloarthritis including but not limited to psoriatic arthritis,inflammatory bowel disease (IBD; including Crohn's disease, ulcerativecolitis and Celiac's disease), psoriasis, myasthenia gravis (MG),chronic obstructive pulmonary disease (COPD), asthma, tuberculosis,vascular inflammation and atherosclerosis, atopic dermatitis,tuberculosis and cancer including leukemia.

Due to the multitude of molecules suitable in treatment of, e.g.,disorders associated with inflammation presented herein, the presentinvention also relates to methods of treatment, diagnosing and/orprognosticate the probable course and outcome of such disorders,preferably wherein the immune mediated or autoimmune disease orcondition is associated with the expression, elevated and/or detrimentalactivity of IL-32 and to the use of the molecules of the presentinvention. In one embodiment a method for treating of such a disorder isprovided, which method comprises administering to a subject in needthereof a therapeutically effective amount of the aforementionedantibody or antigen-binding fragment, the cocktail of antibodies whichin combination display the features of an antibody of the presentinvention, the anti-idiotypic antibody or the peptide or peptide-basedcompound.

Furthermore, in one embodiment the present invention relates to a methodof treating an immune mediated or autoimmune disease or conditionassociated with the expression, elevated and/or detrimental activity ofIL-32 comprising administering to a subject a therapeutically effectiveamount of a ligand binding molecule comprising:

-   (i) at least one CDR of the anti-IL-32 antibody or IL-32 binding    fragment thereof of the present invention; or-   (ii) at least one anti-idiotypic antibody and/or peptide or    peptide-based compound as defined hereinabove.

Treatment methods based on the use of only one monoclonal antibodyspecific for an epitope of a particular antigen, which is related orcausing a disease may suffer from several shortcomings. For example,difficulties and probably inefficiency of treatment may stem from themultiplicity of the pathogenic mechanisms causing a specific disorderrequiring targeting of several antigens simultaneously. Furthermore, theinherent diversity of the patient population has to be taken intoaccount concerning, e.g., polymorphism, heterogeneity of glycosylationor slight denaturation of a given antigen, either in different or in onepatient which may lead to a decreased binding efficiency of themonoclonal antibody used at least. Some of these shortcomings may becircumvented by, e.g., pretreatment screenings to determine whether theantigen is immunologically relevant to the patients intended to betreated and whether there are any epitope changes in the particularpatients. However, such screenings are often omitted either due totreatment urgency or to cost restraints. Therefore, the presentinvention further relates to methods based on the application of morethan one type of a binding molecule at once to a patient, i.e. to theapplication of a cocktail of binding molecules. These binding moleculesmay specifically bind to one IL-32 isotype at different epitopes, eachof the binding molecules applied may bind specifically another IL-32isotype or several binding molecules are used binding to severalepitopes of more than one IL-32 isotype. In case the binding moleculesof the present invention are directed (bind specifically) towards oneIL-32 isotype as antigen, their binding specificity is directed towardsdistinct epitopes of said antigen. The use of such cocktails is inparticular envisaged for the treatment of patients suffering fromautoimmune disorders such as APS1, who in view of the presence ofautoantibodies against about 3000 endogenous antigens are often notamenable to monotherapy with one particular antibody. In such cases,combination therapy with two or more monoclonal antibodies and/orpeptides and peptide-based compounds of the present invention with thesame or different antigen specificity are expected to achieve at leastsome relief of the symptoms.

Therefore, in one embodiment a further method of treating a disorder isprovided comprising administering to a subject a therapeuticallyeffective amount of a cocktail consisting essentially of at least two,three, four, five and more components selected from the groupsconsisting of:

-   -   an antibody or antigen-binding fragment thereof of the present        invention specifically binding the IL-32 isotype as defined        hereinabove; and/or    -   an anti-idiotypic antibody of the present invention, and/or from        a peptide or peptide-based compound of the present invention,        which peptide or peptide-based compound comprises an epitope        specifically recognized by an antibody or antigen-binding        fragment thereof of the present invention.

The present invention naturally extents also to diagnostic andprognostic methods directed towards diagnosing immune mediated orautoimmune conditions and disorders associated with expression, elevatedand/or detrimental activity of one or more isotypes of IL-32, preferablyof IL-32γ and/or prognosis of the development of the disease, i.e. itsprogression, response to treatment or recovery. Therefore, in oneembodiment the present invention relates to a method of diagnosing animmune mediated or autoimmune disease or condition in a subjectassociated with the expression, elevated and/or detrimental activity ofIL-32 comprising contacting a biological sample of the subject with ananti-IL-32 antibody or IL-32 binding fragment thereof of the presentinvention, and detecting the presence of IL-32. In a preferredembodiment, the detected IL-32 isotype is IL-32γ. Furthermore, in oneembodiment the present invention relates to a method of detecting ordetermining IL-32 in an isolated biological sample comprising admixingthe sample with an anti-IL-32 antibody of the present invention,allowing the antibody to form a complex with any IL-32 isotype presentin the mixture, and detecting the complex present in the mixture,preferably wherein IL-32 is IL-32γ.

As already mentioned above, in one embodiment the present inventionrelates to a kit for the diagnosis of an immune mediated or autoimmunedisease or condition associated with the expression of IL-32, said kitcomprising the aforementioned antibody or antigen-binding fragment, theanti-idiotypic antibody or the peptide or peptide-based compound, thepolynucleotide, the vector or the cell, optionally with reagents and/orinstructions for use. Associated with the kits of the present invention,e.g., within a container comprising the kit can be a notice in the formprescribed by a governmental agency regulating the manufacture, use orsale of pharmaceuticals or biological products, which notice reflectsapproval by the agency of manufacture, use or sale for humanadministration. In addition or alternatively the kit comprises reagentsand/or instructions for use in appropriate diagnostic assays. Thecompositions, i.e. kits of the present invention are of courseparticularly suitable for the diagnosis, prevention and treatment of adisorder or condition which is accompanied with the expression of IL-32,in particular applicable for the treatment of diseases as mentionedabove. In a particularly preferred embodiment the disorder is associatedwith expression of one or more of IL-32 isotypes.

In another embodiment the present invention relates to a diagnosticcomposition comprising any one of the above described binding molecules,antibodies, antigen-binding fragments, peptides or peptide-basedcompounds, polynucleotides, vectors or cells of the invention andoptionally suitable means for detection such as reagents conventionallyused in immune- or nucleic acid based diagnostic methods. The antibodiesof the invention are, for example, suited for use in immunoassays inwhich they can be utilized in liquid phase or bound to a solid phasecarrier. Examples of immunoassays which can utilize the antibody of theinvention are competitive and non-competitive immunoassays in either adirect or indirect format. Examples of such immunoassays are theradioimmunoassay (RIA), the sandwich (immunometric assay), flowcytometry and the Western blot assay. The antigens and antibodies of theinvention can be bound to many different carriers and used to isolatecells specifically bound thereto. Examples of well-known carriersinclude glass, polystyrene, polyvinyl chloride, polypropylene,polyethylene, polycarbonate, dextran, nylon, amyloses, natural andmodified celluloses, polyacrylamides, agaroses, and magnetite. Thenature of the carrier can be either soluble or insoluble for thepurposes of the invention. There are many different labels and methodsof labeling known to those of ordinary skill in the art. Examples of thetypes of labels which can be used in the present invention includeenzymes, radioisotopes, colloidal metals, fluorescent compounds,chemiluminescent compounds, and bioluminescent compounds; see also theembodiments discussed hereinabove.

In this context, the present invention also relates to meansspecifically designed for this purpose. For example, a protein- orantibody-based array may be used, which is for example loaded witheither antigens derived from one or more IL-32 isotypes and containingthe disease-associated antigen in order to detect autoantibodies whichmay be present in patients suffering from an autoimmune diseases, inparticular RA, IBD or APECED/APS1, or with antibodies or equivalentantigen-binding molecules of the present invention which specificallyrecognize any one of those inflammation-associated antigens. Design ofmicroarray immunoassays is summarized in Kusnezow et al., Mol. CellProteomics 5 (2006), 1681-1696. Accordingly, the present invention alsorelates to microarrays loaded with binding molecules or antigensidentified in accordance with the present invention.

DEFINITIONS AND EMBODIMENTS

Unless otherwise stated, a term and an embodiment as used herein isgiven the definition as provided and used in international applicationWO 2013/098419 A1 and WO 2013/098420 A1. Supplementary, a common term asused herein is given the definition as provided in the Oxford Dictionaryof Biochemistry and Molecular Biology, Oxford University Press, 1997,revised 2000 and reprinted 2003, ISBN 0 19 850673 2.

It is to be noted that the term “a” or “an” entity refers to one or moreof that entity; for example, “an antibody,” is understood to representone or more antibodies. As such, the terms “a” (or “an”), “one or more,”and “at least one” can be used interchangeably herein.

The term “neutralizing” and “neutralizing antibody”, respectively, isused as common in the art in that an antibody is meant that reduces orabolishes at least some biological activity of an antigen or of a livingmicroorganism. For example, a isotype-specific anti-IL-32 antibody ofthe present invention is a neutralizing antibody, if, in adequateamounts, it abolishes or reduces the activity of the respective IL-32isotype(s) for example in an assay as described in the Examples.Neutralization is commonly defined by 50% inhibitory concentrations (IC50) and can be statistically assessed based on the area under theneutralization titration curves (AUC). IC 50 values of exemplaryanti-IL-32 antibodies of the present invention are described and shownherein, e.g., exemplary antibody 2C2 has an IL-32γ IC 50 value of 300ng/ml.

Central and Peripheral Tolerance

Self-tolerance is the process whereby the immune system does not respondto an antigen that is a constituent of that organism. Self-tolerance isachieved by death or inactivation of self-reactive T and B-cells, whichmay occur as part of central tolerance in a central (generative) immuneorgan (thymus or bone marrow) or as peripheral tolerance in what aremost commonly regarded as secondary immune tissues (e.g. spleen, lymphnode, intestine). Self-tolerance is a central feature of the normalimmune system. Failure to establish and/or maintain self-tolerance leadsto autoimmunity, which may result in autoimmune diseases that havesevere health implications for the host organism.

T- and B-cells can develop central tolerance towards those antigens thatare present in generative immune organs. In the bone marrow, B cellsdevelop tolerance to ubiquitously expressed, bone-marrow specificantigens and to antigens imported by the blood circulation. In thethymus, thymic medullary epithelial cells can express many hundreds ofself-antigens that are presented to developing T-cells. The generesponsible for the broad expression of self-antigens in thymicmedullary epithelial cells is AIRE (autoimmune regulator). AIREactivates multiple tissue specific genes that normally are expressedonly in particular peripheral organs such as insulin in pancreaticLangerhans islands. In the absence of the functional AIRE gene, antigensare not presented, T cells are not inactivated, and autoimmunity toself-antigens develops, leading to pathology in APECED patients and inAire deficient mice.

Another important gene in the induction of tolerance is foxp3. Thisencodes a transcription factor that induces a immunosuppressive,regulatory fate in T lymphocytes that engage self-antigen in the thymus,and possibly also in the periphery. Failure to encode a functional FOXP3protein is a characteristic of IPEX patients that as a consequence, alsosuffer widespread autoimmune disease.

Central and peripheral tolerance are described in more detail in therespective chapter of international application WO 2013/098419 A1 onpages 62-63, the disclosure content of which is incorporated herein byreference.

Peptides and Polypeptides:

The term “peptide” is understood to include the terms “polypeptide” and“protein” (which, at times, may be used interchangeably herein) and anyamino acid sequence such as those of the heavy and light chain variableregion as well as constant region of the present invention within itsmeaning. Similarly, fragments of proteins and polypeptides are alsocontemplated and may be referred to herein as “peptides”. Nevertheless,the term “peptide” preferably denotes an amino acid polymer including atleast 5 contiguous amino acids, preferably at least 10 contiguous aminoacids, more preferably at least 15 contiguous amino acids, still morepreferably at least 20 contiguous amino acids, and particularlypreferred at least 25 contiguous amino acids. In addition, the peptidein accordance with present invention typically has no more than 100contiguous amino acids, preferably less than 80 contiguous amino acidsand more preferably less than 50 contiguous amino acids.

As used herein, the term “polypeptide” is intended to encompass asingular “polypeptide” as well as plural “polypeptides” such asantibodies of the present invention, and refers to a molecule composedof monomers (amino acids) linearly linked by amide bonds (also known aspeptide bonds). The term “polypeptide” refers to any chain or chains oftwo or more amino acids, and does not refer to a specific length of theproduct. Thus, “peptides,” “dipeptides,” “tripeptides, “oligopeptides,”“protein,” “amino acid chain,” or any other term used to refer to achain or chains of two or more amino acids, are included within thedefinition of “polypeptide,” and the term “polypeptide” may be usedinstead of, or interchangeably with any of these terms.

The term “polypeptide” is also intended to refer to the products ofpost-expression modifications of the polypeptide, including withoutlimitation glycosylation, acetylation, phosphorylation, amidation,derivatization by known protecting/blocking groups, proteolyticcleavage, or modification by non-naturally occurring amino acids. Apolypeptide may be derived from a natural biological source or producedby recombinant technology, but is not necessarily translated from adesignated nucleic acid sequence. It may be generated in any manner,including by chemical synthesis.

A polypeptide of the invention may be of a size of about 3 or more, 5 ormore, 10 or more, 20 or more, 25 or more, 50 or more, 75 or more, 100 ormore, 200 or more, 500 or more, 1,000 or more, or 2,000 or more aminoacids. Nevertheless, the term “polypeptide” preferably denotes an aminoacid polymer including at least 100 amino acids. Polypeptides may have adefined three-dimensional structure, although they do not necessarilyhave such structure. Polypeptides with a defined three-dimensionalstructure are referred to as folded, and polypeptides which do notpossess a defined three-dimensional structure, but rather can adopt alarge number of different conformations, and are referred to asunfolded. As used herein, the term glycoprotein refers to a proteincoupled to at least one carbohydrate moiety that is attached to theprotein via an oxygen-containing or a nitrogen-containing side chain ofan amino acid residue, e.g., a serine residue or an asparagine residue.

By an “isolated” polypeptide or a fragment, variant, or derivativethereof is intended a polypeptide that is not in its natural milieu. Noparticular level of purification is required. For example, an isolatedpolypeptide can be removed from its native or natural environment.Recombinantly produced polypeptides and proteins expressed in host cellsare considered isolated for purposed of the invention, as are native orrecombinant polypeptides which have been separated, fractionated, orpartially or substantially purified by any suitable technique.

“Recombinant peptides, polypeptides or proteins” refer to peptides,polypeptides or proteins produced by recombinant DNA techniques, i.e.produced from cells, microbial or mammalian, transformed by an exogenousrecombinant DNA expression construct encoding the fusion proteinincluding the desired peptide. Proteins or peptides expressed in mostbacterial cultures will typically be free of glycan. Proteins orpolypeptides expressed in yeast may have a glycosylation patterndifferent from that expressed in mammalian cells.

Also included as polypeptides of the present invention are fragments,derivatives, analogs and variants of the foregoing polypeptides and anycombination thereof. The terms “fragment,” “variant,” “derivative” and“analog” include peptides and polypeptides having an amino acid sequencesufficiently similar to the amino acid sequence of the natural peptide.The term “sufficiently similar” means a first amino acid sequence thatcontains a sufficient or minimum number of identical or equivalent aminoacid residues relative to a second amino acid sequence such that thefirst and second amino acid sequences have a common structural domainand/or common functional activity. For example, amino acid sequencesthat comprise a common structural domain that is at least about 45%, atleast about 50%, at least about 55%, at least about 60%, at least about65%, at least about 70%, at least about 75%, at least about 80%, atleast about 85%, at least about 90%, at least about 91%, at least about92%, at least about 93%, at least about 94%, at least about 95%, atleast about 96%, at least about 97%, at least about 98%, at least about99%, or at least about 100%, identical are defined herein assufficiently similar. Preferably, variants will be sufficiently similarto the amino acid sequence of the preferred peptides of the presentinvention, in particular to antibodies or antibody fragments, or tosynthetic peptide or peptide-based compound comprising epitopesrecognized by the antibodies of the present invention or fragments,variants, derivatives or analogs of either of them. Such variantsgenerally retain the functional activity of the peptides of the presentinvention, i.e. are bound by the antibodies of the present invention.Variants include peptides that differ in amino acid sequence from thenative and wt peptide, respectively, by way of one or more amino aciddeletion(s), addition(s), and/or substitution(s). These may be naturallyoccurring variants as well as artificially designed ones.

The terms “fragment,” “variant,” “derivative” and “analog” whenreferring to antibodies or antibody polypeptides of the presentinvention include any polypeptides which retain at least some of theantigen-binding properties of the corresponding native binding molecule,antibody, or polypeptide. Fragments of polypeptides of the presentinvention include proteolytic fragments, as well as deletion fragments,in addition to specific antibody fragments discussed elsewhere herein.Variants of antibodies and antibody polypeptides of the presentinvention include fragments as described above, and also polypeptideswith altered amino acid sequences due to amino acid substitutions,deletions, or insertions. Variants may occur naturally or benon-naturally occurring. Non-naturally occurring variants may beproduced using art-known mutagenesis techniques. Variant polypeptidesmay comprise conservative or non-conservative amino acid substitutions,deletions or additions. Derivatives of binding molecules of the presentinvention, e.g., antibodies and antibody polypeptides of the presentinvention, are polypeptides which have been altered so as to exhibitadditional features not found on the native polypeptide. Examplesinclude fusion proteins. Variant polypeptides may also be referred toherein as “polypeptide analogs”. As used herein a “derivative” of abinding molecule or fragment thereof, an antibody, or an antibodypolypeptide refers to a subject polypeptide having one or more residueschemically derivatized by reaction of a functional side group. Alsoincluded as “derivatives” are peptides which contain one or morenaturally occurring amino acid derivatives of the twenty standard aminoacids. For example, 4-hydroxyproline may be substituted for proline;5-hydroxylysine may be substituted for lysine; 3-methylhistidine may besubstituted for histidine; homoserine may be substituted for serine; andornithine may be substituted for lysine.

Anti-Idiotypic Antibodies:

The term “anti-idiotypic antibodies” when referring to antibodies orother binding molecules includes molecules which bind to the uniqueantigenic peptide sequence located on an antibody's variable region nearor at the antigen binding site, inhibiting by this a specific immuneresponse by otherwise caused by the given auto-antibody. In an analogousmanner synthetic peptide or peptide-based compound comprising an epitopespecifically recognized by an antibody of the present invention may beused.

Anti-idiotypic antibodies may be obtained in a similar fashion as otherantibodies. The particular anti-idiotypic antibody is detected by anysort of cross-linking, either by agglutination (in turbidimetric ornephelometric assays), precipitation (radial immunodiffusion), orsandwich immunoassays such as ELISAs. U.S. patent application No.20020142356 provides a method for obtaining anti-idiotypic monoclonalantibody populations directed to an antibody that is specific for ahigh-concentration, high-molecular-weight target antigen wherein saidanti-idiotypic antibody populations have a wide range of bindingaffinities for the selected antibody specific to said target antigen andwherein a subset of said anti-idiotypic antibody populations can beselected having the required affinity for a particular application.

U.S. patent application No. 20020142356 describes a competitiveimmunoassay of an antigen using an antibody as coat and ananti-idiotypic antibody as detection or vice-versa. Other referencesdisclosing use of an anti-idiotypic antibody as a surrogate antigeninclude Losman et al., Cancer Research, 55 (1995) (23 suppl.S):S5978-S5982; Becker et al., J. of Immunol. Methods 192 (1996), 73-85;Baral et al., International J. of Cancer, 92 (2001), 88-95; and Kohen etal., Food and Agriculture Immunology, 12 (2000), 193-201. Use ofanti-idiotypic antibodies in treatment of diseases or against parasitesis known in the art; see, e.g., in Sacks et al., J. Exper. Medicine, 155(1982), 1108-1119.

Determination of Similarity and/or Identity of Molecules:

“Similarity” between two peptides is determined by comparing the aminoacid sequence of one peptide to the sequence of a second peptide. Anamino acid of one peptide is similar to the corresponding amino acid ofa second peptide if it is identical or a conservative amino acidsubstitution. Conservative substitutions include those described inDayhoff, M. O., ed., The Atlas of Protein Sequence and Structure 5,National Biomedical Research Foundation, Washington, D.C. (1978), and inArgos, EMBO J. 8 (1989), 779-785. For example, amino acids belonging toone of the following groups represent conservative changes orsubstitutions: -Ala, Pro, Gly, Gln, Asn, Ser, Thr; -Cys, Ser, Tyr, Thr;-Val, Ile, Leu, Met, Ala, Phe; -Lys, Arg, His; -Phe, Tyr, Trp, His; and-Asp, Glu.

The determination of percent identity or similarity between twosequences is preferably accomplished using the mathematical algorithm ofKarlin and Altschul (1993) Proc. Natl. Acad. Sci USA 90: 5873-5877. Suchan algorithm is incorporated into the BLASTn and BLASTp programs ofAltschul et al. (1990) J. Mol. Biol. 215: 403-410 available at NCBI(http://www.ncbi.nlm.nih.gov/blast/Blast.cge).

The determination of percent identity or similarity is performed withthe standard parameters of the BLASTn and BLASTp programs.

BLAST polynucleotide searches are performed with the BLASTn program.

For the general parameters, the “Max Target Sequences” box may be set to100, the “Short queries” box may be ticked, the “Expect threshold” boxmay be set to 10 and the “Word Size” box may be set to 28. For thescoring parameters the “Match/mismatch Scores” may be set to 1, −2 andthe “Gap Costs” box may be set to linear. For the Filters and Maskingparameters, the “Low complexity regions” box may not be ticked, the“Species-specific repeats” box may not be ticked, the “Mask for lookuptable only” box may be ticked, and the “Mask lower case letters” box maynot be ticked.

BLAST protein searches are performed with the BLASTp program. For thegeneral parameters, the “Max Target Sequences” box may be set to 100,the “Short queries” box may be ticked, the “Expect threshold” box may beset to 10 and the “Word Size” box may be set to “3”. For the scoringparameters the “Matrix” box may be set to “BLOSUM62”, the “Gap Costs”Box may be set to “Existence: 11 Extension: 1”, the “Compositionaladjustments” box may be set to “Conditional compositional score matrixadjustment”. For the Filters and Masking parameters the “Low complexityregions” box may not be ticked, the “Mask for lookup table only” box maynot be ticked and the “Mask lower case letters” box may not be ticked.

Polynucleotides:

The term “polynucleotide” is intended to encompass a singular nucleicacid as well as plural nucleic acids, and refers to an isolated nucleicacid molecule or construct, e.g., messenger RNA (mRNA) or plasmid DNA(pDNA). A polynucleotide may comprise a conventional phosphodiester bondor a non-conventional bond (e.g., an amide bond, such as found inpeptide nucleic acids (PNA)). The term “nucleic acid” refers to any oneor more nucleic acid segments, e.g., DNA or RNA fragments, present in apolynucleotide. By “isolated” nucleic acid or polynucleotide is intendeda nucleic acid molecule, DNA or RNA, which has been removed from itsnative environment. For example, a recombinant polynucleotide encodingan antibody contained in a vector is considered isolated for thepurposes of the present invention. Further examples of an isolatedpolynucleotide include recombinant polynucleotides maintained inheterologous host cells or purified (partially or substantially)polynucleotides in solution. Isolated RNA molecules include in vivo orin vitro RNA transcripts of polynucleotides of the present invention.Isolated polynucleotides or nucleic acids according to the presentinvention further include such molecules produced synthetically. Inaddition, polynucleotide or a nucleic acid may be or may include aregulatory element such as a promoter, ribosome binding site, or atranscription terminator.

As used herein, a “coding region” is a portion of nucleic acid whichconsists of codons translated into amino acids. Although a “stop codon”(TAG, TGA, or TAA) is not translated into an amino acid, it may beconsidered to be part of a coding region, but any flanking sequences,for example promoters, ribosome binding sites, transcriptionalterminators, introns, and the like, are not part of a coding region. Twoor more coding regions of the present invention can be present in asingle polynucleotide construct, e.g., on a single vector, or inseparate polynucleotide constructs, e.g., on separate (different)vectors. Furthermore, any vector may contain a single coding region, ormay comprise two or more coding regions, e.g., a single vector mayseparately encode an immunoglobulin heavy chain variable region and animmunoglobulin light chain variable region. In addition, a vector,polynucleotide, or nucleic acid of the invention may encode heterologouscoding regions, either fused or not fused to a nucleic acid encoding abinding molecule, an antibody, or fragment, variant, or derivativethereof. Heterologous coding regions include without limitationspecialized elements or motifs, such as a secretory signal peptide or aheterologous functional domain.

In certain embodiments, the polynucleotide or nucleic acid is DNA. Inthe case of DNA, a polynucleotide comprising a nucleic acid whichencodes a polypeptide normally may include a promoter and/or othertranscription or translation control elements operably associated withone or more coding regions. An operable association is when a codingregion for a gene product, e.g., a polypeptide, is associated with oneor more regulatory sequences in such a way as to place expression of thegene product under the influence or control of the regulatorysequence(s). Two DNA fragments (such as a polypeptide coding region anda promoter associated therewith) are “operably associated” or “operablylinked” if induction of promoter function results in the transcriptionof mRNA encoding the desired gene product and if the nature of thelinkage between the two DNA fragments does not interfere with theability of the expression regulatory sequences to direct the expressionof the gene product or interfere with the ability of the DNA template tobe transcribed. Thus, a promoter region would be operably associatedwith a nucleic acid encoding a polypeptide if the promoter was capableof effecting transcription of that nucleic acid. The promoter may be acell-specific promoter that directs substantial transcription of the DNAonly in predetermined cells. Other transcription control elements,besides a promoter, for example enhancers, operators, repressors, andtranscription termination signals, can be operably associated with thepolynucleotide to direct cell-specific transcription. Suitable promotersand other transcription control regions are disclosed herein.

A variety of transcription control regions are known to those skilled inthe art. These include, without limitation, transcription controlregions which function in vertebrate cells, such as, but not limited to,promoter and enhancer segments from cytomegaloviruses (the immediateearly promoter, in conjunction with intron-A), simian virus 40 (theearly promoter), and retroviruses (such as Rous sarcoma virus). Othertranscription control regions include those derived from vertebrategenes such as actin, heat shock protein, bovine growth hormone andrabbit β-globin, as well as other sequences capable of controlling geneexpression in eukaryotic cells. Additional suitable transcriptioncontrol regions include tissue-specific promoters and enhancers as wellas lymphokine-inducible promoters (e.g., promoters inducible byinterferons or interleukins).

Similarly, a variety of translation control elements are known to thoseof ordinary skill in the art. These include, but are not limited toribosome binding sites, translation initiation and termination codons,and elements derived from picornaviruses (particularly an internalribosome entry site, or IRES, also referred to as a CITE sequence).

In other embodiments, a polynucleotide of the present invention is RNA,for example, in the form of messenger RNA (mRNA), small hairpin RNA(shRNA), small interfering RNA (siRNA) or any other RNA product.

Polynucleotide and nucleic acid coding regions of the present inventionmay be associated with additional coding regions which encode secretoryor signal peptides, which direct the secretion of a polypeptide encodedby a polynucleotide of the present invention. According to the signalhypothesis, proteins secreted by mammalian cells have a signal peptideor secretory leader sequence which is cleaved from the mature proteinonce export of the growing protein chain across the rough endoplasmicreticulum has been initiated. Those of ordinary skill in the art areaware that polypeptides secreted by vertebrate cells generally have asignal peptide fused to the N-terminus of the polypeptide, which iscleaved from the complete or “full-length” polypeptide to produce asecreted or “mature” form of the polypeptide. In certain embodiments,the native signal peptide, e.g., an immunoglobulin heavy chain or lightchain signal peptide is used, or a functional derivative of thatsequence that retains the ability to direct the secretion of thepolypeptide that is operably associated with it. Alternatively, aheterologous mammalian signal peptide, or a functional derivativethereof, may be used. For example, the wild-type leader sequence may besubstituted with the leader sequence of human tissue plasminogenactivator (TPA) or mouse β-glucuronidase. However, intracellularproduction of the polypeptides, in particular of the immunoglobulins andfragments thereof of the present invention is also possible.

Expression:

The term “expression” as used herein refers to a process by which a geneproduces a biochemical, for example, an RNA or polypeptide. The processincludes any manifestation of the functional presence of the gene withinthe cell including, without limitation, gene knockdown as well as bothtransient expression and stable expression. It includes withoutlimitation transcription of the gene into messenger RNA (mRNA), transferRNA (tRNA), small hairpin RNA (shRNA), small interfering RNA (siRNA) orany other RNA product, and the translation of such mRNA intopolypeptide(s). If the final desired product is a biochemical,expression includes the creation of that biochemical and any precursors.Expression of a gene produces a “gene product.” As used herein, a geneproduct can be either a nucleic acid, e.g., small interfering RNA(siRNA), a messenger RNA produced by transcription of a gene, or apolypeptide which is translated from a transcript. Gene productsdescribed herein further include nucleic acids with post transcriptionalmodifications, e.g., polyadenylation, or polypeptides with posttranslational modifications, e.g., methylation, glycosylation, theaddition of lipids, association with other protein subunits, proteolyticcleavage, and the like.

A variety of expression vector/host systems may be utilized to containand express polynucleotide sequences. These include, but are not limitedto, microorganisms such as bacteria transformed with recombinantbacteriophage, plasmid, or cosmid DNA expression vectors; yeasttransformed with yeast expression vectors; insect cell systems infectedwith virus expression vectors (e.g., baculovirus); plant cell systemstransformed with virus expression vectors (e.g., cauliflower mosaicvirus, CaMV; tobacco mosaic virus, TMV) or with bacterial expressionvectors (e.g., Ti or pBR322 plasmids); or animal cell systems.

To express the peptide, polypeptide or fusion protein (hereinafterreferred to as “product”) in a host cell, a procedure such as thefollowing can be used. A restriction fragment containing a DNA sequencethat encodes said product may be cloned into an appropriate recombinantplasmid containing an origin of replication that functions in the hostcell and an appropriate selectable marker. The plasmid may include apromoter for inducible expression of the product (e.g., pTrc (Amann etal, Gene 69 (1988), 301 315) and pET1 Id (Studier et al., GeneExpression Technology: Methods in Enzymology 185, Academic Press, SanDiego, Calif. (1990), 60 89). The recombinant plasmid may be introducedinto the host cell by, for example, electroporation and cells containingthe recombinant plasmid may be identified by selection for the marker onthe plasmid. Expression of the product may be induced and detected inthe host cell using an assay specific for the product.

In some embodiments, the DNA that encodes the product/peptide may beoptimized for expression in the host cell. For example, the DNA mayinclude codons for one or more amino acids that are predominant in thehost cell relative to other codons for the same amino acid.Alternatively, the expression of the product may be performed by invitro synthesis of the protein in cell-free extracts which are alsoparticularly suited for the incorporation of modified or unnatural aminoacids for functional studies; see also infra. The use of in vitrotranslation systems can have advantages over in vivo gene expressionwhen the over-expressed product is toxic to the host cell, when theproduct is insoluble or forms inclusion bodies, or when the proteinundergoes rapid proteolytic degradation by intracellular proteases. Themost frequently used cell-free translation systems consist of extractsfrom rabbit reticulocytes, wheat germ and Escherichia coli. All areprepared as crude extracts containing all the macromolecular components(70S or 80S ribosomes, tRNAs, aminoacyl-tRNA synthetases, initiation,elongation and termination factors, etc.) required for translation ofexogenous RNA. To ensure efficient translation, each extract must besupplemented with amino acids, energy sources (ATP, GTP), energyregenerating systems (creatine phosphate and creatine phosphokinase foreukaryotic systems, and phosphoenol pyruvate and pyruvate kinase for theE. coli lysate), and other co-factors known in the art (Mg²⁺, K⁺, etc.).Appropriate transcription/translation systems are commerciallyavailable, for example from Promega Corporation, Roche Diagnostics, andAmbion, i.e. Applied Biosystems (Anderson, C. et al., Meth. Enzymol. 101(1983), 635-644; Arduengo, M. et al. (2007), The Role of Cell-FreeRabbit Reticulocyte Expression Systems in Functional Proteomics in,Kudlicki, Katzen and Bennett eds., Cell-Free Expression Vol. 2007.Austin, Tx: Landes Bioscience, pp. 1-18; Chen and Zubay, Meth. Enzymol.101 (1983), 674-90; Ezure et al., Biotechnol. Prog. 22 (2006),1570-1577).

Host Cells:

In respect of the present invention, host cell can be any prokaryotic oreukaryotic cell, such as a bacterial, insect, fungal, plant, animal orhuman cell. Preferred fungal cells are, for example, those of the genusSaccharomyces, in particular those of the species S. cerevisiae. Theterm “prokaryotic” is meant to include all bacteria which can betransformed or transfected with a DNA or RNA molecules for theexpression of an antibody of the invention or the correspondingimmunoglobulin chains. Prokaryotic hosts may include gram negative aswell as gram positive bacteria such as, for example, E. coli, S.typhimurium, Serratia marcescens and Bacillus subtilis. The term“eukaryotic” is meant to include yeast, higher plant, insect andpreferably mammalian cells, most preferably HEK 293, NSO, CSO and CHOcells. Depending upon the host employed in a recombinant productionprocedure, the antibodies or immunoglobulin chains encoded by thepolynucleotide of the present invention may be glycosylated or may benon-glycosylated. Antibodies of the invention or the correspondingimmunoglobulin chains may also include an initial methionine amino acidresidue. A polynucleotide of the invention can be used to transform ortransfect the host using any of the techniques commonly known to thoseof ordinary skill in the art. Furthermore, methods for preparing fused,operably linked genes and expressing them in, e.g., mammalian cells andbacteria are well-known in the art (Sambrook, Molecular Cloning: ALaboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor,N.Y., 1989). The genetic constructs and methods described therein can beutilized for expression of the antibody of the invention or thecorresponding immunoglobulin chains in eukaryotic or prokaryotic hosts.In general, expression vectors containing promoter sequences whichfacilitate the efficient transcription of the inserted polynucleotideare used in connection with the host. The expression vector typicallycontains an origin of replication, a promoter, and a terminator, as wellas specific genes which are capable of providing phenotypic selection ofthe transformed cells. Suitable source cells for the DNA sequences andhost cells for immunoglobulin expression and secretion can be obtainedfrom a number of sources, such as the American Type Culture Collection(“Catalogue of Cell Lines and Hybridomas,” Fifth edition (1985)Rockville, Md., U.S.A., which is incorporated herein by reference).Furthermore, transgenic animals, preferably mammals, comprising cells ofthe invention may be used for the large scale production of the antibodyof the invention.

The transformed hosts can be grown in fermentors and cultured accordingto techniques known in the art to achieve optimal cell growth. Onceexpressed, the whole antibodies, their dimers, individual light andheavy chains, or other immunoglobulin forms of the present invention,can be purified according to standard procedures of the art, includingammonium sulfate precipitation, affinity columns, column chromatography,gel electrophoresis and the like; see, Scopes, “Protein Purification”,Springer Verlag, N.Y. (1982). The antibody or its correspondingimmunoglobulin chain(s) of the invention can then be isolated from thegrowth medium, cellular lysates, or cellular membrane fractions. Theisolation and purification of the, e.g., recombinantly expressedantibodies or immunoglobulin chains of the invention may be by anyconventional means such as, for example, preparative chromatographicseparations and immunological separations such as those involving theuse of monoclonal or polyclonal antibodies directed, e.g., against theconstant region of the antibody of the invention. It will be apparent tothose skilled in the art that the antibodies of the invention can befurther coupled to other moieties for, e.g., drug targeting and imagingapplications. Such coupling may be conducted chemically after expressionof the antibody or antigen to site of attachment or the coupling productmay be engineered into the antibody or antigen of the invention at theDNA level. The DNAs are then expressed in a suitable host system, andthe expressed proteins are collected and renatured, if necessary.

Substantially pure immunoglobulins of at least about 90 to 95%homogeneity are preferred, and 98 to 99% or more homogeneity mostpreferred, for pharmaceutical uses. Once purified, partially or tohomogeneity as desired, the antibodies may then be used therapeutically(including extracorporally) or in developing and performing assayprocedures.

The present invention also involves a method for producing cells capableof expressing an antibody of the invention or its correspondingimmunoglobulin chain(s) comprising genetically engineering cells withthe polynucleotide or with the vector of the invention. The cellsobtainable by the method of the invention can be used, for example, totest the interaction of the antibody of the invention with its antigen.

ELISA-Assays:

Enzyme-linked immunosorbent assays (ELISAs) for various antigens includethose based on colorimetry, chemiluminescence, and fluorometry. ELISAshave been successfully applied in the determination of low amounts ofdrugs and other antigenic components in plasma and urine samples,involve no extraction steps, and are simple to carry out. ELISAs for thedetection of antibodies to protein antigens often use direct binding ofshort synthetic peptides to the plastic surface of a microtitre plate.The peptides are, in general, very pure due to their synthetic natureand efficient purification methods using high-performance liquidchromatography. A drawback of short peptides is that they usuallyrepresent linear, but not conformational or discontinuous epitopes. Topresent conformational epitopes, either long peptides or the completenative protein is used. Direct binding of the protein antigens to thehydrophobic polystyrene support of the plate can result in partial ortotal denaturation of the bound protein and loss of conformationalepitopes. Coating the plate with an antibody, which mediates theimmobilization (capture ELISA) of the antigens, can avoid this effect.

However, frequently, overexpressed recombinant proteins are insolubleand require purification under denaturing conditions and renaturation,when antibodies to conformational epitopes are to be analyzed. See, forexample, U.S. patent application No. 20030044870 for a generic ELISAusing recombinant fusion proteins as coat proteins.

Binding Molecules:

A “binding molecule” as used in the context of the present inventionrelates primarily to antibodies, and fragments thereof, but may alsorefer to other non-antibody molecules that bind to the “molecules ofinterest” of the present invention, wherein the molecules of interestare proteins of the class of glycoproteins known as cytokines, inparticular interleukines selected from the group of different IL-32isotypes. In a particularly preferred embodiment, the molecule ofinterest is IL-32γ. The molecules of interest of the present inventionare defined in further detail within the description of the particularembodiments of the present invention above and below. The bindingmolecules of the present invention include but are not limited tohormones, receptors, ligands, major histocompatibility complex (MHC)molecules, chaperones such as heat shock proteins (HSPs) as well ascell-cell adhesion molecules such as members of the cadherin, intergrin,C-type lectin and immunoglobulin (Ig) superfamilies. Thus, for the sakeof clarity only and without restricting the scope of the presentinvention most of the following embodiments are discussed with respectto antibodies and antibody-like molecules which represent the preferredbinding molecules for the development of therapeutic and diagnosticagents.

Antibodies:

The terms “antibody” and “immunoglobulin” are used interchangeablyherein. An antibody or immunoglobulin is a molecule binding to amolecule of interest of the present invention as defined hereinabove andbelow, which comprises at least the variable domain of a heavy chain,and normally comprises at least the variable domains of a heavy chainand a light chain. Basic immunoglobulin structures in vertebrate systemsare relatively well understood; see, e.g., Harlow and Lane, Antibodies:A Laboratory Manual, (Cold Spring Harbor Laboratory Press, 2nd ed.1988). The terms “binds” and “recognizes” are used interchangeably inrespect of the binding affinity of the binding molecules of the presentinvention, e.g., antibodies.

Any antibody or immunoglobulin fragment which contains sufficientstructure to specifically bind to the molecules of interest, as definedhereinabove and below, is denoted herein interchangeably as a “bindingmolecule”, “binding fragment” or an “immunospecific fragment.”

Antibodies or antigen-binding fragments, immunospecific fragments,variants, or derivatives thereof of the invention include, but are notlimited to, polyclonal, monoclonal, multispecific, human, humanized,primatized, murinized or chimeric antibodies, single chain antibodies,epitope-binding fragments, e.g., Fab, Fab′ and F(ab′)2, Fd, Fvs,single-chain Fvs (scFv), single-chain antibodies, disulfide-linked Fvs(sdFv), fragments comprising either a V_(L) or V_(H) domain, fragmentsproduced by a Fab expression library, and anti-idiotypic (anti-Id)antibodies (including, e.g., anti-Id antibodies to antibodies disclosedherein). ScFv molecules are known in the art and are described, e.g., inU.S. Pat. No. 5,892,019. In this respect, antigen-binding fragment ofthe antibody can be as well domain antibodies (dAb) also known as singledomain antibodies (sdAB) or Nanobodies™ (Ablynx, Gent, Belgium), see,e.g., De Haard et al., J. Bacteriol. 187 (2005), 4531-4541; Holt et al.,Trends Biotechnol. 21 (2003), 484-490. As will be discussed in moredetail below, the term “immunoglobulin” comprises various broad classesof polypeptides that can be distinguished biochemically. Those skilledin the art will appreciate that heavy chains are classified as gamma,mu, alpha, delta, or epsilon, (γ, μ, α, δ, ε) with some subclasses amongthem (e.g., γ1-γ4). It is the nature of this chain that determines the“class” of the antibody as IgG, IgE, IgM, IgD, IgA, and IgY,respectively. The immunoglobulin subclasses (isotypes) e.g., IgG1, IgG2,IgG3, IgG4, IgA1, etc. are well characterized and are known to conferfunctional specialization. Immunoglobulin or antibody molecules of theinvention can be of any type (e.g., IgG, IgE, IgM, IgD, IgA, and IgY),class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, etc.) or subclass ofimmunoglobulin molecule. Modified versions of each of these classes andisotypes are readily discernable to the skilled artisan in view of theinstant disclosure and, accordingly, are within the scope of the instantinvention. Although all immunoglobulin classes are clearly within thescope of the present invention, the following discussion will generallybe directed to the IgG class of immunoglobulin molecules. With regard toIgG, a standard immunoglobulin molecule comprises two identical lightchain polypeptides of molecular weight approximately 23,000 Daltons, andtwo identical heavy chain polypeptides of molecular weight53,000-70,000. The four chains are typically joined by disulfide bondsin a “Y” configuration wherein the light chains bracket the heavy chainsstarting at the mouth of the “Y” and continuing through the variableregion.

As evident from the classification of the exemplary anti-IL-32antibodies of the present invention enlisted in Table 1 above, theexemplary antibodies of the present invention are of the IgG3 or IgG1class, possibly implicating regulatory T-cell responses and/or epitheliain their initiation in these AIRE-deficiency states. These findings areconfirmed by the classification of corresponding autoantibodies found inthe AIRE-deficient mice described by Kärner et al., in Clin. Exp.Immunol. (2012); doi: 10.1111/cei.12024, the disclosure content of whichis incorporated herein by reference. Accordingly, in a preferredembodiment of the present invention, the antibodies of the presentinvention are of the IgG type, even more preferred IgG3 or IgG1.

IgG Structure:

Light chains are classified as either kappa or lambda (κ, λ). Each heavychain class may be bound with either a kappa or lambda light chain. Ingeneral, the light and heavy chains are covalently bonded to each other,and the “tail” portions of the two heavy chains are bonded to each otherby covalent disulfide linkages or non-covalent linkages when theimmunoglobulins are generated either by hybridomas, B cells orgenetically engineered host cells. In the heavy chain, the amino acidsequences run from an N-terminus at the forked ends of the Yconfiguration to the C-terminus at the bottom of each chain.

Both the light and heavy chains are divided into regions of structuraland functional homology. The terms “constant” and “variable” are usedfunctionally. In this regard, it will be appreciated that the variabledomains of both the light (V_(L)) and heavy (V_(H)) chain portionsdetermine antigen recognition and specificity. Conversely, the constantdomains of the light chain (CL) and the heavy chain (CH1, CH2 or CH3)confer important biological properties such as secretion, transplacentalmobility, Fc receptor binding, complement binding, and the like. Byconvention the numbering of the constant region domains increases asthey become more distal from the antigen-binding site or amino-terminusof the antibody. The N-terminal portion is a variable region and at theC-terminal portion is a constant region; the CH3 and CL domains actuallycomprise the carboxy-terminus of the heavy and light chain,respectively.

As indicated above, the variable region allows the antibody toselectively recognize and specifically bind epitopes on antigens. Thatis, the V_(L) domain and V_(H) domain, or subset of the complementaritydetermining regions (CDRs), of an antibody combine to form the variableregion that defines a three dimensional antigen-binding site. Thisquaternary antibody structure forms the antigen-binding site present atthe end of each arm of the Y. More specifically, the antigen-bindingsite is defined by three CDRs on each of the V_(H) and V_(L) chains. Anyantibody or immunoglobulin fragment which contains sufficient structureto specifically bind to a molecule of interest of the present inventionis denoted herein interchangeably as a “binding fragment” or an“immunospecific fragment.”

In naturally occurring antibodies, an antibody comprises sixhypervariable regions, sometimes called “complementarity determiningregions” or “CDRs” present in each antigen-binding domain, which areshort, non-contiguous sequences of amino acids that are specificallypositioned to form the antigen-binding domain as the antibody assumesits three dimensional configuration in an aqueous environment. The“CDRs” are flanked by four relatively conserved “framework” regions or“FRs” which show less inter-molecular variability. The framework regionslargely adopt a β-sheet conformation and the CDRs form loops whichconnect, and in some cases form part of, the β-sheet structure. Thus,framework regions act to form a scaffold that provides for positioningthe CDRs in correct orientation by inter-chain, non-covalentinteractions. The antigen-binding domain formed by the positioned CDRsdefines a surface complementary to the epitope on the immunoreactiveantigen. This complementary surface promotes the non-covalent binding ofthe antibody to its cognate epitope. The amino acids comprising the CDRsand the framework regions, respectively, can be readily identified forany given heavy or light chain variable region by one of ordinary skillin the art, since they have been precisely defined; see, “Sequences ofProteins of Immunological Interest,” Kabat, E., et al., U.S. Departmentof Health and Human Services, (1983); and Chothia and Lesk, J. Mol.Biol. 196 (1987), 901-917, which are incorporated herein by reference intheir entireties.

In the case where there are two or more definitions of a term which isused and/or accepted within the art, the definition of the term as usedherein is intended to include all such meanings unless explicitly statedto the contrary. A specific example is the use of the term“complementarity determining region” (“CDR”) to describe thenon-contiguous antigen combining sites found within the variable regionof both heavy and light chain polypeptides. This particular region hasbeen described by Kabat et al., U.S. Dept. of Health and Human Services,“Sequences of Proteins of Immunological Interest” (1983) and by Chothiaand Lesk, J. Mol. Biol. 196 (1987), 901-917, which are incorporatedherein by reference, where the definitions include overlapping orsubsets of amino acid residues when compared against each other.Nevertheless, application of either definition to refer to a CDR of anantibody or variants thereof is intended to be within the scope of theterm as defined and used herein. The appropriate amino acid residueswhich encompass the CDRs as defined by each of the above citedreferences are set forth below in Table 2 as a comparison. The exactresidue numbers which encompass a particular CDR will vary depending onthe sequence and size of the CDR. Those skilled in the art can routinelydetermine which residues comprise a particular hypervariable region orCDR of the human IgG subtype of antibody given the variable region aminoacid sequence of the antibody.

TABLE 2 CDR Definitions¹ Kabat Chothia VH CDR1 31-35 26-32 VH CDR2 50-6552-58 VH CDR3  95-102  95-102 VL CDR1 24-34 26-32 VL CDR2 50-56 50-52 VLCDR3 89-97 91-96 ¹Numbering of all CDR definitions in Table 2 isaccording to the numbering conventions set forth by Kabat et al. (seebelow).

Kabat et al. also defined a numbering system for variable domainsequences that is applicable to any antibody. One of ordinary skill inthe art can unambiguously assign this system of “Kabat numbering” to anyvariable domain sequence, without reliance on any experimental databeyond the sequence itself. As used herein, “Kabat numbering” refers tothe numbering system set forth by Kabat et al., U.S. Dept. of Health andHuman Services, “Sequence of Proteins of Immunological Interest” (1983).Unless otherwise specified, references to the numbering of specificamino acid residue positions in an antibody or antigen-binding fragment,variant, or derivative thereof of the present invention are according tothe Kabat numbering system, which however is theoretical and may notequally apply to every antibody of the present invention. For example,depending on the position of the first CDR the following CDRs might beshifted in either direction.

In one embodiment, the antibody of the present invention is not IgM or aderivative thereof with a pentavalent structure. Particular, in specificapplications of the present invention, especially therapeutic use, IgMsare less useful than IgG and other bivalent antibodies or correspondingbinding molecules since IgMs due to their pentavalent structure and lackof affinity maturation often show unspecific cross-reactivities and verylow affinity.

In a particularly preferred embodiment, the antibody of the presentinvention is not a polyclonal antibody, i.e. it substantially consistsof one particular antibody species rather than being a mixture obtainedfrom a plasma immunoglobulin sample.

Antibody Fragments, Animalization:

Antibody fragments, including single-chain antibodies, may comprise thevariable region(s) alone or in combination with the entirety or aportion of the following: hinge region, CH1, CH2, and CH3 domains. Alsoincluded in the invention are fragments binding to a molecule ofinterest of the present invention, said fragments comprising anycombination of variable region(s) with a hinge region, CH1, CH2, and CH3domains. Antibodies or immunospecific fragments thereof of the presentinvention equivalent to the monoclonal antibodies isolated in accordancewith the method of the present invention, in particular to the humanmonoclonal antibodies may be from any animal origin including birds andmammals. Preferably, the antibodies are human, murine, donkey, rabbit,goat, guinea pig, camel, llama, horse, or chicken antibodies. In anotherembodiment, the variable region may be condricthoid in origin (e.g.,from sharks).

In a particularly preferred embodiment of the present invention, theantibodies are naturally occurring human monoclonal antibodies orbinding fragments, derivatives and variants thereof cloned from humansubjects, which bind specifically to specific IL-32 isotypes of thepresent invention, preferably to IL-32γ, as defined in detail above andbelow, e.g., in Table 1, the Figures, in particular FIGS. 1 to 4 and inthe Examples, e.g., in Examples 2 and 6.

Optionally, the framework region of the human antibody is aligned andadopted in accordance with the pertinent human germ line variable regionsequences in the database; see, e.g., Vbase(http://vbase.mrc-cpe.cam.ac.uk/) hosted by the MRC Centre for ProteinEngineering (Cambridge, UK). For example, amino acids considered topotentially deviate from the true germ line sequence could be due to thePCR primer sequences incorporated during the cloning process. Comparedto artificially generated human-like antibodies such as single chainantibody fragments (scFvs) from a phage displayed antibody library orxenogeneic mice the human monoclonal antibody of the present inventionis characterized by (i) being obtained using the human immune responserather than that of animal surrogates, i.e. the antibody has beengenerated in response to natural IL-32 isotypes in their relevantconformation in the human body, (ii) having protected the individualfrom or minimized at least significant the presence of symptoms of adisease, e.g., SLE, and (iii) since the antibody is of human origin therisks of cross-reactivity against self-antigens is minimized. Thus, inaccordance with the present invention the terms “human monoclonalantibody”, “human monoclonal autoantibody”, “human antibody” and thelike are used to denote a IL-32 binding molecule of a particular IL-32isotype specificity which is of human origin, i.e. which has beenisolated from a human cell such as a B cell or hybridoma thereof or thecDNA of which has been directly cloned from mRNA of a human cell, forexample a human memory B cell. A human antibody is still considered as“human” even if amino acid substitutions are made in the antibody, e.g.,to improve its binding characteristics.

Antibodies derived from human immunoglobulin libraries or from animalstransgenic for one or more human immunoglobulins and that do not expressendogenous immunoglobulins, as described infra and, for example in, U.S.Pat. No. 5,939,598 by Kucherlapati et al., are denoted human-likeantibodies in order distinguish them from truly human antibodies of thepresent invention.

For example, the paring of heavy and light chains of human-likeantibodies such as synthetic and semi-synthetic antibodies typicallyisolated from phage display do not necessarily reflect the originalparing as it occurred in the original human B cell. Accordingly Fab andscFv fragments obtained from recombinant expression libraries ascommonly used in the prior art can be considered as being artificialwith all possible associated effects on immunogenicity and stability.

In contrast, the present invention provides isolated affinity-maturedantibodies from selected human subjects, which are characterized bytheir therapeutic utility.

Grafted Antibodies (Equivalents)

The invention also relates to grafted antibodies (interchangeablyreferred to as equivalents) containing CDRs derived from the antibodiesof the present invention, such as IL-32 antibodies, respectively. Suchgrafted CDRs include animalized antibodies, in which CDRs from theantibodies of the present invention have been grafted or in which a CDRcontaining one or more amino acid substitutions is grafted. The CDRs canbe grafted directly into a human framework or an antibody framework fromanimal origin as indicated above. If desired, framework changes can alsobe incorporated by generating framework libraries. The optimization ofCDRs and/or framework sequences can be performed independently andsequentially combined or can be performed simultaneously, as describedin more detail below.

To generate grafted antibodies donor CDRs of the antibodies of thepresent invention are grafted onto an antibody acceptor variable regionframework. Methods for grafting antibodies and generating CDR variantsto optimize activity have been described previously (see, e.g.,international patent applications WO 98/33919; WO 00/78815; WO01/27160). The procedure can be performed to achieve grafting of donorCDRs and affinity reacquisition in a simultaneous process. The methodssimilarly can be used, either alone or in combination with CDR grafting,to modify or optimize the binding affinity of a variable region. Themethods for conferring donor CDR binding affinity onto an acceptorvariable region are applicable to both heavy and light chain variableregions and as such can be used to simultaneously graft and optimize thebinding affinity of an antibody variable region.

The donor CDRs can be altered to contain a plurality of different aminoacid residue changes at all or selected positions within the donor CDRs.For example, random or biased incorporation of the twenty naturallyoccurring amino acid residues, or preselected subsets, can be introducedinto the donor CDRs to produce a diverse population of CDR species.Inclusion of CDR variant species into the diverse population of variableregions allows for the generation of variant species that exhibitoptimized binding affinity for a predetermined antigen. A range ofpossible changes can be made in the donor CDR positions. Some or all ofthe possible changes that can be selected for change can be introducedinto the population of grafted donor CDRs. A single position in a CDRcan be selected to introduce changes or a variety of positions havingaltered amino acids can be combined and screened for activity.

One approach is to change all amino acid positions along a CDR byreplacement at each position with, for example, all twenty naturallyoccurring amino acids. The replacement of each position can occur in thecontext of other donor CDR amino acid positions so that a significantportion of the CDR maintains the authentic donor CDR sequence, andtherefore, the binding affinity of the donor CDR. For example, anacceptor variable region framework, either a native or alteredframework, can be grafted with a population of CDRs containing singleposition replacements at each position within the CDRs. Similarly, anacceptor variable region framework can be targeted for grafting with apopulation of CDRs containing more than one position changed toincorporate all twenty amino acid residues, or a subset of amino acids.One or more amino acid positions within a CDR, or within a group of CDRsto be grafted, can be altered and grafted into an acceptor variableregion framework to generate a population of grafted antibodies. It isunderstood that a CDR having one or more altered positions can becombined with one or more other CDRs having one or more alteredpositions, if desired.

A population of CDR variant species having one or more altered positionscan be combined with any or all of the CDRs which constitute the bindingpocket of a variable region. Therefore, an acceptor variable regionframework can be targeted for the simultaneous incorporation of donorCDR variant populations at one, two or all three recipient CDR locationsin a heavy or light chain. The choice of which CDR or the number of CDRsto target with amino acid position changes will depend on, for example,if a full CDR grafting into an acceptor is desired or whether the methodis being performed for optimization of binding affinity.

Another approach for selecting donor CDR amino acids to change forconferring donor CDR binding affinity onto an antibody acceptor variableregion framework is to select known or readily identifiable CDRpositions that are highly variable. For example, the variable regionCDR3 is generally highly variable. This region therefore can beselectively targeted for amino acid position changes during graftingprocedures to ensure binding affinity reacquisition or augmentation,either alone or together with relevant acceptor variable frameworkchanges.

Murinized Antibodies:

An example of antibodies generated by grafting, as described above, aremurinized antibodies. As used herein, the term “murinized antibody” or“murinized immunoglobulin” refers to an antibody comprising one or moreCDRs from a human antibody of the present invention; and a humanframework region that contains amino acid substitutions and/or deletionsand/or insertions that are based on a mouse antibody sequence. The humanimmunoglobulin providing the CDRs is called the “parent” or “acceptor”and the mouse antibody providing the framework changes is called the“donor”. Constant regions need not be present, but if they are, they areusually substantially identical to mouse antibody constant regions, i.e.at least about 85-90%, preferably about 95% or more identical. Hence, insome embodiments, a full-length murinized human heavy or light chainimmunoglobulin contains a mouse constant region, human CDRs, and asubstantially human framework that has a number of “murinizing” aminoacid substitutions. Typically, a “murinized antibody” is an antibodycomprising a murinized variable light chain and/or a murinized variableheavy chain. For example, a murinized antibody would not encompass atypical chimeric antibody, e.g., because the entire variable region of achimeric antibody is non-mouse. A modified antibody that has been“murinized” by the process of “murinization” binds to the same antigenas the parent antibody that provides the CDRs and is usually lessimmunogenic in mice, as compared to the parent antibody.

Antibody Fragments:

As used herein, the term “heavy chain portion” includes amino acidsequences derived from an immunoglobulin heavy chain. A polypeptidecomprising a heavy chain portion comprises at least one of: a CH1domain, a hinge (e.g., upper, middle, and/or lower hinge region) domain,a CH2 domain, a CH3 domain, or a variant or fragment thereof. Forexample, a binding polypeptide for use in the invention may comprise apolypeptide chain comprising a CH1 domain; a polypeptide chaincomprising a CH1 domain, at least a portion of a hinge domain, and a CH2domain; a polypeptide chain comprising a CH1 domain and a CH3 domain; apolypeptide chain comprising a CH1 domain, at least a portion of a hingedomain, and a CH3 domain, or a polypeptide chain comprising a CH1domain, at least a portion of a hinge domain, a CH2 domain, and a CH3domain. In another embodiment, a polypeptide of the invention comprisesa polypeptide chain comprising a CH3 domain. Further, a bindingpolypeptide for use in the invention may lack at least a portion of aCH2 domain (e.g., all or part of a CH2 domain). As set forth above, itwill be understood by one of ordinary skill in the art that thesedomains (e.g., the heavy chain portions) may be modified such that theyvary in amino acid sequence from the naturally occurring immunoglobulinmolecule.

In certain antibodies, or antigen-binding fragments, variants, orderivatives thereof disclosed herein, the heavy chain portions of onepolypeptide chain of a multimere are identical to those on a secondpolypeptide chain of the multimere. Alternatively, heavy chainportion-containing monomers of the invention are not identical. Forexample, each monomer may comprise a different target binding site,forming, for example, a bispecific antibody or diabody.

In another embodiment, the antibodies, or antigen-binding fragments,variants, or derivatives thereof disclosed herein are composed of asingle polypeptide chain such as scFvs and are to be expressedintracellularly (intrabodies) for potential in vivo therapeutic anddiagnostic applications.

The heavy chain portions of a binding polypeptide for use in thediagnostic and treatment methods disclosed herein may be derived fromdifferent immunoglobulin molecules. For example, a heavy chain portionof a polypeptide may comprise a CH1 domain derived from an IgG1 moleculeand a hinge region derived from an IgG3 molecule. In another example, aheavy chain portion can comprise a hinge region derived, in part, froman IgG1 molecule and, in part, from an IgG3 molecule. In anotherexample, a heavy chain portion can comprise a chimeric hinge derived, inpart, from an IgG1 molecule and, in part, from an IgG4 molecule.

Thus, as also exemplified in the Examples, in one embodiment theconstant region of the antibody of the present invention or partthereof, in particular the CH2 and/or CH3 domain but optionally also theCH1 domain is heterologous to the variable region of the native humanmonoclonal antibody isolated in accordance with the method of thepresent invention. In this context, the heterologous constant region(s)are preferably of human origin in case of therapeutic applications ofthe antibody of the present invention but could also be of for examplerodent origin in case of animal studies; see also the Examples.

As used herein, the term “light chain portion” includes amino acidsequences derived from an immunoglobulin light chain. Preferably, thelight chain portion comprises at least one of a V_(L) or C_(L) domain.

As previously indicated, the subunit structures and three dimensionalconfiguration of the constant regions of the various immunoglobulinclasses are well known. As used herein, the term “V_(H) domain” includesthe amino terminal variable domain of an immunoglobulin heavy chain andthe term “CH1 domain” includes the first (most amino terminal) constantregion domain of an immunoglobulin heavy chain. The CH1 domain isadjacent to the V_(H) domain and is amino terminal to the hinge regionof an immunoglobulin heavy chain molecule.

As used herein the term “CH2 domain” includes the portion of a heavychain molecule that extends, e.g., from about residue 244 to residue 360of an antibody using conventional numbering schemes (residues 244 to360, Kabat numbering system; and residues 231-340, EU numbering system;see Kabat E A et al. op. cit). The CH2 domain is unique in that it isnot closely paired with another domain. Rather, two N-linked branchedcarbohydrate chains are interposed between the two CH2 domains of anintact native IgG molecule. It is also well documented that the CH3domain extends from the CH2 domain to the C-terminal of the IgG moleculeand comprises approximately 108 residues.

As used herein, the term “hinge region” includes the portion of a heavychain molecule that joins the CH1 domain to the CH2 domain. This hingeregion comprises approximately 25 residues and is flexible, thusallowing the two N-terminal antigen-binding regions to moveindependently. Hinge regions can be subdivided into three distinctdomains: upper, middle, and lower hinge domains; see Roux et al., J.Immunol. 161 (1998), 4083.

As used herein the term “disulfide bond” includes the covalent bondformed between two sulfur atoms. The amino acid cysteine comprises athiol group that can form a disulfide bond or bridge with a second thiolgroup. In most naturally occurring IgG molecules, the CH1 and C_(L)regions are linked by a disulfide bond and the two heavy chains arelinked by two disulfide bonds at positions corresponding to 239 and 242using the Kabat numbering system (position 226 or 229, EU numberingsystem).

As used herein, the terms “linked”, “fused” or “fusion” are usedinterchangeably. These terms refer to the joining together of two moreelements or components, by whatever means including chemical conjugationor recombinant means. An “in-frame fusion” refers to the joining of twoor more polynucleotide open reading frames (ORFs) to form a continuouslonger ORF, in a manner that maintains the correct translational readingframe of the original ORFs. Thus, a recombinant fusion protein is asingle protein containing two or more segments that correspond topolypeptides encoded by the original ORFs (which segments are notnormally so joined in nature). Although the reading frame is thus madecontinuous throughout the fused segments, the segments may be physicallyor spatially separated by, for example, in-frame linker sequence. Forexample, polynucleotides encoding the CDRs of an immunoglobulin variableregion may be fused, in-frame, but be separated by a polynucleotideencoding at least one immunoglobulin framework region or additional CDRregions, as long as the “fused” CDRs are co-translated as part of acontinuous polypeptide. Accordingly, in one embodiment thepolynucleotide is a cDNA encoding the variable region and at least partof the constant domain. In one embodiment, the polynucleotide is a cDNAencoding the variable region and the constant domain of an antibody ofthe present invention as defined herein.

Epitopes:

The minimum size of a peptide or polypeptide epitope for an antibody isthought to be about four to five amino acids. Peptide or polypeptideepitopes preferably contain at least seven, more preferably at leastnine and most preferably between at least about 15 to about 30 aminoacids. Since a CDR can recognize an antigenic peptide or polypeptide inits tertiary form, the amino acids comprising an epitope need not becontiguous, and in some cases, may not even be on the same peptidechain. In the present invention, a peptide or polypeptide epitoperecognized by antibodies of the present invention contains a sequence ofat least 4, at least 5, at least 6, at least 7, more preferably at least8, at least 9, at least 10, at least 15, at least 20, at least 25,between about 15 to about 30 or between about 30 to about 50 contiguousor non-contiguous amino acids of a molecule of interest of the presentinvention, i.e. at least one IL-32 isotype, or the homologous sequencesof the other IL-32 isotypes, in case the antibody recognizes more thanone isotype.

Binding Characteristics:

By “binding” or “recognizing”, used interchangeably herein, it isgenerally meant that a binding molecule, e.g., an antibody binds to apredetermined epitope via its antigen-binding domain, and that thebinding entails some complementarity between the antigen-binding domainand the epitope. According to this definition, an antibody is said to“specifically bind” to an epitope when it binds to that epitope, via itsantigen-binding domain more readily than it would bind to a random,unrelated epitope. The term “specificity” is used herein to qualify therelative affinity by which a certain antibody binds to a certainepitope. For example, antibody “A” may be deemed to have a higherspecificity for a given epitope than antibody “B,” or antibody “A” maybe said to bind to epitope “C” with a higher specificity than it has forrelated epitope “D”. Unrelated epitopes are usually part of anonspecific antigen (e.g., BSA, casein, or any other specifiedpolypeptide), which may be used for the estimation of the bindingspecificity of a given binding molecule. In this respect, term “specificbinding” refers to antibody binding to a predetermined antigen with aK_(D) that is at least twofold less than its K_(D) for binding to anonspecific antigen. The term “highly specific” binding as used hereinmeans that the relative K_(D) of the antibody for the specific targetepitope is at least 10-fold less than the K_(D) for binding thatantibody to other ligands.

Where present, the term “immunological binding characteristics,” orother binding characteristics of an antibody with an antigen, in all ofits grammatical forms, refers to the specificity, affinity,cross-reactivity, and other binding characteristics of an antibody.

By “preferentially binding”, it is meant that the binding molecule,e.g., antibody specifically binds to an epitope more readily than itwould bind to a related, similar, homologous, or analogous epitope.Thus, an antibody which “preferentially binds” to a given epitope wouldmore likely bind to that epitope than to a related epitope, even thoughsuch an antibody may cross-react with the related epitope. In respect ofparticular antigens, such as specific IL-32 isotypes the term“preferentially binding” means that the binding molecule, e.g., antibodyspecifically binds to an IL-32 isotype more readily than it would bindto a related, similar, homologous, or analogous IL-32 isotypes.

By way of non-limiting example, a binding molecule, e.g., an antibodymay be considered to bind a first epitope preferentially if it bindssaid first epitope with dissociation constant (K_(D)) that is less thanthe antibody's K_(D) for the second epitope. In another non-limitingexample, an antibody may be considered to bind a first antigenpreferentially if it binds the first epitope with an affinity that is atleast one order of magnitude less than the antibody's K_(D) for thesecond epitope. In another non-limiting example, an antibody may beconsidered to bind a first epitope preferentially if it binds the firstepitope with an affinity that is at least two orders of magnitude lessthan the antibody's K_(D) for the second epitope.

In another non-limiting example, a binding molecule, e.g., an antibodymay be considered to bind a first epitope preferentially if it binds thefirst epitope with an off rate (k(off)) that is less than the antibody'sk(off) for the second epitope. In another non-limiting example, anantibody may be considered to bind a first epitope preferentially if itbinds the first epitope with an affinity that is at least one order ofmagnitude less than the antibody's k(off) for the second epitope. Inanother non-limiting example, an antibody may be considered to bind afirst epitope preferentially if it binds the first epitope with anaffinity that is at least two orders of magnitude less than theantibody's k(off) for the second epitope.

A binding molecule, e.g., an antibody or antigen-binding fragment,variant, or derivative disclosed herein may be said to bind a moleculeof interest of the present invention, a fragment or variant thereof withan off rate (k(off)) of less than or equal to 5×10⁻² sec⁻¹, 10⁻² sec⁻¹,5×10⁻³ sec⁻¹ or 10⁻³ sec⁻¹. More preferably, an antibody of theinvention may be said to bind a molecule of interest of the presentinvention or a fragment or variant thereof with an off rate (k(off))less than or equal to 5×10⁻⁴ sec⁻¹, 10⁻⁴ sec⁻¹, 5×10⁻⁵ sec⁻¹, or 10⁻⁵sec⁻¹ 5×10⁻⁶ sec⁻¹, 10⁻⁶ sec⁻¹, 5×10⁻⁷ sec⁻¹ or 10⁻⁷ sec⁻¹.

A binding molecule, e.g., an antibody or antigen-binding fragment,variant, or derivative disclosed herein may be said to bind a moleculeof interest of the present invention or a fragment or variant thereofwith an on rate (k(on)) of greater than or equal to 10³ M⁻¹ sec⁻¹, 5×10³M⁻¹ sec⁻¹, 10⁴ M⁻¹ sec⁻¹ or 5×10⁴ M⁻¹ sec⁻¹. More preferably, anantibody of the invention may be said to bind a molecule of interest ofthe present invention or a fragment or variant thereof with an on rate(k(on)) greater than or equal to 10⁵ M⁻¹ sec⁻¹, 5×10⁵ M⁻¹ sec⁻¹, 10⁶ M⁻¹sec⁻¹, or 5×10⁶ M⁻¹ sec⁻¹ or 10⁷ M⁻¹ sec⁻¹.

A binding molecule, e.g., an antibody is said to competitively inhibitbinding of a reference antibody to a given epitope if it preferentiallybinds to that epitope to the extent that it blocks, to some degree,binding of the reference antibody to the epitope. Competitive inhibitionmay be determined by any method known in the art, for example,competition ELISA assays. An antibody may be said to competitivelyinhibit binding of the reference antibody to a given epitope by at least90%, at least 80%, at least 70%, at least 60%, or at least 50%.

As used herein, the term “affinity” refers to a measure of the strengthof the binding of an individual epitope with the CDR of a bindingmolecule, e.g., an immunoglobulin molecule; see, e.g., Harlow et al.,Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press,2nd ed. (1988) at pages 27-28. As used herein, the term “avidity” refersto the overall stability of the complex between a population ofimmunoglobulins and an antigen, that is, the functional combiningstrength of an immunoglobulin mixture with the antigen; see, e.g.,Harlow at pages 29-34. Avidity is related to both the affinity ofindividual immunoglobulin molecules in the population with specificepitopes, and also the valencies of the immunoglobulins and the antigen.For example, the interaction between a bivalent monoclonal antibody andan antigen with a highly repeating epitope structure, such as a polymer,would be one of high avidity. The affinity or avidity of an antibody foran antigen can be determined experimentally using any suitable method;see, for example, Berzofsky et al., “Antibody-Antigen Interactions” InFundamental Immunology, Paul, W. E., Ed., Raven Press New York, N Y(1984), Kuby, Janis Immunology, W. H. Freeman and Company New York, N Y(1992), and methods described therein. General techniques for measuringthe affinity of an antibody for an antigen include ELISA, RIA, andsurface plasmon resonance. The measured affinity of a particularantibody-antigen interaction can vary if measured under differentconditions, e.g., salt concentration, pH. Thus, measurements of affinityand other antigen-binding parameters, e.g., K_(D), IC₅₀, are preferablymade with standardized solutions of antibody and antigen, and astandardized buffer.

Binding molecules, e.g., antibodies or antigen-binding fragments,variants or derivatives thereof of the invention may also be describedor specified in terms of their cross-reactivity. As used herein, theterm “cross-reactivity” refers to the ability of an antibody, specificfor one antigen, to react with a second antigen; a measure ofrelatedness between two different antigenic substances. Thus, anantibody is cross reactive if it binds to an epitope other than the onethat induced its formation. The cross reactive epitope generallycontains many of the same complementary structural features as theinducing epitope, and in some cases, may actually fit better than theoriginal.

For example, certain antibodies have some degree of cross-reactivity, inthat they bind related, but non-identical epitopes, e.g., epitopes withat least 95%, at least 90%, at least 85%, at least 80%, at least 75%, atleast 70%, at least 65%, at least 60%, at least 55%, and at least 50%identity (as calculated using methods known in the art and describedherein) to a reference epitope. An antibody may be said to have littleor no cross-reactivity if it does not bind epitopes with less than 95%,less than 90%, less than 85%, less than 80%, less than 75%, less than70%, less than 65%, less than 60%, less than 55%, and less than 50%identity (as calculated using methods known in the art and describedherein) to a reference epitope. An antibody may be deemed “highlyspecific” for a certain epitope, if it does not bind any other analog,ortholog, or homolog of that epitope.

Binding molecules, e.g., antibodies or antigen-binding fragments,variants or derivatives thereof of the invention may also be describedor specified in terms of their binding affinity to a molecule ofinterest of the present invention. Preferred binding affinities includethose with a dissociation constant or K_(D) less than 5×10⁻²M, 10⁻²M,5×10⁻³M, 10⁻³M, 5×10⁻⁴M, 10⁻⁴ M, 5×10⁻⁵M, 10⁻⁵M, 5×10⁻⁶M, 10⁻⁶M,5×10⁻⁷M, 10⁻⁷M, 5×10⁻⁸M, 10⁻⁸M, 5×10⁻⁹M, 10⁻⁹M, 5×10⁻¹⁰ M, 10⁻¹⁰ M,5×10⁻¹¹ M, 10⁻¹¹ M, 5×10⁻¹² M, 10⁻¹² M, 5×10⁻¹³ M, 10⁻¹³ M, 5×10⁻¹⁴M,10⁻¹⁴ M, 5×10⁻¹⁵ M, or 10⁻¹⁵ M. Typically, the antibody binds with adissociation constant (K_(D)) of 10⁻⁷ M or less to its predeterminedantigen. Preferably, the antibody binds its cognate antigen with adissociation constant (K_(D)) of 10⁻⁹ M or less and still morepreferably with a dissociation constant (K_(D)) of 10⁻¹¹M or less.

Modifications of Antibodies:

The immunoglobulin or its encoding cDNAs may be further modified. Thus,in a further embodiment the method of the present invention comprisesany one of the step(s) of producing a chimeric antibody, humanizedantibody, single-chain antibody, Fab-fragment, bispecific antibody,fusion antibody, labeled antibody or an analog of any one of those.Corresponding methods are known to the person skilled in the art and aredescribed, e.g., in Harlow and Lane “Antibodies, A Laboratory Manual”,CSH Press, Cold Spring Harbor, 1988. When derivatives of said antibodiesare obtained by the phage display technique, surface plasmon resonanceas employed in the BIAcore system can be used to increase the efficiencyof phage antibodies which bind to the same epitope as that of any one ofthe antibodies provided by the present invention (Schier, HumanAntibodies Hybridomas 7 (1996), 97-105; Malmborg, J. Immunol. Methods183 (1995), 7-13). The production of chimeric antibodies is described,for example, in international application WO89/09622. Methods for theproduction of humanized antibodies are described in, e.g., Europeanapplication EP-A1 0 239 400 and international application WO90/07861.Further sources of antibodies to be utilized in accordance with thepresent invention are so-called xenogeneic antibodies. The generalprinciple for the production of xenogeneic antibodies such as humanantibodies in mice is described in, e.g., international applicationsWO91/10741, WO94/02602, WO96/34096 and WO 96/33735. As discussed above,the antibody of the invention may exist in a variety of forms besidescomplete antibodies; including, for example, Fv, Fab and F(ab)₂, as wellas in single chains; see e.g. international application WO88/09344.

The antibodies of the present invention or their correspondingimmunoglobulin chain(s) can be further modified using conventionaltechniques known in the art, for example, by using amino aciddeletion(s), insertion(s), substitution(s), addition(s), and/orrecombination(s) and/or any other modification(s) known in the arteither alone or in combination. Methods for introducing suchmodifications in the DNA sequence underlying the amino acid sequence ofan immunoglobulin chain are well known to the person skilled in the art;see, e.g., Sambrook, Molecular Cloning A Laboratory Manual, Cold SpringHarbor Laboratory (1989) N.Y. and Ausubel, Current Protocols inMolecular Biology, Green Publishing Associates and Wiley Interscience,N.Y. (1994). Modifications of the antibody of the invention includechemical and/or enzymatic derivatizations at one or more constituentamino acids, including side chain modifications, backbone modifications,and N- and C-terminal modifications including acetylation,hydroxylation, methylation, amidation, and the attachment ofcarbohydrate or lipid moieties, cofactors, and the like. Likewise, thepresent invention encompasses the production of chimeric proteins whichcomprise the described antibody or some fragment thereof at the aminoterminus fused to heterologous molecule such as a label or a drug.Antigen binding molecules generated this way may be used for druglocalization to cells expressing the appropriate surface structures ofthe diseased cell and tissue, respectively. This targeting and bindingto cells could be useful for the delivery of therapeutically ordiagnostically active agents and gene therapy/gene delivery.Molecules/particles with an antibody of the invention would bindspecifically to cells/tissues expressing the particular antigen ofinterest, and therefore could have diagnostic and therapeutic use.

Samples:

As used herein, the term “sample” or “biological sample” refers to anybiological material obtained from a subject or patient. In one aspect, asample can comprise blood, cerebrospinal fluid (“CSF”), or urine. Inother aspects, a sample can comprise whole blood, plasma, mononuclearcells enriched from peripheral blood (PBMC) such as lymphocytes (i.e.T-cells, NK-cell or B-cells), monocytes, macrophages, dendritic cellsand basophils; and cultured cells (e.g., B-cells from a subject). Asample can also include a biopsy or tissue sample including tumortissue. In still other aspects, a sample can comprise whole cells and/ora lysate of the cells. In one embodiment a sample comprises peripheralblood mononuclear cells (PBMC). Samples can be collected by methodsknown in the art.

Identification of Anti-IL-32 Antibodies, Isolation of Corresponding BCells and Recombinant Expression of Anti-IL-32 Antibodies:

Identification of B-cells specific for the anti-IL-32 antibodies of thepresent invention, as enlisted in Table 1, and as exemplary shown inrespect of the IL-32γ isotype and molecular cloning of antibodiesdisplaying specificity of interest as well as their recombinantexpression and functional characterization can be generally performed asdescribed in the international applications WO 2013/098419 A1 and WO2013/098420 A1; see Examples sections therein, in particular Examples 1and 2 on pages 118 to 120 of WO 2013/098419 A1 and Examples 1 to 4 onpages 27 to 31 of WO 2013/098420 A1, the disclosure content of which isincorporated herein by reference.

Briefly, in one embodiment of the present invention cultures of singleor oligoclonal B-cells were cultured and the supernatant of the culture,which contains antibodies produced by said B-cells was screened forpresence and affinity of antibodies specific for one or more of theIL-32 isotypes, as described in the Examples. In another embodiment,patient sera were first screened for the presence of autoantibodiesagainst IL-32 isotypes and then those with high titer were selected forperipheral blood mononuclear cells isolation; see Example 2 on pages118-120 of WO 2013/098419 A1, the disclosure content of which isincorporated herein by reference. The screening process comprisesscreening for binding on fragments, peptides or derivatives of IL-32isotypes. Subsequently, the antibody for which binding is detected orthe cell producing said antibody were isolated; see Example 3 on page120 of WO 2013/098419 A1, the disclosure content of which isincorporated herein by reference. Thus, a preliminary screen can be doneon a panel of candidate donors, using samples containing antibodysecreting cells (such as total peripheral blood or serum). Inparticular, mononuclear cells can be isolated from blood or lymphatictissues using standard separation techniques for isolating peripheralblood mononuclear cells (PBMCs), such as gradient centrifugation. Afterand/or before this separation step, the samples of sera (or plasma),cell culture supernatants, or cells (obtained from different patients,from different tissues, and/or at different time points) can beprescreened using standard technologies for detecting the presence ofantibodies and antibody-secreting cells (e.g. ELISA, BIACORE, Westernblot, FACS, SERPA, antigen arrays, neutralization of viral infection ina cell culture system, or ELISPOT assays). The literature providesseveral examples of these technologies showing, for example, the use ofELISPOT for characterizing the immune response in vaccinated donors(Crotty et al., Immunol Meth. 286 (2004), 111-122), the use of antigenmicroarrays as diagnostic tools for newly infected patients (Mezzasomaet al., Clin Chem. 48 (2002), 121-130, and other technologies formeasuring antigen-specific immune responses (Kern et al., TrendsImmunol. 26 (2005), 477-484).

After identification of candidate anti-IL-32 antibodies and B cellssecreting them, respectively, the nucleic acid sequence that encodes theantibody of interest is obtained, comprising the steps of preparing a Bcell and obtaining/sequencing nucleic acid from the B cell that encodesthe antibody of interest and further inserting the nucleic acid into orusing the nucleic acid to prepare an expression host that can expressthe antibody of interest, culturing or sub-culturing the expression hostunder conditions where the antibody of interest is expressed and,optionally, purifying the antibody of interest. It goes without sayingthat the nucleic acid may be manipulated in between to introducerestriction sites, to change codon usage, and/or to add or optimizetranscription and/or translation regulatory sequences. These techniquesare state of the art and can be performed by the person skilled in theart without undue burden. For example, the heavy chain constant regioncan be exchanged for that of a different isotype or eliminatedaltogether. The variable regions can be linked to encode single chain Fvregions. Multiple Fv regions can be linked to confer binding ability tomore than one target or chimeric heavy and light chain combinations canbe employed. Once the genetic material is available, design of analogsas described above which retain both their ability to bind the desiredtarget is straightforward. Methods for the cloning of antibody variableregions and generation of recombinant antibodies are known to the personskilled in the art and are described, for example, in Gilliland et al.,Tissue Antigens 47 (1996), 1-20; Doenecke et al., Leukemia 11 (1997),1787-1792. In a preferred embodiment of the present invention however, Bcells are obtained and the corresponding antibody is expressed by themethods described in international application WO 2013/098420 A1, inparticular in Example 3, on pages 28-30, the disclosure content of whichis incorporated herein by reference.

Diseases and Disorders:

Unless stated otherwise, the terms “disorder” and “disease” are usedinterchangeably herein. The term “autoimmune disorder” as used herein isa disease or disorder arising from and directed against an individual'sown tissues or organs or a co-segregate or manifestation thereof orresulting condition therefrom. Autoimmune diseases are primarily causedby dysregulation of adaptive immune responses and autoantibodies orautoreactive T cells against self-structures are formed. Nearly allautoimmune diseases have an inflammatory component, too.Autoinflammatory diseases are primarily inflammatory, and some classicautoinflammatory diseases are caused by genetic defects in innateinflammatory pathways. In autoinflammatory diseases, no autoreactive Tcells or autoantibodies are found. In many of these autoimmune andautoinflammatory disorders, a number of clinical and laboratory markersmay exist, including, but not limited to, hypergammaglobulinemia, highlevels of autoantibodies, antigen-antibody complex deposits in tissues,benefit from corticosteroid or immunosuppressive treatments, andlymphoid cell aggregates in affected tissues. Without being limited to atheory regarding B-cell mediated autoimmune disorder, it is believedthat B cells demonstrate a pathogenic effect in human autoimmunediseases through a multitude of mechanistic pathways, includingautoantibody production, immune complex formation, dendritic and T-cellactivation, cytokine synthesis, direct chemokine release, and providinga nidus for ectopic neo-lymphogenesis. Each of these pathways mayparticipate to different degrees in the pathology of autoimmunediseases.

As used herein, an “autoimmune disorder” can be an organ-specificdisease (i.e., the immune response is specifically directed against anorgan system such as the endocrine system, the hematopoietic system, theskin, the cardiopulmonary system, the gastrointestinal and liversystems, the renal system, the thyroid, the ears, the neuromuscularsystem, the central nervous system, etc.) or a systemic disease that canaffect multiple organ systems including but not limited to systemiclupus erythematosus (SLE), rheumatoid arthritis, polymyositis,autoimmune polyendocrinopathy syndrome type 1 (APS1)/autoimmunepolyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) etc.Preferred such diseases include but are not limited to multiplesclerosis (MS), various forms of autoimmune rheumatologic disordersincluding but not limited to rheumatoid arthritis, spondyloarthritis,psoriatic arthritis, Sjogren's syndrome, scleroderma, lupus, includingbut not limited to SLE and lupus nephritis,polymyositis/dermatomyositis, and psoriatic arthritis), autoimmunedermatologic disorders (including but not limited to psoriasis,pemphigus group diseases, bullous pemphigoid diseases, and cutaneouslupus erythematosus), and autoimmune endocrine disorders (including butnot limited to diabetic-related autoimmune diseases such as type 1 orinsulin dependent diabetes mellitus (T1DM or IDDM), autoimmune thyroiddisease (including but not limited to Graves' disease and thyroiditis))and diseases affecting the generation of autoimmunity including but notlimited to autoimmune polyendocrinopathy syndrome type 1(APS1)/autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy(APECED) myasthenia gravis (MG/Thymoma).

Preferred diseases include, for example, SLE, RA, spondyloarthritis,psoriatic arthritis, T1DM, MS, psoriasis, Sjogren's syndrome, Graves'disease, thyroiditis, and glomerulonephritis, and APS1. Still morepreferred are RA, SLE, and MS, and mostly preferred SLE.

Labels and Diagnostics:

Labeling agents can be coupled either directly or indirectly to theantibodies or antigens of the invention. One example of indirectcoupling is by use of a spacer moiety. Furthermore, the antibodies ofthe present invention can comprise a further domain, said domain beinglinked by covalent or non-covalent bonds. The linkage can be based ongenetic fusion according to the methods known in the art and describedabove or can be performed by, e.g., chemical cross-linking as describedin, e.g., international application WO94/04686. The additional domainpresent in the fusion protein comprising the antibody of the inventionmay preferably be linked by a flexible linker, advantageously apolypeptide linker, wherein said polypeptide linker comprises plural,hydrophilic, peptide-bonded amino acids of a length sufficient to spanthe distance between the C-terminal end of said further domain and theN-terminal end of the antibody of the invention or vice versa. Thetherapeutically or diagnostically active agent can be coupled to theantibody of the invention or an antigen-binding fragment thereof byvarious means. This includes, for example, single-chain fusion proteinscomprising the variable regions of the antibody of the invention coupledby covalent methods, such as peptide linkages, to the therapeutically ordiagnostically active agent. Further examples include molecules whichcomprise at least an antigen-binding fragment coupled to additionalmolecules covalently or non-covalently include those in the followingnon-limiting illustrative list. Traunecker, Int. J. Cancer Surp. SuDP 7(1992), 51-52, describe the bispecific reagent janusin in which the Fvregion directed to CD3 is coupled to soluble CD4 or to other ligandssuch as OVCA and IL-7. Similarly, the variable regions of the antibodyof the invention can be constructed into Fv molecules and coupled toalternative ligands such as those illustrated in the cited article.Higgins, J. Infect. Disease 166 (1992), 198-202, described ahetero-conjugate antibody composed of OKT3 cross-linked to an antibodydirected to a specific sequence in the V3 region of GP120. Suchhetero-conjugate antibodies can also be constructed using at least thevariable regions contained in the antibody of the invention methods.Additional examples of specific antibodies include those described byFanger, Cancer Treat. Res. 68 (1993), 181-194 and by Fanger, Crit. Rev.Immunol. 12 (1992), 101-124. Conjugates that are immunotoxins includingconventional antibodies have been widely described in the art. Thetoxins may be coupled to the antibodies by conventional couplingtechniques or immunotoxins containing protein toxin portions can beproduced as fusion proteins. The antibodies of the present invention canbe used in a corresponding way to obtain such immunotoxins. Illustrativeof such immunotoxins are those described by Byers, Seminars Cell. Biol.2 (1991), 59-70 and by Fanger, Immunol. Today 12 (1991), 51-54.

The above described fusion protein may further comprise a cleavablelinker or cleavage site for proteinases. These spacer moieties, in turn,can be either insoluble or soluble (Diener et al., Science 231 (1986),148) and can be selected to enable drug release from the antigen at thetarget site. Examples of therapeutic agents which can be coupled to theantibodies and antigens of the present invention for immunotherapy arechemokines, homing molecules, drugs, radioisotopes, lectins, and toxins.The drugs with which can be conjugated to the antibodies and antigens ofthe present invention depend on the disease context in which theconjugated molecules are intended to be used. For example, antibodiesspecific for targets useful in treatment of tumor diseases can beconjugated to compounds which are classically referred to asanti-neoplastic drugs such as mitomycin C, daunorubicin, andvinblastine. In using radioisotopically conjugated antibodies orantigens of the invention for, e.g., tumor immunotherapy, certainisotopes may be more preferable than others depending on such factors asleukocyte distribution as well as stability and emission. Depending onthe autoimmune response, some emitters may be preferable to others. Ingeneral, α and β particle emitting radioisotopes are preferred inimmunotherapy. Preferred are short range, high energy a emitters such as²¹²Bi. Examples of radioisotopes which can be bound to the antibodies orantigens of the invention for therapeutic purposes are ¹²⁵I, ¹³¹I, ⁹⁰Y,⁶⁷Cu, ²¹²Bi, ²¹²At, ²¹¹Pb, ⁴⁷Sc, ¹⁰⁹Pd and ¹⁸⁸Re. Other therapeuticagents which can be coupled to the antibody or antigen of the invention,as well as ex vivo and in vivo therapeutic protocols, are known, or canbe easily ascertained, by those of ordinary skill in the art.Non-limiting examples of suitable radionuclides for labeling are ¹⁹⁸Au,²¹² Bi, ¹¹C, ¹⁴C, ⁵⁷Co, ⁶⁷CH, ¹⁸F, ⁶⁷Ga, ⁶⁸Ga, ³H, ¹⁹⁷Hg, ¹⁶⁶Ho, ¹¹¹In,^(113m)In, ¹²³I, ¹²⁵I, ¹²⁷I, ¹³¹I, ¹¹¹In, ¹⁷⁷Lu, ¹⁵O, ¹³N, ³²P, ³³P,²⁰³Pb, ¹⁸⁶Re, ¹⁸⁸Re, ¹⁰⁵Rh, ⁹⁷Ru, ³⁵S, ¹⁵³Sm and ^(99m) Tc. Othermolecules suitable for labeling are a fluorescent or luminescent dye, amagnetic particle, a metal, and a molecule which may be detected througha secondary enzymatic or binding step such as an enzyme or peptide tag.Commercial fluorescent probes suitable for use as labels in the presentinvention are listed in the Handbook of Fluorescent Probes and ResearchProducts, 8th Edition, the disclosure contents of which are incorporatedherein by reference. Magnetic particles suitable for use in magneticparticle-based assays (MPAs) may be selected from paramagnetic,diamagnetic, ferromagnetic, ferromagnetic and superpara-magneticmaterials.

General methods in molecular and cellular biochemistry useful fordiagnostic purposes can be found in such standard textbooks as MolecularCloning: A Laboratory Manual, 3rd Ed. (Sambrook et al., HarborLaboratory Press 2001); Short Protocols in Molecular Biology, 4th Ed.(Ausubel et al. eds., John Wiley & Sons 1999); Protein Methods (Bollaget al., John Wiley & Sons 1996). Reagents, detection means and kits fordiagnostic purposes are available from commercial vendors such asPharmacia Diagnostics, Amersham, BioRad, Stratagene, Invitrogen, andSigma-Aldrich as well as from the sources given any one of thereferences cited herein, in particular patent literature.

Treatment and Drugs:

As used herein, the terms “treat” or “treatment” refer to boththerapeutic treatment and prophylactic or preventative measures, whereinthe object is to prevent or slow down (lessen) an undesiredphysiological change or disorder, such as the development of anautoimmune and/or autoinflammatory disease. Beneficial or desiredclinical results include, but are not limited to, alleviation ofsymptoms, diminishment of extent of disease, stabilized (i.e., notworsening) state of disease, delay or slowing of disease progression,amelioration or palliation of the disease state, and remission (whetherpartial or total), whether detectable or undetectable. “Treatment” canalso mean prolonging survival as compared to expected survival if notreceiving treatment. Those in need of treatment include those alreadywith the condition or disorder as well as those prone to have thecondition or disorder or those in which the manifestation of thecondition or disorder is to be prevented.

If not stated otherwise the term “drug,” “medicine,” or “medicament” areused interchangeably herein and shall include but are not limited to all(A) articles, medicines and preparations for internal or external use,and any substance or mixture of substances intended to be used fordiagnosis, cure, mitigation, treatment, or prevention of disease ofeither man or other animals; and (B) articles, medicines andpreparations (other than food) intended to affect the structure or anyfunction of the body of man or other animals; and (C) articles intendedfor use as a component of any article specified in clause (A) and (B).The term “drug,” “medicine,” or “medicament” shall include the completeformula of the preparation intended for use in either man or otheranimals containing one or more “agents,” “compounds”, “substances” or“(chemical) compositions” as and in some other context also otherpharmaceutically inactive excipients as fillers, disintegrants,lubricants, glidants, binders or ensuring easy transport,disintegration, disaggregation, dissolution and biological availabilityof the “drug,” “medicine,” or “medicament” at an intended targetlocation within the body of man or other animals, e.g., at the skin, inthe stomach or the intestine. The terms “agent,” “compound” or“substance” are used interchangeably herein and shall include, in a moreparticular context, but are not limited to all pharmacologically activeagents, i.e. agents that induce a desired biological or pharmacologicaleffect or are investigated or tested for the capability of inducing sucha possible pharmacological effect by the methods of the presentinvention.

Examples of “anti-rheumatic drugs” and immunosuppressive drugs includechloroquine, hydroxycloroquine, myocrisin, auranofin, sulfasalazine,methotrexate, leflunomide, etanercept, infliximab (plus oral andsubcutaneous methotrexate), adalimumab etc., azathioprine,D-penicilamine, gold salts (oral), gold salts (intramuscular),minocycline, cyclosporine including cyclosporine A and topicalcyclosporine, tacrolimus, mycophenolate mofetil, cyclophosphamide,staphylococcal protein A (Goodyear and Silverman, J. Exp. Med., 197(2003), 125-39), including salts and derivatives thereof, etc.

Examples of “non-steroidal anti-inflammatory drugs” or “NSAIDs” includeaspirin, acetylsalicylic acid, ibuprofen and ibuprofen retard,fenoprofen, piroxicam, flurbiprofen, naproxen, ketoprofen, naproxen,tenoxicam, benorylate, diclofenac, naproxen, nabumetone, indomethacin,ketoprofen, mefenamic acid, diclofenac, fenbufen, azapropazone,acemetacin, tiaprofenic acid, indomethacin, sulindac, tolmetin,phenylbutazone, diclofenac and diclofenac retard, cyclooxygenase (COX)-2inhibitors such as GR 253035, MK966, celecoxib (CELEBREX®;445-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl),benzenesulfonamide and valdecoxib (BEXTRA®), and meloxicam (MOBIC®),including salts and derivatives thereof, etc. Preferably, they areaspirin, naproxen, ibuprofen, indomethacin, or tolmetin. Such NSAIDs areoptionally used with an analgesic such as codenine, tramadol, and/ordihydrocodinine or narcotic such as morphine.

By “subject” or “individual” or “animal” or “patient” or “mammal,” ismeant any subject, particularly a mammalian subject, e.g., a humanpatient, for whom diagnosis, prognosis, prevention, or therapy isdesired.

Pharmaceutical Carriers:

Pharmaceutically acceptable carriers and administration routes can betaken from corresponding literature known to the person skilled in theart. The pharmaceutical compositions of the present invention can beformulated according to methods well known in the art; see for exampleRemington: The Science and Practice of Pharmacy (2000) by the Universityof Sciences in Philadelphia, ISBN 0-683-306472, Vaccine Protocols. 2ndEdition by Robinson et al., Humana Press, Totowa, N.J., USA, 2003;Banga, Therapeutic Peptides and Proteins: Formulation, Processing, andDelivery Systems. 2nd Edition by Taylor and Francis. (2006), ISBN:0-8493-1630-8. Examples of suitable pharmaceutical carriers are wellknown in the art and include phosphate buffered saline solutions, water,emulsions, such as oil/water emulsions, various types of wetting agents,sterile solutions etc. Compositions comprising such carriers can beformulated by well-known conventional methods. These pharmaceuticalcompositions can be administered to the subject at a suitable dose.Administration of the suitable compositions may be effected by differentways. Examples include administering a composition containing apharmaceutically acceptable carrier via oral, intranasal, rectal,topical, intraperitoneal, intravenous, intramuscular, subcutaneous,subdermal, transdermal, intrathecal, and intracranial methods. Aerosolformulations such as nasal spray formulations include purified aqueousor other solutions of the active agent with preservative agents andisotonic agents. Such formulations are preferably adjusted to a pH andisotonic state compatible with the nasal mucous membranes.Pharmaceutical compositions for oral administration, such as singledomain antibody molecules (e.g., “Nanobodies™”) etc are also envisagedin the present invention. Such oral formulations may be in tablet,capsule, powder, liquid or semi-solid form. A tablet may comprise asolid carrier, such as gelatin or an adjuvant. Formulations for rectalor vaginal administration may be presented as a suppository with asuitable carrier; see also O'Hagan et al., Nature Reviews, DrugDiscovery 2(9) (2003), 727-735. Further guidance regarding formulationsthat are suitable for various types of administration can be found inRemington's Pharmaceutical Sciences, Mace Publishing Company,Philadelphia, Pa., 17th ed. (1985) and corresponding updates. For abrief review of methods for drug delivery see Langer, Science 249(1990), 1527-1533.

Dosage Regimen:

The dosage regimen will be determined by the attending physician andclinical factors. As is well known in the medical arts, dosages for anyone patient depends upon many factors, including the patient's size,body surface area, age, the particular compound to be administered, sex,time and route of administration, general health, and other drugs beingadministered concurrently. A typical dose can be, for example, in therange of 0.001 to 1000 μg (or of nucleic acid for expression or forinhibition of expression in this range); however, doses below or abovethis exemplary range are envisioned, especially considering theaforementioned factors. Generally, the regimen as a regularadministration of the pharmaceutical composition should be in the rangeof 1 μg to 10 mg units per day. If the regimen is a continuous infusion,it should also be in the range of 1 μg to 10 mg units per kilogram ofbody weight per minute, respectively. Progress can be monitored byperiodic assessment. Preparations for parenteral administration includesterile aqueous or non-aqueous solutions, suspensions, and emulsions.Examples of non-aqueous solvents are propylene glycol, polyethyleneglycol, vegetable oils such as olive oil, and injectable organic esterssuch as ethyl oleate. Aqueous carriers include water, alcoholic/aqueoussolutions, emulsions or suspensions, including saline and bufferedmedia. Parenteral vehicles include sodium chloride solution, Ringer'sdextrose, dextrose and sodium chloride, lactated Ringer's, or fixedoils. Intravenous vehicles include fluid and nutrient replenishers,electrolyte replenishers (such as those based on Ringer's dextrose), andthe like. Preservatives and other additives may also be present such as,for example, antimicrobials, anti-oxidants, chelating agents, and inertgases and the like. Furthermore, the pharmaceutical composition of theinvention may comprise further agents such as anti-tumor agents andcytotoxic drugs, depending on the intended use of the pharmaceuticalcomposition.

In addition, co-administration or sequential administration of otheragents may be desirable. A therapeutically effective dose or amountrefers to that amount of the active ingredient sufficient to amelioratethe symptoms or condition. Therapeutic efficacy and toxicity of suchcompounds can be determined by standard pharmaceutical procedures incell cultures or experimental animals, e.g., ED50 (the dosetherapeutically effective in 50% of the population) and LD50 (the doselethal to 50% of the population). The dose ratio between therapeutic andtoxic effects is the therapeutic index, and it can be expressed as theratio, LD50/ED50.

Preferably, the therapeutic agent in the composition is present in anamount sufficient for preventing inflammation or suppression of theimmune response.

These and other embodiments are disclosed and encompassed by thedescription and examples of the present invention. Further literatureconcerning any one of the materials, methods, uses and compounds to beemployed in accordance with the present invention may be retrieved frompublic libraries and databases, using for example electronic devices.For example the public database “Medline” may be utilized, which ishosted by the National Center for Biotechnology Information and/or theNational Library of Medicine at the National Institutes of Health.Further databases and web addresses, such as those of the EuropeanBioinformatics Institute (EBI), which is part of the European MolecularBiology Laboratory (EMBL) are known to the person skilled in the art andcan also be obtained using internet search engines. An overview ofpatent information in biotechnology and a survey of relevant sources ofpatent information useful for retrospective searching and for currentawareness is given in Berks, TIBTECH 12 (1994), 352-364.

The above disclosure generally describes the present invention. Severaldocuments are cited throughout the text of this specification. Fullbibliographic citations may be found at the end of the specificationimmediately preceding the claims. The contents of all cited references(including literature references, issued patents, published patentapplications as cited throughout this application, including thedisclosure in the background section and manufacturer's specifications,instructions, etc.) are hereby expressly incorporated by reference;however, there is no admission that any document cited is indeed priorart as to the present invention.

A more complete understanding can be obtained by reference to thefollowing specific examples which are provided herein for purposes ofillustration only and are not intended to limit the scope of theinvention.

EXAMPLES

The Examples 1 to 6 which follow and corresponding FIGS. 1 to 12 furtherillustrate the invention, but should not be construed to limit the scopeof the invention in any way. Detailed descriptions of conventionalmethods, such as those employed herein can be found in the citedliterature; see also “The Merck Manual of Diagnosis and Therapy”Seventeenth Ed. ed. by Beers and Berkow (Merck & Co., Inc., 2003).

The practice of the present invention will employ, unless otherwiseindicated, conventional techniques of cell biology, cell culture,molecular biology, transgenic biology, microbiology, recombinant DNA,and immunology, which are within the skill of the art.

Methods in molecular genetics and genetic engineering are describedgenerally in the current editions of Molecular Cloning: A LaboratoryManual, (Sambrook et al., (1989) Molecular Cloning: A Laboratory Manual,2nd ed., Cold Spring Harbor Laboratory Press); DNA Cloning, Volumes Iand II (Glover ed., 1985); Oligonucleotide Synthesis (Gait ed., 1984);Nucleic Acid Hybridization (Hames and Higgins eds. 1984); TranscriptionAnd Translation (Hames and Higgins eds. 1984); Culture Of Animal Cells(Freshney and Alan, Liss, Inc., 1987); Gene Transfer Vectors forMammalian Cells (Miller and Calos, eds.); Current Protocols in MolecularBiology and Short Protocols in Molecular Biology, 3rd Edition (Ausubelet al., eds.); and Recombinant DNA Methodology (Wu, ed., AcademicPress). Gene Transfer Vectors For Mammalian Cells (Miller and Calos,eds., 1987, Cold Spring Harbor Laboratory); Methods In Enzymology, Vols.154 and 155 (Wu et al., eds.); Immobilized Cells And Enzymes (IRL Press,1986); Perbal, A Practical Guide To Molecular Cloning (1984); thetreatise, Methods In Enzymology (Academic Press, Inc., N.Y.);Immunochemical Methods In Cell And Molecular Biology (Mayer and Walker,eds., Academic Press, London, 1987); Handbook Of ExperimentalImmunology, Volumes I-IV (Weir and Blackwell, eds., 1986). Reagents,cloning vectors, and kits for genetic manipulation referred to in thisdisclosure are available from commercial vendors such as BioRad,Stratagene, Invitrogen, and Clontech. General techniques in cell cultureand media collection are outlined in Large Scale Mammalian Cell Culture(Hu et al., Curr. Opin. Biotechnol. 8 (1997), 148); Serum-free Media(Kitano, Biotechnology 17 (1991), 73); Large Scale Mammalian CellCulture (Curr. Opin. Biotechnol. 2 (1991), 375); and Suspension Cultureof Mammalian Cells (Birch et al., Bioprocess Technol. 19 (1990), 251.

Material and Methods

Patients selection, peripheral blood mononuclear cells (PBMC) isolationfrom APECED/APS1 Patients memory, B cell culture and antibody isolationwere carried out as described in the international applications WO2013/098419 A1 and WO 2013/098420 A1with the difference that specificityof the antibodies isolated and analyzed was directed towards IL-32isotypes as defined hereinabove and below instead of IL-17 and IL-22,which were specifically used in the mentioned PCT applications; seeExamples sections therein, in particular Examples 1 and 2 on pages 117to 120 and Example 17 on pages 168-171 of WO 2013/098419 A1 and Examples1 to 4 on pages 27 to 31 of WO 2013/098420 A1, the disclosure content ofwhich is incorporated herein by reference.

The molecular cloning of human antibodies of the present invention andsubsequent antibody production and purification were performed asdescribed in the international application WO 2013/098419 A1, see theExamples section of the application and in particular Examples 1 to 3 onpages 117-120 therein, the disclosure content of which is incorporatedherein by reference.

Mutation analysis of the AIRE gene was performed as described in theinternational application WO 2013/098419 A1; see the Examples therein,in particular the “Mutation analysis of the AIRE gene” section inMaterials and Methods of the Examples, on pages 115-116, the disclosurecontent of which is incorporated herein by reference, with particularsteps performed as described in WO99/15559. In this concern, genotypingof the respective mutations in the AIRE (APECED) gene is performed asdescribed in international application WO99/15559 in Example 2 at pages12 to 13; a confirmation of the mutations in exons 2 and 6 of the AIREgene as described in Example 3 of international application WO99/15559at page 13, line 5 bridging to page 14, line 13, the disclosure contentof which is incorporated herein by reference in its entirety. Inparticular, for the mutation analysis the DNA samples are purified fromperipheral blood mononuclear cells from patients with APECED and fromsuspected carriers of APECED and from normal healthy controls (accordingto Sambrook et al. 1989, Molecular Cloning. A Laboratory Manual. CSHPress) and subjected to PCR using primers specific for all identifiedexons.

Example 1 Detection of Human Cytokine Specific Antibodies in the Serumof Patients by ELISA

The general presence of various cytokine and disease specific antibodiesin the sera of the patients suffering from the genetic condition APECED(Autoimmune polyendocrinopathy candidiasis epidermal dysplasia, alsocalled Autoimmune polyendocrinopathy type 1 (APS1)) has been obtained byProtoarray analysis as described in Example 7 on page 128 and indicatedTables 1 and 2 on pages 128-130 of applicant's international applicationWO 2013/098419 A1, the disclosure content of which is incorporatedherein by reference. Furthermore, ELISA (Enzyme linked immunosorbentassay) was used for differential analysis of IL-32gamma vs. alphaanalysis in the sera of the patients suffering from the geneticcondition APECED (Autoimmune polyendocrinopathy candidiasis epidermaldysplasia, also called Autoimmune polyendocrinopathy type 1 (APS1).Altogether sera from 30 patients, presented by codes from APS1-1 toAPS1-30 were used in the assays (see FIG. 2).

ELISA—IL-32γ and IL-32α

96 well microplates (Costar, USA) were coated with human IL-32γ (R&D) orIL-32α (ImmunoTools). Plates were washed with PBS-T and blocked 1 h atroom temperature with PBS containing 2% BSA (Sigma, Buchs, Switzerland).Patient sera, B cell conditioned medium, or recombinant antibodypreparations were incubated for 2h at room temperature. Binding of humanIgG to the antigen of interest was determined using a horseradishperoxidase conjugated goat anti human Fc-gamma-specific antibody(Jackson ImmunoResearch, Europe Ltd., Cambridgeshire, UK) followed bymeasurement of the HRP activity using a TMB substrate solution (TMB,Sigma, Buchs, Switzerland).

Example 2 EC50 ELISA Determination of the Antibodies of the PresentInvention

EC50 binding of exemplary anti-IL-32 antibodies of the present inventionto IL-32γ (R&D) or IL-32α (ImmunoTools), was determined by ELISA. Serialdilutions of MABs (from 100,000 ng/ml down to 1.69 ng/ml) were incubatedfor 2 hours with antigen-coated plates (coating overnight at 1 μg/ml inPBS, followed by wash out and blocking with 2% BSA in PBS). The plateswere subsequently washed and binding of MABs was detected withanti-human HRP-conjugated Fc-gamma-specific secondary antibody (JacksonImmunoResearch, Europe Ltd., Cambridgeshire, UK). Concentrations of MABresulting in half of maximal binding to respective antigens (EC50,ng/ml) were calculated using Prism 4 GraphPad software on sigmoidaldose-response curves (variable slope, 4 parameters) obtained by plottingthe log of the concentration versus OD 450 nm measurements; for theresults see FIG. 3 and Table 4 below.

TABLE 3 Summary of EC50 values of binding of MABs to IL-32gamma andIL-32alpha MABs 14B3, 19A1, 26A6 did not bind to IL-32alpha at thehighest concentration tested (100 ug/ml). MAB 2C2 bound to IL-32alphaonly at very high concentrations indicating that EC50 binding is higherthan 30 μg/ml. EC50 (ng/ml) 14B3 19A1 26A6 2C2 IL-32gamma 604 460 1332526 IL-32alpha n.b. n.b. n.b. >30.000

Example 3 IL-6 Neutralization Assay

The neutralizing assays are carried out on cell lines that respond tothe studied cytokine. The ligand binding to receptor in generalactivates a corresponding signaling pathway, translocation oftranscription factors to the nucleus and upregulate responder genetranscription, translation and if applicable product secretion. Thecytokine concentration used is selected from the beginning of the linearpart of the dose-response curve to maximize the sensitivity of theassay. To test the neutralizing capacity of antibodies the optimalconcentration of the target cytokine is preincubated with serialdilutions of serum, supernatant or purified antibody samples. Theresults are expressed as titer or concentration of antibody that showthe value half-way between the positive and negative controls. Althoughthe interleukin-32 receptor has not yet been reported, it is known thatinterleukin-32 can induce other inflammatory cytokines such as IL-6 frommonocytes/macrophages in vitro and in vivo (Shoda et al., Arthritis ResTher. 8 (2006); R166). Accordingly, secreted IL-6 may be and was used asreadout of IL-32 activity and was quantitated with a commercial ELISAkit (Biolegend) in the neutralization assay of the present invention.

RAW 264.7 macrophages were conditioned in serum-free DMEM overnight.IL-32gamma (R&D, final concentration 50 ng/ml) was preincubated withserial dilutions of serum-free supernatant of HEK293T cells expressingthe indicated monoclonal antibodies in serum-free DMEM for 2 hours at37° C. in the wells of 96-well culture plate. Cells were added at 10,000cells per well and incubated 18 hours at 37° C. in CO2 incubator.Subsequently, secretion of IL-6 was used to monitor the neutralizingactivity of the anti-IL-32 antibodies of the present invention; see FIG.4B

Example 4 Validation of Subject Antibodies Ear Inflammation Assay

Ear inflammation phenotype was induced in 8 weeks old C57BL/6J (WT; fromCharles River) mice by intradermal injection of human cytokine IL-32γ,or IgG control in 20 μl of PBS (or PBS control) into each ear given onalternate days at Day 1, Day 4, Day 6 and Day 8 (20 μl/ear, 125 ng/ear,250 ng/mouse/day) using a 30-gauge needle. Treatment with the exemplaryanti-IL-32 2C2 antibody of the present invention was tested on theseanimals in respect of its neutralizing potential to reduce the inducedear inflammation phenotype. Only one IP injection of 2C2 or controlhuman IgG [200 μg, 100 μg or 50 μg/IP] was administered to the animalsat Day 0, prior to induction of ear inflammation. The mice weresacrificed at day 11.

To test a potential therapeutic effect of the antibodies of the presentinvention ear thickness measurements of the animals were taken with aMitutoyo digital micrometer during the IL-32 administration by dailymeasurements prior to IL-32 injection.

Furthermore, body weight has been monitored during the treatment,however, no significant weight changes have been observed in any of theanimal groups due to the treatment applied; see FIG. 7. In addition,after sacrifice of the animals H&E (hematoxylin and eosin; see Harris,H. F., J. Appl. Microscopy III (1900), 777-781 and Mallory, F. B.:Pathological technique. Philadelphia, Saunders, (1938)) histologystainings of the ears are performed.

Combination of two independent experiments shows that the induction ofear swelling with intradermal injection of human IL-32γ is reduced inthe presence of 2C2 neutralizing antibody; see FIGS. 5 and 6. This issignificant at Day 9 for the lower antibody doses of 100 μg, respective50 μg/IP; see FIG. 5C, D and FIG. 6 C, D. For the highest dosage of 200μg/IP, significant reduction of the ear swelling can be even observedstarting with day 5; see FIG. 5B and FIG. 6B. The level of ear swellingfollowing the continuous intradermal injection of PBS control is notaffected by the presence of IgG or 2C2; see FIG. 6A-D.

Exemplary anti-IL-32 antibody 2C2 demonstrates dose dependent effectsand is able to neutralize the injected IL-32γ in a mouse model.Furthermore, as shown in FIGS. 9 and 10 antibody 19A1 effectivelyneutralizes hIL-32γ induced inflammation in comparison to antibody 2C2in the CytoEar assay. Accordingly, the data presented herein indicatethat the anti-IL-32 antibody of the present invention is effectiveagainst IL-32γ in cytokine induced ear inflammation experiments,demonstrating the therapeutic value of the IL-32 specific bindingmolecules of the present invention.

CytoAnkle Assay:

Despite the fact that no mouse homologue of IL-32 has been identifiedyet, there are hints, as for example the induced ear swelling phenotypeas described supra, that at least some members of the IL-32 pathway arepresent in the mice as well. Furthermore, Joosten et al. (2006) haveinjected human IL-32 into the knee joints of mice, which led to theinduction of joint swelling, and used such experiments as a model forRA. Such experiments have been also performed in connection with thepresent invention, however, the animals have demonstrated no measurableswelling after IL-32 injections, which might be due to the difficulty ofmeasuring knee thickness through intervening muscle tissue. Due to thisfact the present invention established a novel assay to test the effectsof IL-32 in mice and in particular of the exemplary anti-IL-32antibodies of the present invention, as described below.

In this assay mice cohorts (C57/BL6, 7-8 weeks) are intraarticular (IA)injected with 62.5-250 ng cytokine, e.g., an IL-32 isotype such as IL32γor IL-32α or mixtures of several IL-32 isotypes in 10 ul of PBS (or PBScontrol) into ankles every 48-72 hours. Axial ankle thicknessmeasurements are than taken with a Mitutoyo digital micrometer. Animalsare weighed each day and respective IL-32 isotype or isotypes areadministered while the mice are anaesthetized with isofluorane. Theexperimental time frame is designed as indicated above for the earinflammation assay, with injections of the anti-IL-32 antibody orantibodies of the present invention, respective the control groupsobtaining either PBS or human IgGs of IL-32 non-related bindingspecificity as indicated above. Reduction of the ankle swelling is usedas a readout of the therapeutic effect of the antibodies.

In addition the weight of the anti-IL32 antibody treated and of thecontrol animals is monitored during the treatment, and after sacrificeof the animals H&E (hematoxylin and eosin) histology stainings of theears are performed.

FIG. 11 shows an exemplary experimental set up of the CytoAnkle assay(FIG. 11 A, B) and the dose dependency of IL-32 in inducing inflammationin the CytoAnkle assay (FIG. 11 C, D). As further shown in FIG. 12, theanti-IL-32 inflammatory effect of the 2C2 antibody could be confirmed inthe CytoAnkle assay (FIG. 12 C-E).

Example 5 Epitope Mapping of Exemplary IL-32 Antibodies

As a first step of mapping, differential binding of a-IL-32 MABs todistinct antigen binding sites is examined to determine the number ofdifferent binding sites.

For this purpose, two approaches are used. In the first approach MABsare expressed either with human (hMAB) or mouse (hmMAB) Fc andcross-competition experiments are carried out by coating antigen onplates and by detecting binding of hmMABs in the presence of largeexcess of human MABs. Detection of hmMABs bound to the ligand isperformed by a HRP-conjugated secondary antibody directed against the Fcportion of the primary antibody.

Subsequent the binding regions of MABs to their respective antigens areattempted to map using PepStar™ analysis. Herein, overlapping 20merpeptides (15 amino acid overlap) are designed to cover the IL-32isotypes of interest, e.g., IL-32γ, IL-32α, IL-32δ. IL32β and theremaining isotypes 5 and 6, including all known variants. The peptidesand full length antigen (as positive control) are spotted on microarrayand the peptide microarray is incubated with the primary antibodyfollowed by a fluorescently labelled secondary antibody directed againstthe Fc portion of the primary antibody. To avoid false negatives causedby steric hindrance, an optimized hydrophilic linker moiety is insertedbetween the glass surface and the antigen derived peptide sequence.

Example 6 Antibody Affinity Measurements Using SPR Technology

For affinity determination of the antibodies of the present inventionsurface plasmon resonance SPR measurements were performed using aProteOn™ XPR36 instrument, according to the instructions of themanufacturer (BIO-RAD; Hercules Calif., USA) using the molecules ofinterest of the present invention in an analogous experimental setup asdescribed in Example 14 of international application WO 2013/098419 A1on pages 163-165, the disclosure content of which is incorporated hereinby reference. By this method, affinity of the exemplary IL-32 antibodyof the present invention, 2C2 has been determined by SPR to be in thenanomolar range at about 4 nM; see FIG. 8 and the table in FIG. 8C.

1. A human monoclonal anti-interleukin-32 (IL-32) antibody or IL-32binding fragment thereof wherein the antibody or antigen-bindingfragment thereof comprises in its variable region the complementaritydetermining regions (CDRs) depicted in any one of FIG. 1A-D, and whereinthe antibody has at least one property selected from: (i) binds torecombinant human IL-32gamma (IL-32γ); (ii) preferentially binds tohuman IL-32γ over IL32-alpha (IL-32α); (iii) does not substantially bindIL-32α; and, (iv) neutralizes a biological activity of IL-32γ or anantibody or antibody fragment that competes with the binding of thehuman monoclonal anti-IL-32 antibody or the IL-32 binding fragmentthereof.
 2. (canceled)
 3. The human monoclonal anti-IL-32 antibody orIL-32 binding fragment thereof of claim 1 comprising in its variableregion: (a) at least one complementarity determining region (CDR) of theV_(H) and/or V_(L) variable region amino acid sequences depicted in (i)FIG. 1 (V_(H)) (SEQ ID NOs: 2, 10, 18 and 26); and (ii) FIG. 1 (V_(L))(SEQ ID NOs: 4, 12, 20 and 28); (b) an amino acid sequence of the V_(H)and/or V_(L) region as depicted in FIG. 1A-D; (c) at least one CDRconsisting of an amino acid sequence at least 95% identical to any oneof the amino acid sequences of (a); and/or (d) a heavy chain and/orlight variable region comprising an amino acid sequence at least 95%identical to the amino acid sequence of (b).
 4. The human monoclonalanti-IL-32 antibody of claim 1, which is an IgG1 or an IgG3 isotype. 5.The human monoclonal anti-IL-32 antibody or IL-32 binding fragmentthereof of claim 1 comprising a C_(H) and/or C_(L) constant region atleast 95% identical to an amino acid sequence selected from SEQ ID NOs.:6, 8, 14, 16, 22, 24 and
 30. 6. (canceled)
 7. The human monoclonalanti-IL-32 antibody or IL-32 binding fragment thereof of claim 1, whichis selected from the group consisting of a single chain Fv fragment(scFv), an F(ab′) fragment, an F(ab) fragment, an F(ab′)₂ fragment and asingle domain antibody fragment (sdAB).
 8. A polynucleotide encoding thehuman monoclonal anti-IL-32 antibody or IL-32 binding fragment thereofof claim
 1. 9-12. (canceled)
 13. The human monoclonal anti-IL-32antibody or IL-32 binding fragment thereof of claim 1, which is (i)detectably labeled with a label selected from the group consisting of anenzyme, a radioisotope, a fluorophore, a peptide and a heavy metal; or(ii) attached to a drug.
 14. (canceled)
 15. A method of: (a) treating orpreventing the progression of an immune mediated or autoimmune diseaseor condition; and/or (b) ameliorating symptoms associated with an immunemediated or autoimmune disease or condition comprising administering toa subject in need of such treatment the human monoclonal anti-IL-32antibody or IL-32 binding fragment thereof of claim 1, wherein theimmune mediated or autoimmune disease or condition is associated withthe expression of IL-32 in a patient selected from the group consistingof inflammatory bowel disease (IBD; including Crohn's Disease,ulcerative colitis and Celiac's Disease), psoriasis, rheumatoidarthritis (RA), ankylosing spondylitis and other forms ofspondyloarthritis, psoriatic arthritis, myasthenia gravis, chronicobstructive pulmonary disease (COPD), asthma, tuberculosis, cancerincluding leukemia, vascular inflammation and atherosclerosis.
 16. Amethod for diagnosing an immune mediated or autoimmune disease orcondition in a a subject associated with the expression of IL-32comprising contacting a biological sample of the subject with ananti-IL-32 antibody or IL-32 binding fragment thereof of claim 1, anddetecting the presence of IL-32γ in the biological sample. 17.(canceled)
 18. (canceled)
 19. The human monoclonal anti-IL-32 antibodyor IL-32 binding fragment thereof of claim 1, comprising a set ofcomplementarity determining regions (CDRs) selected from: (i) V_(H)CDRs: positions 31-37 of SEQ ID NO:2 and positions 52-67 of SEQ ID NO:2and positions 100-107 of SEQ ID NO:2; V_(L) CDRs: positions 23-35 of SEQID NO:4 and positions 51-57 of SEQ ID NO:4 and positions 90-101 of SEQID NO:4; and, (ii) V_(H) CDRs: positions 31-35 of SEQ ID NO:10 andpositions 50-66 of SEQ ID NO:10 and positions 99-105 of SEQ ID NO:10;V_(L) CDRs: positions 23-33 of SEQ ID NO:12 and positions 49-55 of SEQID NO:12 and positions 88-97 of SEQ ID NO:12; and, (iii) V_(H) CDRs:positions 31-35 of SEQ ID NO:18 and positions 50-66 of SEQ ID NO:18 andpositions 99-105 of SEQ ID NO:18; V_(L) CDRs: positions 23-33 of SEQ IDNO:20 and positions 49-55 of SEQ ID NO:20 and positions 88-97 of SEQ IDNO:20; and, (iv) V_(H) CDRs: positions 31-35 of SEQ ID NO:26 andpositions 50-66 of SEQ ID NO:26 and positions 99-105 of SEQ ID NO:26;V_(L) CDRs: positions 23-33 of SEQ ID NO:28 and positions 49-55 of SEQID NO:28 and positions 88-97 of SEQ ID NO:28.
 20. The human monoclonalanti-IL-32 antibody or IL-32 binding fragment thereof of claim 1,wherein the variable region is at least partially encoded by apolynucleotide selected from the group consisting of SEQ ID NOs:1, 3, 9,11, 17, 19, 25, and
 27. 21. The human monoclonal anti-IL-32 antibody orIL-32 binding fragment thereof of claim 1, wherein the variable regioncomprises an amino acid sequence selected from the group consisting ofSEQ ID NOs:2, 4, 10, 12, 18, 20, 26, and
 28. 22. The human monoclonalanti-IL-32 antibody or IL-32 binding fragment thereof of claim 1,wherein the constant region is at least partially encoded by apolynucleotide selected from the group consisting of SEQ ID NOs:5, 7,13, 15, 21, 23, and
 29. 23. The human monoclonal anti-IL-32 antibody orIL-32 binding fragment thereof of claim 1, wherein the constant regioncomprises an amino acid sequence selected from the group consisting ofSEQ ID NOs:6, 8, 14, 16, 22, 24, and 30.